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Summary
The therapeutic applications of gene therapy have been realised for over a decade. One 
of the many approaches to transferring DNA into cells is the inclusion of a membrane 
active peptide (termed fusogenic peptide). In this project, fusogenic peptides based on 
the 23 amino terminus of the haemagglutinin sub-unit (HA-2) of the influenza virus 
were synthesized using solid-phase peptide synthesis method. Fusogenic peptides with 
10 or 25 lysine residues attached to the carboxyl terminus (termed “bifunctional 
peptides”) were also synthesized. Complexes consisting of DNA, oligolysine and 
fusogenic peptides (termed ternary complexes) were formulated by sequential mixing 
of DNA and oligolysine followed by mixing with fusogenic peptide (in a process termed 
“two-step complex formation”). The in vitro transfection efficiency of ternary 
complexes were compared with that of complexes of bifunctional peptides with plasmid 
DNA (termed “binary complexes”). The latter were prepared by mixing solutions 
separately containing the two components (a process termed “single-step complex 
formation”). It was found that complexes formed with the novel bifunctional peptides 
(containing a 25-lysine chain) were 100- to 74000-fold more active than ternary 
complexes at transfection in vitro in six mammalian cell lines tested. The ability of both 
the fusogenic peptides and bifunctional peptides to disrupt cell membranes was 
demonstrated at pH 5 and pH 7 using an erythrocyte lysis assay. The bifunctional 
peptide with a 1 0 -lysine chain attached did not show transfection activity even though it 
had membrane disruptive activity and could bind to DNA (though higher molar 
concentrations were required than the peptide containing a 25-lysine chain). The ability 
of the bifunctional peptide to effectively bind to DNA was demonstrated by comparison 
to polylysine and oligolysine, using an ethidium bromide exclusion assay. It was shown 
that the length of the lysine chain in the bifunctional peptide had to greater than 1 0  
residues in order to achieve transfection activity. It was also shown that at the charge 
ratio optimum for in vitro transfection, bifunctional peptides protected DNA from 
degradation by serum proteases and thus enzymatic degradation was not responsible for 
the total loss of transfection activity observed in the presence of 1 0 % (v/v) serum. 
Physical characterisation experiments to determine the particle size and zeta potential of 
binary complexes were performed in 5% (w/v) glucose solution. It was also discovered 
that a single amino acid deletion from the fusogenic component of the bifunctional
ii
peptide resulted in over 1 0 0 -fold reduction in transfection activity in vitro.
Preliminary in vivo testing of bifunctional peptides complexed with DNA was 
performed by injecting bifunctional peptide/DNA complex formulations in muscle and 
into dermal RIF-1 tumours implanted in host C3H mice. There was no transfection 
activity of bifunctional/DNA complexes in either muscle or tumour tissue at charge 
ratios which were optimum in vitro (+/- 3.2). However at a charge ratio of 0.8, there was 
a 2-fold increase in transfection activity in muscle compared to naked DNA, but this 
effect was not statistically significant.
Attempts were made to synthesis a fusogenic peptide with an oleoyl chain attached 
covalently via the side chain (s-amino) of a lysine residue. This peptide proved difficult 
to purify by HPLC using the equipment available within the research group. Preliminary 
transfection studies showed that it could have a potential to increase the transfection 
efficiency of complexes made with the cationic lipid DOTAP.
This project is proof in principle that a single polypeptide consisting of a DNA-binding 
oligolysine component and a fusogenic component is a better and more robust gene 
delivery agent in vitro than systems that use self-assembly process via ionic interaction 
between positively charged oligo/polylysine and negatively charged fusogenic peptides 
(ternary complexes). The synthesis of a single, long bifunctional peptide by solid-phase 
synthesis was costly and the product was tedious to purify, but the end product had the 
advantage of guaranteed co-localisation of the functional components in the required 
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The objective in human gene therapy is to transfer plasmid deoxyribonucleic acid 
(DNA) encoding for deficient or defective proteins/peptides into human somatic cells in 
vivo in order to treat the resulting diseases from enzyme, transmembrane protein or 
hormone deficiencies. Due to their large and polar natures, gene expression vectors 
cannot overcome the lipid cell membrane barrier to enter cells in therapeutic quantities.
Also, once internalised, the DNA has to escape from the endosome to avoid lysosomal
1 0 degradation and overcome the barrier of the nuclear membrane . Gene therapy depends
on efficient and safe devices for the delivery of nucleic acid into the target cells. A gene
transfer particle has to serve at least two major delivery functions: (i) it has to deliver
the gene within the patient from the site of administration to the surface of the target
cell/tissue and (ii) it has to aid the uptake and successful trafficking of DNA to the
nucleus of the cell. Combining the functions of a gene delivery vehicle (GDV) to meet
the extracellular and intracellular requirements for successful gene delivery is a major
challenge.
Gene delivery vehicles can be broadly divided into viral and non-viral gene reagents. 
The distinction between viral and non-viral gene therapy relates to the methods used for 
gene delivery. The viral gene therapy approach employs genetically engineered viral 
particles to deliver genes to the target cell, and the non-viral gene therapy approach 
employs gene delivery systems comprised of synthetic and semi synthetic gene 
formulations2. Viral gene delivery systems are effective and make use of the highly 
evolved mechanisms of viruses to transfer the therapeutic gene. The main drawback of 
viral systems is one of safety. Non-viral delivery vehicles are safe but suffer from low 
gene transfer efficiency in vivo. The solution to achieving safe and efficient gene 
delivery systems may be a compromise of the two methods: non-viral/synthetic “virus­
like” particles.
There are a variety of non-viral gene delivery systems that are capable of transfecting 
cells in vitro 1’3,4,5,6. However, little concordance has been observed between the 
effectiveness of transfection in immortal or primary cell lines in vitro and their 
effectiveness for gene delivery in vivo1. Since human gene therapy is aimed at treating
1
human diseases in vivo, it is important that candidates for GDVs and gene delivery 
protocols are selected and developed based their in vivo activity via a practical (potential 
clinical) route of administration as an initial step, before they are proposed as possible 
gene delivery vehicles for human gene therapy. Generally, GDVs are more efficient at in 
vitro gene transfer than in vivo.
The following sections will briefly describe some of the main viral and non-viral GDVs 
tested in vitro and/or in vivo to date and then concentrate on the in vivo barriers (intra- 
and extra- cellular) to the delivery plasmid DNA using non-viral gene delivery vehicles, 
and the attempts that researchers in the field are making to overcome the barriers to 
gene delivery.
1.1 V ir a l  v e c t o r s
Viruses have evolved efficient strategies for transferring their genetic material from one 
host cell to the other. The principle of viral gene delivery is that genes encoding viral 
functions (which results in host cell death) may be replaced with genes encoding 
therapeutic functions within the infectious viral particles without eliminating the ability 
of the virus to infect the target cell efficiently and direct the expression of the gene 
product2.
Viral vectors, such as recombinant adenovirus vectors have a number of advantages for 
gene transfer, including their high transfection efficiency and their wide range of cell
o
targets in vivo . However viral vectors have a number of disadvantages including the 
fact that they can generate several types of immune response reducing the effectiveness 
of subsequent administration of the vector. Research in cotton rats has shown that the 
immunological responses to administration of viral vectors can be reduced by treating 
them with immunosuppressive drugs prior to administration of recombinant adenoviral 
vector9. Also viral vectors often contain viral genes which can be transcribed, and there 
is a possibility of recombination with a wild-type virus, to produce a replication
0 Hcompetent virus ’ . The advantages and disadvantages of three of the main viral 
approaches to gene therapy are discussed here.
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1.1.1 Retr o v ira l  V ectors
Retroviruses (RV) are enveloped RNA viruses that can introduce genes permanently
into somatic cells by integration its genetic material into chromosomal DNA of dividing
cells10. Recombinant RV vectors can accommodate up to 6-7 kb of foreign 
11 10sequences ’ and represent the most widely used vectors for human gene therapy, 
accounting for over 50% of current phase I trials. For the purposes of gene therapy, RV 
has been introduced into cells ex-vivo where cells have been stimulated with growth- 
promoting media or specific factors, before re-introduction into the host. Direct in vivo
•  •  •  •  •  1 "Xapproaches including injection of retroviral vector producing cells into the brain or 
intramuscular injection14 have been described. Recombinant retroviruses are rapidly 
cleared from the systemic circulation by a complement mediated inactivation process15, 
however, the use of alternative human packaging cell lines has partly resolved this 
problem16. A major disadvantage with RV is the possibility of inducing cancer by 
insertional mutagenesis; a consequence of random integration of the vector into the host 
cell chromosome17. Stable transformation of cells by RV vectors is often cited an 
advantage but the permanent integration of therapeutic genes by retroviral vectors 
removes the ability to modify or terminate the therapy in response to any adverse side 
effects or cure of the disease. Also, RNA viruses can recombine with other viral or 
cellular RNAs to produce new oncogenic viruses or replication-competent retroviruses 
of unknown characteristics11,15.
1.1.2 A d en o v ir a l  V ectors
Adenoviruses are double-stranded DNA viruses capable of efficiently transducing 
dividing and non-dividing cells such as airway epithelial cells, endothelial cells,
1 Shepatocytes and cancer cells . Due to its natural tropism for respiratory tissue, AV was 
first used to study the cystic fibrosis transmembrane conductance regulator (CFTR) gene 
transfer to patients with cystic fibrosis19. Adenoviruses do not integrate genes within the 
host cell chromosome hence transgene expression is only transient and there is the need 
for repeat administration if prolonged gene expression is necessary. The ability of 
adenoviruses to cause inflammation and stimulate other immunological response is a 
major disadvantage in their use for human gene therapy. Attenuated adenoviral vectors
express several viral proteins that can lead to immunogenic responses directed toward
9ftthe adenoviral vectors and inflammation in the target tissues thus making further
91administration of AV vectos inefficient or impossible . In addition to the humoral 
response, a cellular immune response (cytotoxic T lymphocytes) against the transduced
9ft 99cells has been reported ’ . Some of the efforts that have been made to reduce 
inflammatory responses involve deletion of El and E4 genes23, pre-treatment with anti­
inflammatory drugs such as dexamethasone9 or simultaneous administration with 
cyclophosphamide (an alkylating agent used in the treatment of cancers)24. Clinical data 
in cystic fibrosis patients treated with adenoviral vector containing the gene encoding
9 c
for CFTR protein have been rather disappointing .
1.1.3 A d e n o -a sso c ia t e d  vir u s  (AAV)
Adeno-associated viruses (AAV) are single-stranded DNA paroviruses, which are not 
associated with any known human diseases. This naturally defective virus, which 
requires co-infection with a helper virus (adeno, herpes or vaccinia virus) for 
replication, is capable of permanently inserting their genome into the chromosomes of
9 (\the host cell . The main advantage of the AAV for gene therapy is its ability to infect 
both dividing and non-dividing cells although chromosomal integration may not occur
97in quiescent cells . As a DNA virus, AAV may be less susceptible to recombmation
9 0
than retroviruses . A major drawback to the use of AAV in gene therapy is that only a 
small size of foreign DNA can be incorporated (3.5-4.0 kb). There are also difficulties 
in developing packaging cell lines that produce sufficient titres of virus without the 
presence of a helper virus29. Successful in vivo application of AAV vector mediated
Oft
gene delivery include transduction CFTR gene in rabbit lung , the expression of 8 - 
sarcoglycan gene in a hamster model of limb girdle muscular dystrophy31. Wang et al. 
have reported the efficient in vitro expression of CFTR using AAV vectors, which 
contain a downsized CFTR cDNA, thus allowing for the inclusion of an efficient
09
promoter in the vector . It remains to be seen how this “second generation” AVV
0 9
vectors will perform in vivo.
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1.2 N o n -v ir a l  G e n e  D e l iv e r y  S y s t e m s
A A* jy a A ■ « /
Non-viral gene transfer formulations ’ ’ ’ ’ are attractive for the following reasons: 
(a) The whole diversity of chemical reactions and physical interactions may be utilised 
for the synthesis and assembly of transfection material, in contrast to viral vectors which 
have to be assembled by cells in a biological environment, therefore being restricted to a 
proteinaceous composition, (b) They can be generated by assembly of few, defined 
components, (c) They can be very flexible regarding the size of DNA to be transported.
(d) Plasmid DNA and transfection reagents can be produced at large scale with rather 
low costs.
(e) Safety testing of synthetic material is less laborious than testing of recombinant 
material.
Non-viral gene delivery methods may be classified into two categories: a) naked DNA 
gene transfer systems and b) particulate gene delivery systems.
1.2.1 N a k ed  DNA G ene  Tr a n sfe r  sy ste m s
Intramuscular application of naked DNA results in efficient gene expression in rodent 
muscle33. In addition, conditions have been worked out for the local gene transfer of 
naked DNA to the skin37, the liver 38,39, heart40, the lung epithelium41 and tumours42,43. 
Intramuscular injection of naked DNA has been used to introduce the dystrophin gene 
into muscles in animal models of Duchenne muscular dystrophy yielding long term 
expression of dystrophin in a limited number of muscle fibres and protection of those 
fibres against degeneration44,45.
Transfection efficiency using injected naked DNA is species-dependent and very large 
amounts of DNA have to be applied. Nevertheless, there appears to be room for further 
improvement by optimising the formulation. Naked DNA have been formulated in 
polymers like polyvinyl pyrrolidone (PVP) and polyvinyl alcohol (PVA) 46 which are 
designed to be protective, interactive, non-condensing (PINC) for intramuscular gene 
delivery to the muscle resulting in higher and longer transgene expression47.
Alternatives to injection by needle include administration by needle-free jet injection
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or biolistic delivery of DNA loaded gold microparticles49 by the use of the gene gun or 
the pneumatic gun50,51. Improved local expression was obtained by electropermeation of 
the DNA-loaded area with some few microsecond electrical pulses . The naked DNA 
technology has been successfully applied in murine models for genetic vaccinations53,54.
1.2.2 Pa rticulate  gene  d eliver y  a g en ts
Cationic lipids and cationic polymers have been used to condense DNA to form cationic 
lipid-DNA complexes (lipoplexes) and cationic polymer-DNA complexes (termed 
“polyplexes”) respectively, or combination of both (lipopolyplexes) and to enhance 
DNA uptake by cells and have formed the bases of the development of non-viral gene 
delivery vehicles.
1.2.2.1 Ca t io n ic  l ip id s  a n d  l ip o s o m e s
Since the first description of successful in vitro transfection with cationic lipid 
transfection by Feigner et al. in 198755, there has been substantial progress their 
application of liposomes in their application for gene delivery3,4,56. Following some 
early structure-activity relationship studies of cationic lipids it was hoped that some 
‘magic’ lipid could be discovered. While some new lipids are more efficient than the 
first generation cationic lipids in gene transfer, that goal will find a ‘magic’ lipid has
cn
been far from being realized . A variety of cationic lipids (see Figure 1.1) currently 
available for liposome formulation consist of molecules with spacers of differing 
lengths and a variety of positively charged single or multiple amine head groups 
(reviewed by Gao and Huang58). The first generation of cationic lipids contained polar 
head groups with a single protonable amine (e.g. DOTMA, DOTAP). Other cationic 
lipids e.g. DOSPA and DOGS, incorporate multiple amine groups derived from 
spermine59,60,61. Other types of lipidic structure with good transfection activity include 
facial amphiphiles62, peptido-lipids63,64, pH sensitive liposomes65, and cationic pH- 
sensitive liposomes66. Although various cationic lipids and lipid combinations exhibits 
quantitatively different gene delivery efficiencies in different cells, no clear patterns 
have emerged concerning the features of the lipid carriers that are necessary or optimal 
for gene delivery2.
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F igure 1.1 Structure o f  some commonly used cationic lipids.
Legend: DOTMA, l,2-dioleyloxypropyl-3-trimethyl ammonium chloride;
DMRIE, 1,2-dimyristyloxypropyl dimethyl 2-hydroxyethylammonium;
DDAB, dimethyldioctadecylammonium;
DOTAP, N-[l-(2,3,-dioleoyloxy)propyl]-N,N,N-trimethylammonium;
DC-chol, 3P[N ’-(N ’-dimethylaminoethane)carbamoyl]cholesterol;





The efficiency of cationic liposomes in vivo is relatively low in comparison with viral 
vectors but they have the advantage of low toxicity and are unlikely to provoke 
inflammation or immune response on repeated administration . The activity of 
liposomes and cationic lipids and modifications that have been made to improve lipidic 
transfection efficiency in vivo are discussed in sections 1.4.2.1 and 1.4.3.1. Some 
efforts that have been made by scientists to overcome cellular barriers are discussed in 
section 1 .5.2.1.
1.2.2.2 Ca t io n ic  p o l y m e r s
Cationic polymers self-assemble with DNA to form small composite particles that 
protect DNA against enzymatic degradation and are suitable for cellular uptake. When 
formulated with positive charge, these particles interact readily with cell surfaces and 
are internalized by endocytosis. Like cationic lipids, cationic polymers are generally 
non-immunogenic and can be easily applied to nucleic acid-based macromolecules of 
varying sizes. Cationic polymer-based delivery systems can be more stable than cationic 
lipids because their polyvalent interactions with DNA are not readily reversed. The main 
cationic polymers that have been used to condense DNA and transfect cells include 
linear polypeptide polymers like polylysine (PLL), polyarginine and polyomithine ’ ’ , 
histones70 poly[(2 -dimethylamino)ethyl methacrylate] 71 and other chromosomal
77proteins and branched polymers including polyamidoamine cascade polymer 
("starburst dendrimer" )73,74 and polyethylenimine (PEI)5.
Multivalent cations and polycations readily self-assemble with DNA and induce DNA 
compaction. In general, DNA is condensed to small toroidal or spherical structures with 
diameters as small as 30 nm. For cationic polymer-induced compaction, the structures 
of the resulting polyplexes have a greater dependency on the structure of the cationic 
polymer than on the structure of the DNA. DNA molecules of various lengths, 
sequences and forms (plasmid or linear) condense with cationic polymers in water to 
particles with similar dimensions.
Condensation efficiency is affected by polymer molecular weight and structure. High 
molecular weight polymers act similarly in DNA condensation. Tang et al. studied DNA
condensation by PLL (27 kDa), PEI (25 kDa), intact dendrimers and fractured 
dendrimers (sixth generation) and reported no differences in the size or zeta potential of 
the resulting polyplexes. All cationic polymers completely excluded ethidium bromide 
intercalation into DNA by charge ratios of +/- 1 (charge ratio is the positive charge of 
the polymer divided by the negative charge of the DNA) and condensed plasmid DNA
nc
to small toroids (40 to 60 nm in diameter) .
Cationic oligomers are also able to self-assemble with and condense DNA. Because 
condensation is thought to be driven by entropic forces arising from counter ion release, 
a minimum number of charge sites per polymer chain are necessary for achieving 
condensation. Gottschalk et al. and Plank et al. each found the minimum consensus 
polycation for DNA condensation to contain six to eight charges; however, these
77oligomers required high charge ratios for DNA condensation ’ . Additionally, the 
polymer structure influences DNA condensation efficiency. Incorporation of a single
<70
tryptophan residue into oligomers of polylysine greatly increased DNA binding . 
Polymers with charge centres located close to the backbone are more efficient in DNA 
condensation and show increased stability to competitive displacement by anions78. 
Structure-function studies with cationic, cyclodextrin-based polymers revealed a 
significant DNA-binding dependence on charge centre distance from the sterically bulky 
cyclodextrin moieties but no differences in DNA condensation between polymers with
#70charge centres separated by four to ten methylene units along the polymer backbone .
The use of polyplexes for gene delivery is hampered by inefficient mechanisms of 
endosomal escape and requires lysosomotropic agents such as chloroquine and
on
ammonium chloride to enhance in vitro gene transfer . Efforts to improve polyplexes 
gene delivery efficiency in vivo are discussed in detail the next section (section 1.3).
1.3 B a r r ie r s  t o  n o n -v ir a l  g e n e  d e l iv e r y  f o r  c a t io n ic  p o l y m e r s
PLL, PEI and dendrimers were not specifically developed for gene therapy applications. 
Recent developments in cationic vectors have included the preparation of new classes of 
polymers prepared specifically for gene delivery applications that reveal improvements 
in toxicity, solubility and biodegradability; however, the majority of research has
9
focused on modifying the more traditionally used polymers to increase their suitability 
for in vivo gene delivery. Major improvements in gene delivery have been made by 
modifying cationic polymers such as PLL and PEI with agents that enhance transfection 
efficiency, in vivo stability and tolerability. As a class of materials, cationic polymers 
generally utilise the same physicochemical interactions to bind and condense DNA, and 
the resulting polyplexes ultimately face the same barriers in in vivo delivery. Three 
major classes of barriers that need to be overcome in the development of non-viral, in 
vivo gene delivery systems are barriers to formulation and manufacturing, and 
extracellular and intracellular barriers.
1.3.1 Fo r m u latio n  barriers
Cationic polymer-mediated delivery of gene-based drugs at a therapeutic dose requires 
high concentrations of polyplexes. Aggregation of these colloidal systems occurs with 
neutral particles, in concentrated solutions, or in the presence of salt. Formulation of 
polyplexes at near neutral zeta potential results in rapid aggregation of particles due to 
van der Waals interactions. For charge-mediated uptake, this problem is bypassed by 
formulating polyplexes with positive zeta potentials. However, positively-charged 
polyplexes also aggregate more readily as their concentration increases and they quickly 
precipitate out of solution above their critical flocculation concentration. For example,
O 1
PLL-based polyplexes precipitate at 20 pg DNA/ml water , thereby severely limiting 
the injectable dosage of these particles. The concentration of polyplexes can increase 
with the hydrophilicity of the cationic polymers. Conjugation of hydrophilic polymers or 
proteins to the cationic polymers also increases polymer solubility. PEGylated 
(polyethylene glycol-conjugated) polylysine-based particles show no aggregation even at
O ')
neutral zeta potentials ’ . The solubility of PEG-PLL particles depends on the degree 
of PEGylation84 and molecular weight of PEG85, with formulated concentrations as high 
as 2 mg DNA/ml in water85. Ogris et al were able to concentrate PEGylated PEI to 400 
pg/ml water without precipitation86. Dextran-modified PLL also increases the solubility 
of complexes to 40 pg of DNA/ml87, as does conjugation of water-soluble proteins such 
as transferrin (increases the concentration of PLL-based polyplexes to 300 pg DNA/ml
oo
water ). Thus, injection of cationic polymer-based gene therapies at a pertinent dose 
generally requires concentrations of polyplexes above their critical flocculation
10
concentration. Efforts to raise polyplex concentration limits by increasing their 
hydrophilicities and by providing steric stabilization have resulted in formulations 
appropriate for in vivo use.
H—|-OCH2GH2-J^-OH
Figure 1.2 Structure o f polyethylene glycol (PEG)
1 .3 .2  E x t r a c e l l u l a r  b a r r ie r s
Extracellular barriers to systemic delivery are hurdles to gene delivery that can be 
encountered from the point of injection to the surface of the cellular target.
1.4 B a r r ie r s  t o  g e n e  d e l iv e r y  in  v iv o
There are a number of biological barriers to in vivo gene delivery depending on the route 
of administration and the on the location of the target cells. The location of the target 
tissues are as varied as there are diseases for which gene therapy are propounded to be
useful in treating. Some relatively accessible target tissues that are candidates for direct
80 80injection include intratumoural, intrasynovium ’ , intraoccular, intramuscular, 
subcutaneous, intrapericardial and intracranial administration. For less accessible target 
tissues, the intravenous route is the most practical route of delivery and presents most 
challenging and widest range obstacles to gene delivery.
1.4.1 B a r r ie r s  t o  in t r a m u s c u l a r  a n d  in t r a t u m o u r a l  in je c t io n
Naked DNA can be active in vivo after direct injection in muscle although 'naked' DNA 
plasmid has little or no activity in a typical cell culture transfection experiment33’90’91. 
Efficiency of transfection is low, usually with approximately 1% of cells being 
transfected after an intramuscular injection. It is conceivable that this level of activity 
could be the result of passive processes. It is not yet known how myocytes take up
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plasmids in vivo, or how the DNA escapes lysosomal degradation. The unusual 
persistence of expression in muscle tissue has been attributed to the slow turnover of 
myofibre nuclei. In addition, access of DNA to the nucleus appears to be unusual in
92myocytes .
Staining of muscle or tumour tissues suggests that expression following direct injection 
of lipoplexes is often localized in regions that are close to the injection site. 
Formulations of plasmids with hydrophilic polymers appear to be more effective than 
particulate systems at promoting transfection in solid tissues46, and the pattern of 
expression is more uniform and widespread, which supports the hypothesis that 
dispersion is a critical factor. As yet, it is not clear what the relative contributions of 
diffusion and convection are in the dispersion of DNA formulations within a solid 
tissue.
There are some similarities between expression of DNA in muscle and tumour tissue, 
although, in general, the levels of expression after intratumoural injection are much 
lower. Naked DNA appears to be as active as lipid formulations , presumably due to 
poor dispersion of particles within solid tumour tissue. Solid tumours lack effective 
lymphatic drainage, thus, gene delivery systems are likely to be forced towards the 
perimeter of the tumour tissue, where the material may become immobilized, unless 
extracellular fluid is able to drain into the surrounding tissue. High hydrostatic pressure 
within solid tumours presents a serious barrier to dispersion. In animal models, fluid 
may be forced away from the injection site after intratumoural administration. The use 
of micropump delivering 100 pi at a rate of 20 pl/min DNA formulation into solid 
tumours in mice has been successfully used to circumvent the problem of high 
hydrostatic pressure in tumours43.
1.4.2 B a rriers  to  lu n g  ad m in istr a tio n
The lung as a target for gene delivery deserves a special mention because of the 
immense clinical interest for the treatment of cystic fibrosis. Cystic fibrosis (CF) is 
inherited as an autosomal recessive disorder, and is caused by mutations of a single gene 
coding for CFTR. CFTR is a cAMP-regulated chloride channel, which is required for
12
ion and water movement across the epithelial cell layers. Defective CFTR function leads 
to respiratory and intestinal disorders.
The lung is particularly attractive for gene delivery because it is easily accessible and 
avoids the need for any targeting component in a gene delivery product. The array of 
obstacles that oppose gene delivery particles reaching the cell surface and become 
internalised are reviewed by Pouton and Seymour94. Barriers to lung gene delivery 
include lack of endocytic capacity, lack of cell division, polarised epithilium with tough 
apical surfaces, which have tight junctions, and mucus, which acts as a physical and 
diffusional barrier. The dependence of successful gene delivery on mitotic activity can 
be modelled in vitro. Uduehi et al showed that filter-cultured, differentiated Caco-2 cell 
could not be transfected, thus demonstrated the resistance of non-dividing cells to gene 
delivery by cationic lipoplexes95. Mortimer et al have also shown the requirement of 
mitotic activity for lipid-mediated transfection of cells in culture96. The lungs also have 
alveolar macrophages, which would clear particulate material, which reaches the deeper 
respiratory airways.
1.4.2.1 Ca  tjo n ic  l ip id / l ip o s o m e s  b a s e d  g e n e  t r a n sf e r  t o  t h e  l  u ng
Successful reporter gene expression to the lungs have been reported by several 
researchers using cationic lipoplexes to deliver reporter genes to the lung of various 
species including mice, rats, and sheep after intratracheal administration97,98,99. In vivo 
expression of therapeutic genes such as ai anti-trypsin100 and CFTR101,102,103,104,105 using 
cationic lipids in animal models have also been reported. These results suggested that 
DNA-cationic liposome complexes were efficient and relatively mild gene transfer 
agents for treatment in CF patients. Phase 1 human trials in CF patients using DC- 
chol/DOPE liposome-DNA complex applied by nasal drip to the nasal epithelium 
resulted in a partial restoration of chloride channel function (as measured by 
improvement in the membrane potential difference deficit in treated individuals)106.
1.4.2.2 N a k e d  D N A  d e l iv e r y  to  t h e  l u n g
Suprisingly, naked DNA is seldom used as a standard for gene delivery vectors to be 
compared against in transfections to the lungs by direct instillation or aerosolisation. A
study by Zabner et al. found that a CFTR expressing pDNA partially corrected the 
electrophysiological abnormalities within the nasal epithelium of cystic fibrosis patients 
to the same extent as when administered alone or when complexed with a cationic 
lipid107.
1.4.2.3 CATION1C POLYMER-BASED GENE TRANSFER TO THE LUNG
Polylysine on its own is inefficient as a GDV for in vivo transfection but replication 
deficient adenoviruses coupled to transferrin polylysine has been shown to be efficient 
in transfection to the airways of cotton rats108,109.
1.4.3 B arriers to  g ene  d eliver y  v ia  in tr a v en o u s  route
The barriers to intravenous delivery of DNA complexes are quite formidable and are 
reviewed in detail by Pouton and Seymour94. The barriers include targeting to distal 
sites, opsonization and removal by mononuclear phagocytic system, degradation by 
serum enzymes, instability of particles when they come into contact with serum 
proteins, particle instability, difficulties with extravasation due to increased particle size 
and difficulty in crossing the extracellular matrix. In the absence of a hydrophilic 
surface, many particles interact with, and become coated by, specific plasma proteins 
(opsonins), which have evolved to participate in clearance of particles from the blood in 
a process known as opsonization. Opsonization prepares a particle for uptake by fixed 
macrophages of the mononuclear phagocytic system (MPS)110. The MPS is a collection 
of phagocytic cells that are present in tissues of the reticulo-endothelial system and are 
collectively responsible for clearance of particles from the circulation. Typically, 
80-90% of hydrophobic and charged particles are opsonized and taken up by fixed 
macrophages of the liver and spleen, often within a few minutes of intravenous 
administration. Opsonization represents a major biological barrier to the delivery of 
DNA using condensed particles94.
When the gene delivery particle all of the above-mentioned barriers, it also faces the 
obstacle of targeting the required tissue. Targeting of gene delivery to the cell surface is
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best achieved by direct and local application, however this is not always possible. For 
example, in the use of gene therapy for cancer treatment, most work on targeted 
liposomes has been designed to deliver cytotoxic drugs to cancer cells. Miller and Vile 
have reviewed the incorporation of targeting functionality in liposomes111. Expression 
of a plasmid DNA in the target cells makes greater demands on the vector system when 
delivered via the intravenous route in that, it must not only target the appropriate ceil 
type but also allow efficient delivery of undegraded DNA to the nucleus.
1.4.3.1 Ca t io n ic  lip id / l ip o s o m e -b a s e d  g e n e  tr a n sf e r  via in t r a  v e n o u s  r o u t e
In vivo use of conventional liposomes requires first avoiding the reticuloendothelial 
system (RES), and second, display of appropriate tropic and fusogenic molecules. 
Uptake by the RES can be considerably delayed, but not altogether avoided, by the use 
of “stealth” liposomes that display charged moieties such as the ganglioside GM1 and 
polyethylene glycol112. For most systemic purposes, the stealth formula is probably 
essential. Coupling of transferrin to liposomes followed by intravenous injection in a 
rabbit model resulted in significantly greater localisation to bone marrow 
erythroblasts113, and incorporation of surfactant protein A into liposomes increased the 
uptake of the liposome cargo by alveolar type II cells114.
Immunoglobulin complement coupled to liposomes ("immunoliposomes") has been 
shown to exhibit tropisms conferred by the displayed antibody. Coupling to liposomes 
of an antibody against glioma cells increased the efficiency of gene delivery to these 
cells in vitro by about 70-fold115. However, it is not sufficient merely to confer upon the 
vector a particular binding ability; the particle must bind to a ligand that also allows 
fusion of liposome and cell membranes. Such considerations of appropriate 
internalisation of vector cargo are especially important for gene delivery vectors, where 
the DNA must not only reach the appropriate cell type but also must reach the nucleus 
in an undegraded form111.
Conjugating virions to liposomes or incorporating viral surface glycoproteins into 
liposomes might create a vector that has the efficient cell attachment and entry 
mechanisms of a virus but not the safety drawbacks; much work has been done in this
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area with Sendai vims in particular116. Another system used liposomes that displayed 
only the fusogenic protein of Sendai vims (F-protein) and not the cell binding protein
117(haemagglutinin) . However, although such approaches can make liposomes up to 
10-fold more efficient than lipofection at gene delivery116, in terms of targeting all it can 
do is confer upon the liposome the tropism of the vims, and there are very few native 
viral receptors that exhibit narrow and precise cell type specificity. Respiratory 
epithelium has been targeted by means of the surface proteins of respiratory syncytial vi­
ms (ReSV), which is responsible for infections of the lower respiratory tract. 
Liposome-type envelopes were constructed that displayed both the attachment and 
fusion proteins of ReSV, and these have been shown to enter all cells of a cultured
1 1 Q
respiratory epithelial cell line within 1 hour .
Cationic liposomes such as the commercially produced lipofectin can efficiently avoid 
the lysosomal pathway because the particular lipid composition allows direct fusion of 
liposome and cell membranes and have replaced conventional liposomes111. Several 
studies have shown that intravenous administration of cationic liposome-DNA or 
cationic liposome-polycation-DNA complexes gives systemic gene expression 
particularly to the lung119,120,121,122,123,124. Study of the dynamic changes in the 
characteristic of cationic lipidic vectors in serum have revealed that lipidic vectors 
undergo aggregation, then disintegration of vectors leading to degradation of DNA . 
PEGylation of cationic lipids could offer a solution to the problem of serum protein 
recmitment , but its difficult to see how that could be achieved without compromising 
the ability of existing lipids to bind to DNA. A new class of cationic lipids with 
“stealth” properties could better meet intravenous delivery requirements.
1 .4 .3 .2  N a k e d  D N A  d e l iv e r y  via in t r a  v e n o u s  r o u t e
Naked pDNA is rapidly degraded in the presence of serum125. Intravenous injection of 
high doses (66 mg/kg) of pDNA in mice as a control in the study of cationic liposome- 
mediated intravenous gene delivery, showed that plasmid DNA only was capable of 
transgene expression in major organ tissues (heart, liver, spleen, kidney and uterus) but 
were between 57-fold (in the heart) and 1000-fold (in the spleen) lower than DNA-
196liposome complex .
16
1 .4 .3 .3  C a t io n i c  p o l y m e r -b a s e d  g e n e  t r a n s f e r  via in t r a  v e n o u s  r o u t e
For cationic polymer-based systems, the extracellular barriers to gene delivery that must 
be overcome can be summarised as follows: toxicity of the polyplex, interactions with 
serum proteins, extracellular matrices and non-specific cell surfaces, clearance by the 
innate immune system, aggregation due to physiological salt conditions and evasion of 
the adaptive immune response.
There has been a relatively few reported work on in vivo transfection using unmodified 
polylysine-based complexes since the early work by Wu and Wu and this is a 
reflection of the difficulty with particle stability in serum and associated toxicity in vivo.
1 no
In order to enhance uptake and specificity, Wu and Wu generated polylysine-based, 
receptor-specific gene transfer system by incorporation of asialoorosomucoid-polylysine 
conjugates into DNA complexes to obtain expression of reporter genes in hepatocytes of 
normal animals. By attaching the DNA to a domain that can bind a cell surface receptor 
such as the asialoglycoprotein receptor, insulin, transferrin and CD3 receptors
198  1 9Q 1 3fi 131 139 133’ ’ • ’ ’ efficiency of receptor-mediated endocytosis has been explored. Other
published work included the use of low-density lipoprotein (LDL) receptor in LDL-- 
deficient rats134, albumin in analbuminemic rats and methylmalonyl Co A mutase in 
mice. Evidence of specific gene delivery to hepatocytes in vivo has been obtained with
1 3<the use of hepatocyte-specific promoters and histological analysis . The delivery of 
plasmids to hepatocytes in vivo has also been reported using polylysine covalently
13 f \  1 37coupled to galactosyl residues as targeting ligands ’ . As with PEI, a reduction of
surface charge by complexing with polyethylene glycol, should reduce toxicity and 
particle instability, but polylysine does not have the inherent pH buffering effect which 
is responsible for the efficiency of PEI.
The reduction of the surface positive charge of TfPEI-DNA complex by covalently 
linking polyethylene glycol (PEGylation) to TfPEI, has been shown to reduce 
interaction with blood components, increase particle stability against salt induced 
aggregation, extended the circulating duration of the resulting GDV, and cause less 
toxicity due to lung embolism following intravenous administration to mice86,138. This 
effort at solving the problem of aggregation of polycation-DNA particles in serum also
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involved forming the transfection complexes at low DNA concentration (where the 
chance of formation of large aggregates was low) and then concentrating the PEGylated 
complexes up to the required DNA concentration138. The degree of PEGylation had to 
be balanced so as to provide adequate protection of the TfPEI-DNA complex without 
occluding the targeting ligand, and results in this work shows that this balance was 
achieved.
For effective in vivo gene delivery, polyplexes should have a number of properties: (i) it 
should remain non-toxic, small and discrete; (ii) it should bypass the immune system; 
and (iii) it should interact only with the cells of interest. Efforts to prepare polymer 
systems that endow polyplexes with these characteristics are discussed below.
1.4.3.3.1 Salt and serum stabilization
Injection of polyplexes systemically results in particle aggregation, thus limiting 
successful in vivo gene delivery. Although cationic polyplexes are stable in water, they 
aggregate in ionic solutions due to a decrease in the protective electrostatic double layer.
O'! # 9
Polyplexes aggregate rapidly in physiological salt concentration (~150 mM) . Injection 
of PEI-based polyplexes into mice results in 50% lethality, with the likely cause being
o /
blockage of lung vasculature with aggregated polyplexes . In addition to salt-induced 
aggregation, serum proteins readily adsorb onto positively charged particles, initiating 
rapid blood clearance by macrophage uptake (a first step in the removal of polyplexes 
by the innate immune system). PLL-based polyplexes are eliminated quickly with a 
half-life less than 5 minutes. Clearance from blood has been shown to correlate with the 
amount of plasma associated with the particles139. One approach to minimising 
salt-induced aggregation and nonspecific protein or cell surface adsorption is steric 
stabilization with hydrophilic polymers. Steric stabilization can be achieved by grafting 
a 'brush' layer of hydrophilic polymers to the surface of nanoparticles, thereby 
decreasing particle-particle and particle-protein interactions. Hydrophilic polymers used 
for polyplex modification include PEG, pHPMA (poly- 
N-(2-hydroxypropyl)methacrylamide], Figure 1.3), oligosaccharides85,140 and soluble 
proteins. PEGylation and use of pHPMA have shown substantial promise in polyplex 
stabilization and will be discussed in more detail below.
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1.4.3.3.1.1 Stabilization by PEGylation
Efforts to provide salt and serum stabilisation of polyplexes by PEGylation have yielded 
mixed results. The factors affecting the success of PEGylated polyplexes to resist salt 
and serum mediated aggregation include the degree of polymerisation (DP) of the 
cationic polymer, the PEG grafting density, the length of PEG and the method of 
PEGylation. The cationic polymer DP influences the efficiency of DNA binding and 
compaction, and the effects are magnified with low MW polymers. Conjugation of PEG 
to cationic polymers often reduces the charge density of the polymers by reacting away 
cationic amine groups while adding hydrophilic, bulky polymer fragments. Thus, 
PEGylation reduces the DNA-binding efficiency of cationic polymers and alters the 
thermodynamics of DNA condensation as manifested by changes in polyplex structure. 
PEGylation of PEI (MW 2000, 'PEI2K', DP ~ 45) resulted in polyplex structures with 
thick threads and donuts, which were incapable of DNA transfection. On the other hand, 
PEG-PEI25K condensed DNA to small dense granules without extended threads141. 
Similarly, PEGylation of PLL4K (DP =19) altered the polyplex structure from toroids 
to rods. In addition, these structures were not stable against salt-induced aggregation, 
unlike PEG-PLL10K that offered salt stabilisation . PEGylation of thermine derivatives 
(~ 4 charges per chain) also prevents DNA condensation142. Vinogradov et a l143 and 
Kwok et a lu  reported successful DNA condensation after PEGylation of short 
polycations (PEG-PEI2K + PEG-Polyspermine and AlkCWK18, respectively). The 
PEI2K-PEG complexes are stable at physiological salt conditions and the PEG-CWK18 
complexes give high concentrations in water.
Steric stabilisation occurs by protection of particle surfaces with hydrophilic polymers. 
The thickness of the protective layer, i.e. the MW of PEG, therefore influences the 
degree of particle protection. Analysis of plasma protein adsorption to PEG-coated 
nanoparticles of sizes 160 to 270 nm as a function of PEG thickness revealed decreased 
protein adsorption with increased MW. PEG2K reduced protein adsorption by 43%, 
while PEG5K reduced protein adsorption by 73%. Further increases in PEG length offer 
only marginal increases in protein protection, indicating PEG5K to be a critical length 
for steric stabilisation of nanoparticles in this size range144. Indeed, PEGylation of 
PEI-based polyplexes with PEG3400 only slows salt-induced aggregation, while
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PEG6K completely prevents aggregation in physiological salt conditions. PEG6K was 
also more effective than PEG3400 in preventing complement activation and serum 
binding145.
The density of the PEG layer also influences the degree of stabilisation. PEGylated 
nanoparticle studies determined the threshold PEGylation density (by weight %) for 
maximum reduction of protein adsorption to nanoparticles to be 5%, with total adsorbed 
protein content decreasing as PEG density increased. The average distance between 
PEG strands at this density was calculated to be 1.4 nm144. It should be noted that while 
PEG significantly decreases protein adsorption, it cannot be completely eliminated due 
to the inability to completely coat particle surfaces. Nevertheless, protection from 
complement activation by PEGylation of PEI/DNA complexes depends on the amount 
of PEG associated with the particle surface145. Incorporation of PEG into polyplexes, in 
addition to providing salt and serum protection, can also reduce non-specific cellular 
uptake as a function of PEGylation density. PEG5K-PEI25K particles have reduced 
transfection potential that is dependent on PEG grafting density in the PEI: 10% 
modification of PEI amine groups renders the polyplexes completely inactive141. 
PEG550PLL25K polyplexes transfect optimally with 10% PEG grafting. Further 
increases in PEGylation reduce transfection, most likely by inhibiting uptake. Increasing 
the density of high MW PEG also affects the DNA-binding affinity of the cationic 
polymer, both by sterically interfering with DNA binding interactions and by reducing 
the number of cationic charges available for binding. High PEG:PLL ratios in 
PEG5K-PLL10K polymers result in decreased DNA binding and polyplexes with 
worm-like structures83. Therefore the following dichotomy exists: higher grafting 
densities and longer PEG chains are necessary to maximise salt and serum stabilisation; 
however, these conditions lead to particle destabilisation and low transfection 
efficiencies. An approach to circumvent this problem is to PEGylate the cationic 
polymers after polyplex formation in order to minimize disruption of DNA binding.
Two groups have demonstrated post-polyplex formation PEGylation. Ogris et al 
modify transferrin-PEI (Tf-PEI) or PEI-based polyplexes by reacting activated PEG5K 
to primary amino groups in the PEI molecules86. This PEGylation method therefore 
modifies only surface-available amine groups and prevents polyplex instability due to
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the PEG polymers trapped in the polyplex core. One-third of the primary amine moieties 
in PEI were modified without any change in polyplex size. In addition, the PEGylated 
particles were stable in ionic solutions up to 70 mM. PEGylation prevented 
plasma-mediated aggregation and significantly increased blood circulation (33% of the 
PEGylated particles remained in blood 30 minute after injection in mice versus 6% of 
unmodified particles). In addition, tumour-site gene expression was increased after 
systemic gene injection of PEGylated DNA/Tf-PEI complexes over unmodified 
complexes. Finsinger et al also PEGylated preformed PEI and PLL polyplexes by the 
addition of anionic peptide-PEG conjugates145. The anionic peptide self-assembled to 
the polyplex surface by electrostatic interactions. The coated particles also retained their 
size and demonstrated steric stabilisation against physiological salt conditions and 
proteins such as BSA.
1.4.3.3.1.2 Stabilization with HPMA
Seymour and colleagues focused on particle stabilisation using the hydrophilic polymer, 
HPMA. Initial work concentrated on PLL grafting with HPMA. The copolymers formed 
were capable of binding to and condensing DNA and these copolymers slightly
oc
increased polyplex solubility . In more recent years, Seymour et al have also explored 
the modification of preformed complexes. Modification of preformed complexes 
involves HPMA grafting to PLL based particle surfaces in order to minimize disruptive 
interactions with the PLL/DNA core 146. Complexes modified with monofunctional 
HPMA were stable in 150 mM salt solutions and relatively inert to serum protein 
binding. In spite of the encouraging in vitro results, the monofunctional HPMA-coated 
particles still suffered from low circulation lifetimes since they showed no improvement 
over unmodified complexes. A possible explanation for the lack of increased circulation 
time is the reversibility of polymer/DNA interactions, as was demonstrated by heparan 
sulphate displacement of the polymer from the DNA146. A major difference between the 
aforementioned modified polyplexes and Stealth liposomes that have long circulation 
times is the lateral stabilisation between lipids147. Polyplexes can be further stabilised by 
crosslinking polymer strands on particle surfaces, and efforts to crosslink preformed 
polyplexes are discussed below.
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Figure 1.3 Structure o f  pHPMA polymer bearing pendant tetrapeptide (Gly-Phe-Leu-Gly) side chains 
terminating in reactive 4-nitrophenoxy groups.
1.4.3.3.1.3 Stabilization by crosslinking o f polyplex surfaces
Seymour and coworkers further stabilised PLL-based polyplexes by including multiple 
reactive pendant groups on the HPMA that react with the primary amino groups of PLL 
and effectively crosslink PLL chains while coating the polyplex with HPMA polymers. 
The resulting complexes were negatively charged, discrete and spherical, and 
demonstrated serum stability and decreased non-specific cellular uptake147. 
Oligolysine-based polyplexes crosslinked by glutaraldehyde improved particle stability 
in that they exhibited enhanced resistance to serum endonucleases148. Transfection of 
these crosslinked, particles to cultured cells gave low, steady-state gene expression for 
10 days. Crosslinked polyplexes can also demonstrate increased salt stabilization. 
Cationic polyplexes crosslinked with a short crosslinker were stable in salt solutions for 
at least 7 days; however, they were unable to provide gene delivery and were resistant to 
polymer displacement by dextran sulphate149. A proposed mechanism for stabilization 
by crosslinking is 'caging' of the DNA by preventing crossbridging of polymer chains 
between polyplex particles. While these crosslinking experiments demonstrate
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important concepts for particle stabilization, future cross-linking methods need to be 
more labile to allow for DNA release after internalization.
1.4.3.3.2 Complement activation
Plank et al. reported that complement activation could limit the circulation half-life of 
polyplexes in vivo150. However, the complement-mediated haemolysis was obtained at 
elevated polymer concentrations with high molecular weight polymers. Additionally, the 
potential for complement activation by cationic polymers was found to strongly depend 
on polymer chain length; cationic oligomers were weak activators of the complement 
system150,151. Polymer complexation with DNA also greatly reduced the potential for 
complement activation. Dash et al. studied the mechanisms for polyplex clearance from 
the blood and found minimal contributions from complement at the concentrations
11Qtested . Therefore, while complement activation should be monitored for stabilised, 
long circulating polyplexes, it may not be a major mechanism of polyplex clearance for 
stabilised particles at concentrations that are appropriate for gene delivery.
1.4.3.3.3 Toxicity
Toxicity, is a major drawback of polyplexes that has limited their progress in clinical 
trials. Although the molecular basis of toxicity is unclear, the polycationic nature of the 
polymers appears to be the main origin of toxicity. Thus, recent efforts to develop 
polymers with reduced toxicity have focused on low molecular weight polymers, 
biodegradable polymers and polymers with reduced cationic charge density.
Both polylysine and polyethylenimine complexes with DNA suffer from high toxicity in 
mammalian cells. The L D 5 0  of high molecular weight forms of these polymers (25 kDa)
1 ^ 9 1 Oin mice range from 5 to 30 mg/kg when complexed to DNA ’ . Low molecular
weight (MW) preparations of PEI154 and PLL155 are significantly less toxic to cultured 
cells. In addition, low molecular weight chitosan demonstrates significant increase in 
tolerability in vitro over long-chain chitosan156. The lower molecular weight polymers 
are likely to have a higher packing efficiency on the DNA, resulting in less excess
1 <7positive charges on the polyplex . Biodegradable polymers such as poly(beta-amino
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esters) also have reduced toxicity, possibly as a result of reduction to smaller units after 
internalization . Polymer detoxification has also been achieved by reducing cationic 
charges. Glycolylation of amine groups in PEI reduces the number of free amines and 
introduces hydrophilic residues. Glycolylation of 70% amine groups resulted in a 
polymer with low cytotoxicity even at an N:P ratio of 30. PEGylation of polylysine by 
reacting with the primary amine groups also reduces the polymer amine content and 
yields polymers with significantly lower toxicities85,159. Polymers with high charge 
density, e.g. PEI and PLL, tend to have higher toxicities. Although the molecular 
mechanisms leading to cell death when cultured cells are exposed to polycations is not 
completely understood, it is clear that the spatial arrangement of charge along the 
polymer backbone has significant effects on the pathways leading to cell death. Thus, 
the polymer structure must be designed to effectively bind and condense DNA and to 
interact sufficiently strongly to protect the DNA from nucleases yet have arrangements 
of the charge sites that minimise toxicity.
1.5 C e l l u la r  B a rr iers
An effective gene delivery system will need to bind to an appropriate cell (targeting), be 
internalised (usually by endocytosis), escape the degradative pathway (endosomal 
escape) and ultimately allow delivery of the expression plasmid to the nucleus (nuclear 
uptake)94. Viruses have perfected these mechanisms and are often used as templates in 
designing of polymer based non-viral gene delivery systems. Some of the approaches 
taken to by researchers to surmount these obstacles are reviewed by Pouton and 
Seymour94.
1.5.1 T he ba r r ier  of the  pla sm a  m e m b r a n e
The plasma membrane in non-dividing cells is a formidable barrier for macromolecules. 
Most macromolecules and particles have low solubility in lipid bilayers, thus limiting 
their uptake into cells by means of passive diffusion into cells160. Uptake of most 
marcromolecules or particles occur into cells by pinocytosis, adsorptive endocytosis, 
receptor mediated endocytosis or phagocytosis161,162. When the endocytosis inhibitor 
cytochalasin B was added to the medium during transfection in vitro, transfection was
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inhibited163. In addition, electron microscopy images of gold-labelled plasmid have
107revealed an entry process typical of endocytosis . Clathrin-mediated endocytosis is the 
major pathway for uptake of receptor-ligand complexes, including the transport 
mechanisms for transferrin and low-density lipoprotein (LDL)160. The formation of 
clathrin/AP2 adaptor-coated vesicles at the plasma membrane is preceded by the 
formation of a clathrin-coated pit, when there is concomitant mechanical invagination of 
a patch of membrane (associated with the formation of a clathrin polyhedral lattice) and 
sorting of selected membrane proteins into the pit. The invagination process continues 
under the control of a number of accessory/regulatory proteins until a mature vesicle is 
‘pinched off the parent membrane. The vesicle coat, which consists mainly of 
mechanical clathrin scaffold and adaptors, is removed to allow the vesicle to fuse with 
its target membrane164. At least three other pathways of endocytosis have been 
described: i) macropinocytosis is induced in response to mitogenic factors and involves 
the formation of large, heterogeneous ‘macropinosomes’. This mechanism may be 
responsible for the uptake of large lipoplexes or polyplexes by dividing cells in culture, 
ii) Non-coated vesicle formation can contribute to bulk pinocytosis and some receptor- 
mediated events, iii) Caveolae have been implicated in endocytosis and transcytosis 
involving uptake into endothelia from the vasculature165. Some receptor-mediated 
endocytosis takes place preferentially into caveolae including folate uptake and some 7- 
transmembrane domain cell surface receptors166.
Ligand-mediated endocytosis are employed either to coffer rapid uptake or 
specific/selective uptake of gene delivery particles. The use of ligand-mediated 
endocytosis for the purpose of targeting liposome and cationic polymer vectors have 
already be reviewed in section 1.4.3.1 and section 1.4.3.3. Transferrin has been 
extensively used for ligand-mediated delivery of plasmid DNA into cells in
O /  1 / ' ' I  1 / O  I  /" Q
vitro ’ 5 ’ . Cells of various phenotypes express transferrin receptors, so the use of
transferrin does not offer opportunities for receptor mediated targeting but it does offer a 
means of rapid uptake. Peptide sequences that have affinity for integrins (heterodimeric 
membrane proteins found on all cells and important for attachment of cells to the 
extracellular matrix, cell-cell interactions and signal transduction), have been used to
1 7 0  171 1 7 7improve uptake of cationic lipid-based GDV into cells in vitro ’ and in vivo . The 
low transfection activity of non-viral gene delivery systems in vivo is partly indicative of
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the lack of rapid uptake mechanisms for these systems in the absence of mitotic 
activity95,96,173. Therefore the inclusion of ligands to increase the rate of uptake of 
particles is important to the success of non-viral gene therapy.
1.5.2 T he ba r r ier  of e n d o so m a l  d eg r a d a t io n
The default pathway particles taken up by endocytosis, in the absence of a mechanism 
of escape or a trafficking mechanism (which directs the particle to a specific 
intracellular organelle) will be fusion with lysosomes, resulting in degradation of 
biodegradable systems160. The implication is that a specific or generic means of escape 
is required, or much of the internalised DNA will be lost by degradation. Biological 
events like entry of viruses and toxins into cells, the action of antibacterial peptides, 
defense toxins, or the performance of complement, defensins, and perforins of the 
vertebrate immune system are examples demonstrating how efficiently nature can 
modulate membrane barriers. A series of natural membrane destabilizing agents has 
been characterised on the molecular level. In several cases the membrane-active 
principle was found to be located in defined, small amphipathic peptide 
domains174,175,176,177,178. Synthetic peptides derived from the N-terminus of influenza 
virus haemagglutinin167,179,180,181 and the rhinovirus VP-1 protein182, or artificial 
amphipathic peptides167,183,184 have been used. Of the fusogenic/fusion peptides of viral 
origin known, the N-terminal sequence of influenza virus haemagglutinin HA-2 is the 
most studied or used for gene therapy1,2,185,186,187,188. The ability of influenza virus to 
escape from the endosome depends on a conformational change in the haemagglutinin 
(HA) at the low pH of the endosome (between 5 and 6) to expose a fusogenic peptide 
sequence189, which in itself changes conformation to form a membrane disruptive 
amphiphilic a-helix167. Fusogenic peptides sequences based on the N-terminal sequence
170 1fi1of the influenza virus haemagglutinin HA-2 have the ability of disrupt liposomes ’ 
and cause erythrocyte lyses167. The erythrocyte lysis activity (rather than the liposome 
disruptive activity) of fusogenic peptides was particularly shown to correlate with 
enhancement of gene expression when fusogenic peptides were complexed through 
ionic interactions to polylysine-transferrin/DNA complexes167. It is this ability of 
fusogenic peptide sequences to disrupt membranes at low pH that has been exploited to 
enhance gene expression mediated by polylysine/DNA/fusogenic peptide complexes.
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The following discussion will look the main groups of non-viral gene delivery agents 
(cationic liposomes and cationic polymers) and how researchers are working to meet the 
cellular requirements for endosomal escape in order to improve gene delivery.
1.5 .2 .1  E n d o so m a l  e s c a p e  o f  c a t io n ic  l ip id -b a s e d  v e c t o r s
Although lipidic systems are the most progressed non-viral systems in terms of reported 
work in vivo and clinical trials, their development has usually been empirically 
driven57,190. The need for further improvement in transfection efficiency in vivo is 
however leading to the gradual departure from synthesis of the ‘magic’ lipidic structure, 
and towards incorporating features of viruses to overcome cellular barriers.
Complexes of DNA and cationic lipids can bind to the cell surface by charge 
interactions3,191,192. Experimental data suggest that uptake proceeds via endocytosis65,107, 
193,194 and can be observed in membrane bound perinuclear vesicles107. The mechanism
107by which lipoplexes escape the membrane bound vesicles is not well understood but 
the release of DNA from the endosome to the cytoplasm, release of DNA from the 
cationic lipid, and transfer to the nucleus107,195 are considered to represent bottlenecks in 
lipid-based gene transfer. The cationic lipids may mix with the cellular anionic 
lipids195,196 which may trigger destabilisation of the endosomal membrane. Gene
107expression can be enhanced by the inclusion of helper lipid DOPE to lipoplexes , 
DOPE presumably induces destabilisation of the endosomal membrane by membrane 
transition to the inverted hexagonal phase198,199.
The activity of lipoplexes (in the presence or absence of another DNA-binding protein) 
has been enhanced by mixing with Sendai virus envelopes200,201. This approach and 
related systems utilizing neutral lipids and liposome-like reconstituted envelopes 
("virosomes") based on Sendai virus (which triggers membrane fusion at the cell
707 7H7 • » •surface) ’ or influenza virus (which promotes delivery via fusion with the
endosomal membrane after endocytosis)204 have been found effective for gene delivery.
The amphipathic cationic peptide gramicidin S was included into a DOPE lipid/DNA 
composition; this has been found to strongly facilitate DNA delivery205,206.
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Incorporation of gramicidin S and DNA into asialofetuin-labeled liposomes was used 
for receptor-mediated gene transfer into primary hepatocytes . Wagner et al. and 
Kamata et al.209 have investigated the influence of influenza-based peptides on cationic 
lipid-based transfection. When positively charged lipospermine/DNA complexes were 
used, only a slight but significant (3- to 30-fold) enhancement of the gene expression
a^o 700was obtained by association with the peptides . Kamata et al. showed that 
influenza-derived peptides could increase the level of gene expression of a lipofectin 
formulation by up to 5-fold, in related findings. Thus, escape from endocytic vesicles 
seems to be no major barrier for optimised, positively charged DNA/lipospermine or 
lipofectin complexes. However, for less positively charged lipospermine complexes 
gene transfer efficiency was found to be increased by a factor of 50 to 1000 by synthetic
7A 0
peptides INF6 (influenza virus derived sequence) and INF 10 (artificial sequence) . 
Simoes et al. formed ternary complexes by ionic interactions of lipoplexes (DOTAP 
with or without DOPE) with GALA or HA-2 derived fusogenic peptides and showed 
that negatively charged ternary lipoplexes were efficient at transfection in vitro, and 
proposed the possibility of reduced interactions with negatively charged
710macromolecules in vivo. The real test will be how these systems perform in vivo . 
Wilke and colleagues generated novel DNA complexes containing a palmitoyl modified
1 77DNA-binding peptide . They demonstrated that association with an influenza peptide 
strongly enhances transfection activity. Gene transfer was found to be restricted to 
mitotic cells. The fact that mitotic activity (and subsequent disruption of the nuclear
711 717membrane) is required for transfection ’ , suggests that nuclear entry of DNA from
lipoplexes are takes advantage of the cellular disruptions that occur during mitosis. 
Although in vitro experimental results with these complexes are encouraging, in vivo 
results with these complexes have not yet been reported, and it remains to be seen if 
these complexes can meet the demands of the in vivo environment for successful gene 
delivery.
1 .5 .2 .2  E n d o so m a l  e s c a p e  o f  ca  t io n ic  p o l y m e r -b a s e d  v e c t o r s
Although cationic polymer-based gene deliver vectors have progressed slowly towards 
in vivo transfection success and clinical trials, they probably hold more promise of
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overcoming the extracellular and cellular obstacles to a successful gene delivery vector 
than do cationic lipid because of one main reason: cationic polymer-based GDVs have a 
large number of reactive sites available for the attachment of various ligands that may 
promote uptake of DNA/polymer complexes or provide a favourable intracellular 
trafficking pathway for the DNA/polymer complex. However, as it will be discussed 
later, the presence of these numerous unprotected reactive sites are a drawback if the 
aim is to produce a well defined, homogenous GDV.
Strategies for the delivery of DNA into target cells have been developed that are based 
on the construction of artificial viral-like particles incorporating only activities required 
for efficient DNA transport and expression but avoiding viral genomic information2,35. 
Complexes of DNA with ligand-polylysine conjugates for cellular uptake via 
receptor-mediated endocytosis fulfil some of the requirements of such reconstructed 
pseudo-viral vectors and have been developed extensively during the last years213,214. By 
covering plasmid DNA with polylysine molecules covalently attached to different ligand 
moieties, multimolecular toroid structures can be obtained which are small enough (80-
1 f\7100 nm) to be engulfed by endocytosis . However, these particles lack the ability to 
actively escape from the endosome before reaching the lysosomal compartment, which 
strongly decreases transfection efficiency169,215. In several cell lines, the addition of 
chloroquine or glycerol considerably increases transfection efficiency, presumably 
by interfering with lysosomal degradation and enhancing the release of the DNA into 
the cytoplasm. Adenovirus particles have been incorporated to polymer-based vectors 
supply an endosome escape activity218,219. Addition of replication-defective adenovirus 
particles or rhinovirus particles either to the transfection medium 5 or directly linked
199A  991 0 0 0to the PLL-DNA complex ’ ’ was found to strongly enhance gene delivery 
through the endosome destabilizing activity. Cotten et al. showed that it was possible to
completely inactivate the viral genome, by treatment with methoxypsoralen plus
0 0 0irradiation and still retain endosmolytic activity carried by the viral capsid . Although 
the adenovirus-enhanced trans(ferrin)fection system is highly efficient of in vitro and in 
ex vivo gene therapy, in vivo gene transfer efficiency however are relatively low, and 
further optimization is required108,109.
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Virus-free, synthetic systems have been generated containing specific cell binding 
ligands and synthetic membrane-destabilizing (fusogenic) peptides. Analogues of the 
23 N-terminal amino acids of HA-2 ionically bound to polylysine-DNA complex (see 
Figure 1.4) has been shown to have endosome disruptive properties in a pH dependent 
manner and improve transfection efficiency1. The addition of fusogenic peptides of 
viral origin to the DNA-polylysine complex provides endosome escape activity in the 
absence of a viral genome, but is not able to fully reproduce the efficiency of the whole 
viral particle1,167.
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F igure  1.4 Schematic representation o f the assembly o f a quaternary gene transfer complex containing 
peptides ionically bound to polylysine. Abbreviations used are: TF/Tf, transferrin; TfpLys, transferrin- 
poly (L-lysine). Adapted from  reference 167.
Peptides have been incorporated into polylysine/DNA complexes by i) covalent linkage 
to polylysine179,181 (ii) biotinylation and subsequent binding to polylysine-modified 
streptavidin167 or (iii) noncovalent ionic interaction of the acidic, negatively charged 
peptides to positively charged DNA/polylysine complexes167,183. Often the DNA 
complexes also contained conjugates of polylysine with ligands for receptor-mediated 
endocytosis, but the effects of peptides were not dependent on the presence of a ligand. 
By the incorporation of the peptides, gene transfer was strongly (10 up to > 1000-fold) 
enhanced in several cell lines. The enhancement of gene expression was strongly
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dependent on the peptide sequence. Investigations with influenza HA-2-derived 
sequences showed that the transfection levels largely correlate with the capacity of 
peptides to disrupt liposomes of natural lipid composition or erythrocytes in a 
pH-specific manner ’ . The hypothesis that the peptides enhance transfection activity
by endosomal release is supported by the observation that the block of endosomal 
protonation by the specific inhibitor bafilomycin A reduces gene transfer activity167. 
There has as yet not been any reported in vivo work using polylysine/fusogenic 
peptide/DNA complexes.
The effect of membrane-active peptides on gene transfer with other polycation/DNA 
complexes has also been evaluated. Gottschalk and colleagues replaced polylysine by 
the lysine-rich DNA-binding peptide K8 (sequence: YKA(K)gWK). Transfections with 
DNA/K8 complexes resulted in modest expression levels; incorporation of an 
endosomolytic peptide, JTS-1, into these complexes enhanced gene expression by up to 
>1000-fold, similarly as previously seen with DNA/polylysine/peptide complexes. 
Wyman et al. have described another approach, which applies the cationic amphipathic 
peptide KALA (repeats of lysine-alanine-leucine-alanine) to serve for both DNA 
binding and membrane destabilization224. Efficient transfection of K562 and CV-1 cells 
was obtained with KALA/DNA complexes at a 10/1 (+/-) charge ratio. The efficiency 
was about 100-fold greater than found for polylysine/DNA complexes, but about 
10-fold lower than with an optimized dendrimer developed by the same research lab 
(see below).
A positively-charged polyamidoamine cascade polymer ("dendrimer") has high 
transfection potential already in the absence of any membrane-active agent, as described
I'Xin . The polymer can be regarded as an endosomal buffering agent because of the low 
pKa of the terminal amines (6.9) and internal amines (3.9). This might prevent 
lysosomal degradation of the DNA and destabilize the endosomal/lysosomal vesicle. In 
agreement with this hypothesis, for optimum efficiency rather high dendrimer to DNA 
charge ratios (amine: phosphate, 6:1) have to be applied. At lower charge ratio (1:1, 
when amines are neutralized by the phosphates) the transfection activity is lost. When 
the pH-specific membrane destabilising peptide GALA184 (’GALA1, contains repeats of 
the motif Glutamic acid-alanine-leucine-alanine) is covalently attached to the
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dendrimer, the transfection activity of the electroneutral complexes is recovered .
Similar findings were reported by using DNA complexes with the cationic polymer 
polyethylenimine PEI15. PEI is only partially protonated at physiological pH (only one of 
approximately 3-6 amino nitrogen molecules protonated). Upon acidification within the 
endosome/lysosome, PEI acts as proton sponge, with the protonation presumably 
triggering osmotic swelling and destabilisation of the endosomal/lysosomal vesicle. In 
order to improve transfection efficiency, cell-binding ligands have been incorporated by
>y<y c
covalent linkage to PEI . Incorporation of cell-binding ligands (transferrin or anti CD3 
antibody) into DNA/PEI complexes resulted in an up to 100-fold increased transfection 
efficiency through the mechanism of receptor-mediated endocytosis. Notably, high-level 
gene expressions were found in the absence of chloroquine or DNA complex-linked 
adenovirus. Transferrin-PEI-mediated gene transfer can be significantly (up to 10-fold)
99^augmented by the addition of an endosome-destabilizing influenza peptide . Again, 
like with dendrimer but in contrast to the findings with polylysine or related peptides, 
the transfection is not strongly dependent on the presence of endosomolytic agents.
Wells and Fominaya have used genetic molecular biology techniques to engineer a 
modular multidomain DNA carrier protein (based on Pseudomonas exotoxin A) which 
has cell specific gene transfer ability but still needed polylysine to facilitate the
99 f\condensation of the protein-DNA complex . Whilst this approach may be more 
economical than chemical synthesis of large peptides/protein in large-scale manufacture, 
it is a very time consuming and tedious process which limits its use in research. It 
demonstrated however that a single multifunctional gene transfer agent could improve 
the transfection efficiency of DNA with a high degree of cell selectivity in vitro.
1.5.3 Th e  ba r r ier  of la c k  of tr a n spo r t  within the c y to pla sm
Much research activity has focused on endosomal escape, the implication being that 
delivery to the cytoplasm would enable the particle to approach the nuclear envelope. 
However, the cytoplasm is a viscous fluid and diffusion of macromolecular particulate 
systems within this medium is slow227, 228,229. Escape early in the endosomal pathway 
may leave a condensed particle stranded some distance from the nuclear envelope.
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Microinjection of plasmid into rat myotubes near the boundary of the nucleus resulted in 
a 56% rate of transfection, compared to 8% when injected 60 to 90 nm distal to the
Q9nucleus . The transport of colloidal systems from one site to the other is a vital cellular 
process, but it is not a passive process. Vesicles, organelles and other colloidal 
structures are transported actively using molecular motors associated with the 
microtubule network or actin microfilaments230 231>232’233’234. Movement along 
microtubules is mediated by two classes of motor proteins in an orientated manner. 
Kinesins (+ kinesin-associated proteins) direct movement in an outward direction, 
usually linked to the secretory pathway while Dyneins (+ dynactin) move vesicles in the 
inward direction, normally associated with the endocytic pathway. The complex system 
of the secretory pathway at the molecular level is rapidly being unravelled. Viruses 
appear to have evolved mechanisms to use the dynein system, which directs vesicles 
from the endosome toward the perinuclear region. It is possible that binding domains for 
dynein could be present within viral capsids, allowing active transport of the virus in the 
cytoplasm.
The method of genetic mutation employed by biochemists to study the natural role of 
transport proteins, amongst others, has yet to be applied to the study of gene delivery 
vehicles. Gene therapy scientists have begun to explore the fate of transfection 
complexes once in the cytoplasm. Injection of naked DNA into Xenopus oocytes gave 
negligible expression but injection of either PEI or poly-L-lysine polyplexes into the 
cytoplasm of cells resulted in expression ’ . Researchers found that higher molecular
weight poly-L-lysines/DNA complexes gave higher expression levels following 
injection into the cytoplasm. This observation suggests that polylysine probably protects 
DNA from nuclease degradation and that higher molecular weight poly-L-lysines 
provide better nuclease protection. An alternative explanation put forward by Wolfert 
and Seymour was that higher positive zeta potential of pLL/DNA complexes provided 
enhanced nuclear delivery by binding to nuclear-import protein . Lipoplexes have also 
been injected into the cytoplasm. Zabner et al. and Pollard et al. found no expression 
following cytoplasmic injection of DOTAP or DMRIE/DOPE lipoplexes
107 9^ 5respectively ’ . Nuclear injection of lipoplexes also results in no expression unless
1 07the charge ratio is below neutrality . The reason for expression following cytoplasmic 
injection of polyplexes but not lipoplexes may be because of the presence of cationic
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residues on the surface of polyplexes which may act as nuclear localisation signals 
(NLSs) enhancing nuclear uptake (section 1.5.4) and/or due to the large size of the large 
size of lipoplexes.
For gene delivery vehicles to be effective in mediating gene delivery, following 
endocytosis, the must be utilising the cytoplasmic transport system to some extent. For 
example, Zabner et al observed that lipoplexes, which remained within endosomal
107vesicles, appear to localise to the perinuclear region . Also depolymerisation of 
microtubules and inhibition of microfilament formation by vinblastine and cytochalasin 
B respectively, prevented movement of DNA within endosomes and lysosomes towards
9^ 7the nucleus, resulting in reduced expression . It seems likely that cytoplasmic transport 
is a limitation in non-viral gene delivery but these issues have yet to be adequately 
resolved.
1.5.4 The ba r r ier  of the n u c l e a r  m e m b r a n e
The barrier of the nuclear membrane of non-dividing cells to macromolecules and 
particles that are not actively transported is formidable and has been demonstrated by 
the observation that a 1000-times more plasmid copies are required to achieve 
expression following injection into the cytoplasm compared with direct injection into 
the nucleus . Pouton has discussed the importance of the recognition of 
oligopeptide sequences termed nuclear localisation signals (NLS), which mediate the 
uptake of nucleoproteins, in a review of the requirements for active nuclear uptake of 
polynucleotides and supramolecular complexes. Sebestyen et al.239 and Ciolina et al.240 
have both reported the enhancement of nuclear uptake of modified plasmid DNA, but 
not expression of reporter protein, following the linking of NLS sequences to DNA and 
incubating with digitonin-permeabilized cells. The preservation of the function of NLS 
sequences in a GDV after endocytosis and endosomal escape to provide a significant 
enhancement of transduction in non-dividing cells in vitro and particularly in vivo 
remains a challenging prospect.
The nuclear membrane prevents uptake of the majority of macromolecules greater than 
70 kDa into the nucleus, unless they are able to interact with the nuclear transport
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system241,242,243. Poor access of DNA plamids to the nucleus represents a major barrier 
to the success of non-viral gene therapy107,173. Dividing cells are easier to transfect as 
the DNA may enter the nucleus prior to the end of telophase and nuclear envelope 
reassembly. Wilke and colleagues found that over 40% of expressing HeLa or NIH3T3 
cells occur as adjacent pairs with comparable expression, suggesting they are the 
products of a previous mitotic event1'3. Feldherr and Akin244, found that the rate of 
nuclear uptake was also slower in non-dividing confluent NIH3T3 cells compared to 
dividing NIH3T3 cells. Since most of the target cells in vivo are in a non-dividing 
(quiescent) state the aim of non-viral delivery development must be the improvement of 
gene expression within in vitro models of quiescent cells.
Research on viral tropisms suggests that some viruses have evolved means of
A J f A < / *\AQ
interaction with nuclear transport systems ’ 5 ’ , and there is a good chance that
active transport can be utilized for delivery of plasmids . The nuclear transport system 
involves both stationary components and mobile factors acting in concert to move 
macromolecules through the nuclear pore complex (NPC). The nuclear membrane of 
mammalian cells usually has several thousand NPCs embedded in them. The NPC 
allows passive diffusion of molecules up to diameters of 9 nm, although even smaller 
nucleoproteins, such as histones, are actively transported through the NPCs. 
Nucluoproteins include motifs terms nuclear localization signals (NLSs), which interact 
with cytosolic receptors known collectively as importins, and initiate the active transport 
of nucleoproteins through the nuclear pore into the nucleus . Nucleoprotein NLSs do 
not have a strict consensus sequence but are characterised by clusters of four or more 
cationic residues and are often flanked by the a-helix-breakers, proline or glycme . It is 
clear that poor access of DNA plasmids to the nucleus represents a major barrier to the 
success of non-viral gene delivery. Researchers are studying the possibility of including 
NLSs sequences to gene delivery vehicles to improve uptake of plasmids into the 
nucleus and ultimately to improve transfection efficiency239,240.
Another group of researchers are investigating the role of DNA base sequences 
indirectly promoting plasmid DNA uptake. Work by Dean has suggested that plasmid 
sequences can mediate nuclear localisation in non-dividing cells without the need for 
nuclear localisation peptides249. Nuclear import was found to be sequence specific: a
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region of SV40 DNA contains binding sites for many transcription factors. Since these 
transcription factors contain NLSs to facilitate their nuclear targeting/uptake and bind 
DNA, they may interact with the cytoplasmic DNA and then shuttle it to the nucleus. 
Nuclear targeting sequences were shown to be able to mediate increased expression in 
liposome and polycation- transfected non-dividing cells in a cell-specific manner250. 
This result is significant, as the level of expression obtained in non-dividing cells has to 
date been low. The barrier of the nuclear membrane will have to be overcome in order 
to improve gene delivery to non-dividing cells.
1.6 A im s  a n d  O b je c t iv e s
Commercially available polylysine used in polymer-based vectors are very 
heterogeneous, containing between 50-200 lysine residues, based on viscosity 
measurement and molecular sizing chromatography . Such a high degree of 
heterogeneity is less than ideal in the development of a gene delivery product. 
Gottschalk et al. showed that shorter and chemically pure 13-mer peptide, K8, (with 
eight lysine residues in a central cluster) was better than commercially available 
polylysine in condensing DNA and was much less toxic167.
The dependence on commercially available polylysine to condense DNA has meant that 
many attempts to construct a synthetic virus-like gene transfer agent utilise a multi­
staged process of self-assembly by spontaneous electrostatic interactions of charged 
reagents1,35,167, as illustrated in Figure 1.4. Other attempts that have been made by some 
researchers to depart from the reliance on commercially available polylysine involved 
the use of a cyclic integrin-binding peptide with a DNA-binding 16-lysine tail (a
1 70 171bifunctional peptide) which has been reported to be effective in vitro ’ and in vivo
1 77(in combination with lipofectin) .
This project involved the design, synthesis, assembly, characterisation and biological 
evaluation of polypeptides that could be used to improve the delivery of plasmid DNA, 
using solid-phase synthetic peptide chemistry. The aim of this project was to construct a 
single polypeptide which has three components: (i) a biologically active peptide to 
promote the escape of the DNA-polymer complex from the endosome (fusogenic
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peptide), (ii) an oligolysine section to provide a biodegradable DNA-binding region and 
(iii) a ligand to promote receptor-mediated uptake.
The approach taken was to biologically test the initial bifunctional construct using in 
vitro and in vivo transfection experiments before making modifications to it in order to 
overcome any in vivo barriers to gene delivery that would be encountered. The N- 
terminal sequence of influenza virus haemagglutinin HA-2 was used as a template to 
synthesize analogues of fusogenic peptides linked to an oligolysyl chain as a first step 
towards a synthetic virus-like gene transfer agent.
Chapter 2 describes the synthesis of membrane-active fusogenic peptides and DNA- 
binding oligolysyl peptides, and novel bifunctional peptides that combine the two 
capabilities: DNA-binding and endosomal escape. A schematic representation of how a 
bifunctional peptide might interact with plasmid DNA is shown in Figure 1.5.
Attempts were also made to synthesize and purify fusogenic peptides with 
oligo/polylysyl and oligo/polyhistidyl chains. The investigation of the effect of charge 
ratio on the ability of bifunctional peptides to promote gene transfer in mammalian cells 
in vitro and comparison with ternary complexes consisting of membrane-active 
fusogenic peptides and DNA-binding oligolysyl peptides are described in Chapter 3. 
Also the initial investigation into effect of a novel fusogenic peptide with an oleoyl 
attachment on the transfection efficiency of a cationic lipid is described in Chapter 3. 
Physical characterisation of bifunctional peptides (particle size and zeta potential 
measurements) and investigation of the effect of serum, serum albumin and chloroquine 
on the in vitro transfection efficiency of bifunctional peptides are also described in 
Chapter 3. Chapter 3 also describes the in vivo transfection activity of bifunctional 
peptides following intramuscular and intratumoural injection in mice.
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Figure 1.5 Schematic representation o f  two-step ternary complex formation (left) by ionic self- assembly 
obtained by sequential mixing o f excess oligolysine with DNA followed by addition o f  fusogenic peptide. 
The right pane shows a single-step complex formation o f a binary complex between a linear bifunctional 
peptide consisting o f  a DNA-binding moiety and a fusogenic peptide moiety. The positively charged 
component would interact and condense DNA whilst the negatively charge fusogenic component would 
be repelled by negatively charged DNA towards the surface o f  particle, freeing it to interact with 
membranes.
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2 SYNTHESIS AND PURIFICATION OF PEPTIDES
2.1 In tr o d uc tio n
This chapter describes the synthesis and extent of purification of fusogenic peptides, 
oligo/polylysine peptides, oligo/polyhistidyl polylysine, and bifunctional peptides 
comprising oligolysine coupled to fusogenic peptide sequences with or without 
oligohistidyl sequences. The synthesis and purification attempt at an oleoyl analogue of 
a fusogenic peptide is also described.
2.1.1 O ver v iew  of solid-p h a se  peptide synth esis
Solid-phase peptide synthesis is the step-wise construction of a polypeptide chain 
attached to an insoluble polymeric support. Solid-phase peptide synthesis strategy 
retains the chemistry proved in solution while adding a covalent attachment step that 
links the peptide chain to an insoluble polymeric support. This strategy permits 
unreacted reagents to be removed by simple washing steps without loss of product. A 
schematic overview of this process is shown in Figure 2.1. An overview of the 
chemistry behind the method is described below.
Synthesis proceeds from the carboxyl terminus to the amino terminus of the polypeptide 
to minimize the risk of racemization. The carboxyl group of each incoming amino acid 
is activated by one of several strategies and couples with the group of the preceding 
amino acid. The 7V°-amino group of the incoming amino acid is temporarily protected in 
order to prohibit peptide bond formation at this site. The "temporary" protecting group 
of the A^-amino group of the newly attached amino acid is deprotected (removed) at the 
beginning of the next synthesis cycle. In addition, reactive side chains on the amino 
acids are protected with "permanent" protecting groups. Repeating the synthesis cycle 
extends the polypeptide chain. Excess reagents and high concentrations of reagents 
drive reactions as close to completion as possible. This generates the maximum possible 
yield and highest quality of the final product.
When the peptide has been fully assembled, the side chain protecting groups are 
removed and the peptide is released from the solid support, using conditions that inflict
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minimal damage on labile residues. Following synthesis and cleavage, the product is 
analysed to verify the sequence and, if necessary, can be purified by gel chromatography 
or high performance liquid chromatography (HPLC).
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Figure 2.1 Schematic overview o f  solid-phase peptide synthesis.
2.1.2 TEMPORARY AND PERMANENT PROTECTING GROUPS
The identity of the A^-amino blocking group determines both the synthetic chemistry 
employed and the nature of the side chain protecting groups. The two most commonly 
used A^-amino protecting groups are Fmoc (9-Fluorenylmethoxycarbonyl, Figure 2.2) 
and tBoc (tert-butyloxycarbonyl).
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Figure 2.2 9-fluorenylmethoxycarbonyl (Fmoc).
In Fmoc chemistry, the A^-amino groups are protected using the Fmoc 
(9-fluorenylmethoxycarbonyl) group, while side chain protection is generally provided 
by ester, ether and urethane derivatives of tert-butanol. The Fmoc protecting group is 
base-labile, and is usually removed with a base such as 2 0 % (v/v) piperidine in 
A^A-dimethylformamide (DMF). The mechanism of deprotection of the A^-amino Fmoc 
group is shown in Figure 2.3. Synthesis conditions used in Fmoc chemistry procedures 
are much milder than those employed in tBoc chemistry. In Fmoc chemistry, the peptide 
chain is not subjected to acid solution at each cycle and the final deprotection and 
cleavage step can be achieved using TFA rather than the much stronger HF acid 
conditions required for tBoc peptide chemistry.
At the end of the synthesis using Fmoc peptide chemistry, the side chain protecting 
groups are removed by a single treatment with trifluoroacetic acid (TFA), which also 
cleaves the bond anchoring the peptide to the resin support (see Figure 2.4 and Figure 
2.5 for mechanisms). In tBoc chemistry, the tBoc protecting group is removed with a 
mild acid (usually dilute TFA), and hydrofluoric acid (HF) is used both to deprotect the 










F igure 2.4 Mechanism o f  deprotection o f permanent side chain protection groups using 90%  (v/v) TFA 












F igure 2.5 Mechanism o f  deprotection o f peptide from resin using 90% (v/v) TFA and 10% (v/v) 
scavengers (thioanisole/ethanedithiol/anisole).
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2 . 1.3 A t t a c h m e n t  o f  f i r s t  a m in o  a c i d  t o  s o l i d  s u p p o r t :  a n c h o r i n g
Polyethylene glycol polystyrene (PEG-PS) is the current solid support of choice for
Fmoc chemistry. The PEG incorporated on the resin closely matches the hydrophilic
nature of the growing peptide backbone and side chains. This effects a higher level of
solvation of the growing peptide and thus more efficient coupling and deprotecting 
1
reactions . The PEG-PS resin is available prederivatised with a linker, 
hydroxymethylphenoxyacetic acid (HMPA) as peptide acid resin (PAC-PEG-PS, Figure 
2.6) from PerSeptive Biosystems, Framingham, MA, USA. Attachment of the 
C-terminal amino acid to the PAC-PEG-PS support is by an esterification procedure 
where the activated amino acid is coupled in the presence of 0 .1  equivalent of 
4-dimethylaminopyridine. This method ensures coupling of the first amino acid to the 




F igure 2.6 Peptide Acid PEG-PS resin.
2 .1 .4  C o u p l in g  r e a c t io n s
The carboxyl group of the incoming amino acid must be activated to provide a better 
leaving group and activation generally utilises several methods two of which are 
described as follows: 1) Preactivated active esters/HOAt: These are pentafluorophenyl 
(OPfp) esters of the amino acids. Coupling reactions using preactivated active esters are 
catalysed by l-hydroxy-7-azabenzotriazole (HOAt). The mechanism of the coupling 
reaction is shown in Figure 2.7. 2) In situ activation by HATU: The amino acid 
derivative is mixed with 0-(7-azabenzotriazol-l-yl)l,l,3,3-tetramethyluronium 
hexafluorophosphate (HATU) together with diisopropylethylamine (DIPEA). HATU 
enhances reactivity, reduces racemization and is suited for hindered amino acids and 
difficult couplings252. The mechanism of coupling reaction of amino acid catalysed by 
HATU is shown in Figure 2.8.
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F igure 2.8 Mechanism o f coupling reaction o f  amino acid catalysed by HATU.
2.1.5 P o s t  s y n t h e s is  w o r k -u p
After completion of the automated synthesis, the PEG-PS support to which the peptide 
is attached is washed in succession with DMF, methanol and dichloromethane. After 
thorough drying under high vacuum, the solid support is transferred to a flask for the 
cleavage reaction. When the PAC-PEG-PS support is used to produce the peptide acid, 
cleavage is achieved using trifluoroacetic acid (TFA) plus appropriate scavengers. In 
Fmoc solid-phase peptide synthesis strategy, the protecting group and resin linkage 
design is such that the final release of the peptide chain from the support can be carried 
out without the use of strong acids or bases to provide the C-terminal residue either as 
the acid or carboxamide. Peptides synthesized by this approach are released at room 
temperature by TFA scavenger cocktails with concurrent side chain deprotection. The 
presence of scavengers with the cleavage reagent is required to suppress the damaging 
effect that the carbonium ions, produced during cleavage, can have on amino acid 
residues most at risk to damage (methionine, cysteine, tryptophan and possibly 
tyrosine). Cleavage of peptides containing methionine, cysteine and tryptophan require 
conditions using the mixture TFA/anisole/l,2-ethanedithiol (95:2.5:2.5; v/v/v) as 
scavenging reagents.
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2.2 M a t e r ia l s  a n d  M e th o d s
2.2.1 P eptide sy n th esis
Peptides were assembled on a Millipore 9050 plus PepSynthesizer™ (Millipore Corp. 
Bedford, MA, USA) using Fmoc solid-phase peptide synthesis method (the Atherton- 
Sheppard approach) . All peptides should be assumed as L- isomers, unless 
specifically stated as D- isomers.
Polyethylene-glycol-polystyrene (PEG-PS) (Perseptive Biosystems, Framingham, MA, 
USA), pre-derivatised with a linker group and the first amino acid residue of the desired 
peptide sequence to be synthesized, was used as the solid support resin. For D-amino 
acid peptide analogues, the first amino acid (lysine) was coupled onto PAC-PEG-PS 
(Figure 2.6) in the presence of 0.1 equivalent of 4-dimethylaminopyridine. Amino acids 
protected at the primary amino end with Fmoc and activated as Opfp esters, (Perseptive 
Biosystems) were coupled for 30 minutes in situ using 0.3 M 1-hydroxybenzotriazole 
(HOAt) in N,N-Dimethylformamide (DMF, peptide synthesis grade; Rathbum Ltd, 
Scotland). Where unactivated Fmoc protected amino acids were used, HATU was used 
as the activating/coupling reagent. All coupling reactions were performed using reagents 
at a 4-fold excess of the required molar equivalent. The side chain protection groups for 
the amino acid used were as follows: Asp(tert-butyl ester), Glu(fert-butyl ester), 
Lys(tert-butyloxycarbonyl), Tyr(terf-butyl ether). Deprotection of primary amino group 
was achieved by washing the resin with 20% (v/v) piperidine in DMF for 5 minutes 
followed by the automated removal of piperidine traces by a DMF-wash cycle for 10 
minutes prior to each coupling step. After the final coupling and deprotection step, the 
resin was washed in succession with DMF, dichloromethane (DCM) and diethyl ether 
and dried by passing nitrogen gas.
The removal of side chain protecting groups from relevant amino acids and the cleavage 
of the peptide from the resin and was achieved by treating 1 g of resin with 5 ml of 
Trifluoroacetic acid (TFA)/thioanisole/ethanedithiol/anisole (90:5:3:2) for 4 hours. The 
duration of cleavage from the resin was arrived at by performing small-scale cleavage 
reactions (trial deprotections) at time points 1.5, 2, 2.5, 3, 3.5, 4, 5 and 6  hours after
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adding TFA/scavengers mixture and analysing the precipitated peptide (procedure 
described below) by HPLC (conditions described below). The resin was separated from 
the liquid mixture of peptide/TFA/scavengers by filtrating through a sintered glass 
funnel under vacuum. Removal of TFA from the reaction mixture was achieved by 
adding 5-fold volume petroleum spirit (40-60%) and gently decanting off the petroleum 
spirit layer. This process was repeated twice, leaving a yellow oily liquid residue 
containing a mixture of the cleaved peptide, residual TFA and scavengers. The peptide 
was precipitated by gentle addition of ether (3 x 20 ml) and decanted to remove the 
scavengers. The crude peptide was dissolved in distilled water (sometimes adding a 
drop of ammonia solution to aid dissolution of the fusion peptides sequences which 
have a net negative charge) and lyophilised.
2 .2 .2  S y n th esis  of oleoyl-fuso g enic  peptide
A fusogenic peptide sequence GLF EAIA GFI ENGW EGMI DGWYGK- 
(allyloxycarbonyl) was first synthesized by solid-phase method as described above. An 
allyloxycarbonyl group protected the side chain e-amino of lysine in the sequence 
above, whereas all the other residues requiring side chain protection had tert-butyl 
protection as mentioned above. The resin with the completed peptide sequence and N- 
terminal temporary Fmoc capping was washed in succession with DMF, 
dichloromethane (DCM) and diethyl ether and dried under high vacuum for 1 hour. The 
following procedure to remove the allyloxycarbonyl group was carried out under 
oxygen-free argon conditions, using an Atmos™ bag (Sigma-Aldrich): 
tetrakistriphenylphosphine palladium (0 ) (Pd(PPh3)4 , 1 gram), in a solution of 
chloroform (5 ml) containing 5% (v/v) acetic acid and 2.5% (v/v) iV-methylmorpholine, 
was added to resin in an aluminium foil-covered round-bottomed glass flask under 
argon. The reaction mixture was stirred with a magnetic flea and stirrer for 2 hours. The 
resin was recovered by filtering off (sintered glass funnel) the reaction mixture and 
washing the resin with a solution of 0.5% (v/v) DIPEA and 0.5% (v/v) sodium 
diethyldithiocarbamate in DMF to remove trace metal ions. The resin tested positive to 
a ninhydrin test, confirming that the allyloxycarbonyl group had been successfully 
removed. After drying the resin under high vacuum for 1 hour, a five-fold excess of 
oleoyl chloride (Sigma-Aldrich) to the dried resin in a round-bottomed flask and stirred
48
under argon for 1 hour. The resin was then recovered from the reaction mixture by 
filtering off the excess oleoyl chloride followed by washing the resin in succession with 
DMF, DCM and diethyl ether. The resin was then dried under high vacuum for 1 hour. 
The resin tested negative to a ninhydrin test, confirming that the coupling of the oleoyl 
chain unto the side chain amino group of lysine was successful. The N-terminal Fmoc 
protection group was then removed by adding a 5 ml aliquot of 20% (v/v) piperidine in 
DMF for 5 minutes, followed by washing in succession with DMF, DCM and diethyl 
ether. The peptide was then cleaved from the resin, with the concomitant removal of the 
tert-butyl side chain protecting groups by treating 1 g of resin with 5 ml of 
Trifluoroacetic acid (TFA)/thioanisole/ethanedithiol/anisole (90:5:3:2) for 4 hours and 
precipitating the peptide as previously described above.
2 .2 .3  Peptide purification
The fusogenic peptides were purified using reverse phase high performance liquid 
chromatography (HPLC). Fusion peptides were dissolved in 5% (v/v) acetonitrile, 0.3% 
(v/v) aqueous ammonia solution and pumped (ConstMetric™ 400 pump, Thermo 
Separation Products or Waters™ 600 multisolvent delivery system under the control of 
the Waters™ 600E Systems controller, MilliQ™, USA) onto a 2.5 x 25 cm POROS™ 
column (POROS™ packing material obtained from PerSeptive Biosystems, 
Framingham, MA, USA, and column assembled in our laboratory). Fusion peptides 
were eluted with a variable linear gradient between 5% (v/v) acetonitrile, 0.3% (v/v) 
aqueous ammonia solution and 50% (v/v) acetonitrile and 0.3% (v/v) ammonia solution. 
POROS™ columns are polymer based and suitable for pH ranges between 1 and 14. 
Fusion peptides with oligolysyl chains (bifunctional peptides) were dissolved in 0.1% 
(v/v) aqueous TFA (HPLC grade, redistilled from glass), 5% (v/v) acetonitrile and 
pumped onto a 10 x 25 cm Vydac™ C l8  column and eluted with a varied gradient (see 
results section for details) between 0.1% (v/v) aqueous TFA, 10% (v/v) acetonitrile and 
0.1% (v/v) aqueous TFA, 65% (v/v) acetonitrile. The purity of the peptides was 
determined by analytical HPLC using either Waters™ 600 multisolvent delivery system 
or the ConstMetric™ 400 pump and the absorption of the elute measured by the 
Waters™ 490E Programmable multiwavelength UV detector or LDC Analytical 
SpectroMonitor™ 5000 photodiode array detector, respectively, at the wavelength of 
217 and 277 nm.
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2 .2 .4  A n a l y t ic a l  m etho ds
The identities of the synthesized peptides were determined by MALDI-TOF mass 
spectrometry or amino acid sequencing. Matrix-assisted laser desorption/ionization 
(MALDI) enables a soft ionisation to take place, with little or no fragmentation, and this 
coupled with time-of-flight mass spectrometry (TOF-MS), permits the accurate 
measurement of biomolecules like DNA, proteins and long peptides. The MALDI 
technique involves co-depositing a solution of a relatively volatile, UV-absorbing 
organic compound, known as the matrix, with the biopolymer on a metal sample plate. 
During evaporation of the solvent, the biomolecule is incorporated into the matrix 
crystalline lattice. The materials in the matrix crystal are then ionised by a short laser 
pulse. The laser energy is primarily absorbed by the matrix and transferred to the 
biomolecule, which ionises with little or no fragmentation. 1 pi of this solution was then 
deposited onto the MALDI plate and allowed to dry at ambient temperature. The 
samples were analysed by Klaus Rumpel at Pfizer Central Research (Sandwich, Kent) 
on an MALDI-TOF Voyager-DE STR BioSpectrometry workstation in positive ion, 
linear mode at an accelerating voltage of 20 kV. Alpha-cyano-4-hydroxycinnamic acid 
was used as the matrix for all samples except for target compounds K25H10AOAI and 
K25H20AOAI, where sinapinic acid was used. The a-cyano-4-hydroxycinnamic acid 
matrix solution was made by preparing a saturated solution of the solid matrix in 50% 
(v/v) acetonitrile/0.3% (v/v) TFA in water. The sinapinic acid matrix solution was made 
by preparing a saturated solution of the solid matrix in 60% acetonitrile/ 0.3% (v/v) 
TFA in water. All samples were dissolved in 100 pi of 0.1% (v/v) TFA in water except 
for those compounds that were insoluble in this solvent, in which case they were 
dissolved in 100% TFA and then diluted 1:10 with water prior to spotting. An aliquot of 
0.5 pi of each sample was spotted on the MALDI plate with 0.5 pi of matrix. K25AOAI, 
K25A0A1#1 (the whole peak of K25AOAI, without peak-splicing, see section 2.3.2.1) 
and K25H20 were calibrated externally with a calibration spectrum of insulin in a-cyano- 
4-hydroxycinnamic acid matrix. Samples named K25H10AOAI and K25H20AOAI were 
calibrated for externally with a calibration spectrum of high mass protein standards: 
horse myoglobin, bovine insulin and thioredoxin in sinapinic acid matrix. All the other 
samples were calibrated externally with a calibration spectrum of low mass protein 
standards: des-Argl-Bradykin, Angiotensin 1, Glul-Fibrinopeptide B and
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adrenocorticotropic hormone sequence residues 18-39 in a-cyano-4-hydroxycinnamic 
acid matrix.
Peptide sequencing was performed was by Dr. J.E. Fox (Alta Bioscience, The 
University of Birmingham) using the ABI 470A protein sequencer (Applied 
Biosystems) based on Edman’s degradation reaction,
2.2.5 N o m e n c l a t u r e  o f  p e p t id e s
The bifunctional peptides were named in the order in which the functional moieties 
were assembled on the peptide synthesizer, i.e. K25AOAI is H0 2C-K25A0 A 1 -NH2.
The following peptides were synthesized (subscript denotes the number of consecutive 
lysyl or histidyl residues):
Name Sequence
AOA1 H2N-GLF EAIA GFI ENGW EGMI DGWYG-C02H
AOA2 H2N-GLF EAIA GFI ENGW EGMI DGWYGF-C02H
INF7 H2N-GLF EAIE GFI ENGW EGMI DGWYG-C02H
K10AOA1 H2N-GLFEAIA GFI ENGW EGMI DGWYG-K10-CO2H
K25A0A1 H2N-GLFEAIA GFI ENGW EGMI DGWYG-K25-C 02H
K25INF7 H2N-GLF EAEE GFI ENGW EGMI DGWYG-K25-C 02H
K10INF7 H2N-GLF EAIE GFI ENGW EGMI DGWYG-K10-CO2H
dK25AOA1(N) H2N-GLF EAIA GFI E GW EGMI DGWYG-K25-C 02H
k 25h 10a o a i H2N-GLF EAIA GFI ENGW EGMI DGWYG-H10-K25-CO2H
k 25h 20a o a i H2N-GLF EAIA GFI ENGW EGMI DGWYG-H20-K25-CO2H
T able 2.1 Names and sequence of peptides synthesized in this project
Also, oligo/polylysyl sequences K10 and K25 were synthesized in order to compare 
binary and ternary complex formation systems (Chapter 3). In an attempt to investigate 
the effect of oligo/polyhistidine chain on the transfection activity of the bifunctional 
peptide K25AOAl, oligo/polylysyl sequences with oligohistidyl chains K25H20 and
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K25H 10 were synthesized for use as control reagents in transfection experiments. The D- 
amino analogue of K25AOAI (named DK25AOAI) was synthesized to investigate if 
resistance to protease degradation would make it active in transfection experiments in 
the presence of serum.
2.3 R e su l t s
2 .3 .1  P e p t id e  s y n t h e s is
The quantities of the initial batches peptide that were synthesized and the yields 
obtained are summarised in the table below:
Name Target quantity (number 
of moles)







K 10INF7 0.03 93
K.25H20AOAI 0.025 154
K25H 10AOAI 0.025 142
k 5 0.08 41
K 10 0.06 61
K 15 0.04 62
k 25 0 .0 2 52
k 25h 10 0.05 183
K25H20 0.05 238
T able  2.2 Yield o f crude peptides synthesized.
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2.3.2 P e p t id e  p u r if i c a t io n  a n d  a n a l y s is
2.3.2.1 P u r if ic a t io n  a n d  a n a l y s is  OFLK2 5AOAI a n d  lK 2sINF7
Identical solvent gradients were used to purify LK25AOAI, and LK25INF7 . The 
chromatogram for LK25AOAI shown in Figure 2.9 was obtained by running the solvent 
gradient shown in Table 2.3 on a Waters™ 600 HPLC system (Millipore, USA) at a 
flow rate of 20 ml/min through a Vydac™ C l8  column using solvent A: 0.1% (v/v) 
aqueous TFA and solvent B: 95% (v/v) acetonitrile and 5% (v/v) of 0.1% (v/v) aqueous 
TFA. An investigative linear gradient between 95% (v/v) solvent A (0.1% (v/v) aqueous 
TFA) and 95% (v/v) solvent B (95% (v/v) acetonitrile and 5% (v/v) of 0.1% (v/v) 
aqueous TFA) over a period of 2 hours was run to determine at what percentage of 
solvent B the main peak was eluting, before using a shallower gradient around that 
percentage of solvent B to obtain better separation. The need to use such a long duration 
of gradient over a wide solvent hydrophilicity-hydrophobicity range was an indication of 
how difficult it was to separate the constituents of the crude compound by HPLC. As it 
can be seen from preparative and analytical chromatogram in Figure 2.9, the eluted peak 
rose from a high baseline of eluting related peptides, and it was impractical to separate 
the peptides within the high baseline by HPLC.
The main peak of LK25AOAI eluted at about 48% (v/v) of Solvent B. MALDI-TOF 
mass spectra of the pooled fractions of the peak splicing and the whole peak (see Figure 
2.9) are shown in Figure 2.10A and B respectively. The main peak in the peak-sliced 
batch of LK25AOAI gave a peak at 5787. Other peaks of lower intensities were present 
at 5664 and 5736, the calculated mass. It was difficult to determine what species 
accounted for the extra mass of 61 in the largest peak. Partial deprotection seemed to be 
the only possible explanation for the difference between theoretical molecular mass and 
the mass determined by MALDI-TOF, however, a protecting group species with a mass 
of 61 could not be identified. The sequence of the first 23 N-terminus amino acid 
residues of this batch of LK25AOAI was also confirmed by amino acid sequencing (see 
sequencing report in Figure 2.11). A third batch of LK25AOAI (named K2sAOA1 #3 ) 
was synthesized on contract by Dr. Graham Bloomberg (Department of Biochemistry, 
University of Bristol). The request had been made for this batch of peptide to be
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supplied as a purified peptide with a minimum estimated purity of 90% of the target 
compound. However K2sAOA1 # 3  was supplied as the crude peptide cleaved from the 
resin due to reported insurmountable problems at attempts to purify K2sAOA1 # 3  by 
HPLC. Analysis of K2sAOA1 # 3  by HPLC (Figure 2.12) using the solvent gradient in 
Table 2.3 showed the absence of a single main peak to isolate by preparative HPLC. 
The mass spectrum of K2sAOA1 # 3  (Figure 2.13) suggested that the crude product to 
contain approximately 70% of the target peptide. Separately collecting the peptides from 
the various peaks in HPLC trace in Figure 2.12 and analysing them by protein 
sequencing and mass spectrometry could have resolved the discrepancy between the two 
methods of analysis, HPLC and mass spectrometry.
Time (minutes) % (v/v) Solvent A 
(aqueous)
% (v/v) Solvent B 
(organic)
0 90 1 0





105 90 1 0
1 1 0 90 1 0
T able  2.3 Table o f  gradient o f solvents used in HPLC purification and analysis o f  K25AOAI: solvent A: 




F igu re  2.9 Representative preparative high-pressure liquid chromatogram of crude LK25AOAI showing 
analytical chromatogram of collected peak-splicing fractions a, b, c, d, e and f. The red line shows the 
charting (on the 2-channel LKB 2210 chart recorder) o f the solvent B gradient between 10% (v/v) and 
65% (v/v) at a rate o f 20 ml/min over a period of 90 minutes (see Table 2.3 for details). The blue line is 




Figure 2.10 MALDI-TOF mass spectra o f  (A) LK25A 0A 1, purified by collection o f  peak-splicing o f main 
peak and pooling fractions around the apex o f the peak as described in section 2.2.3 above and illustrated 
in HPLC chromatogram in Figure 2.9 (B) lK 25AOA1, purified by collecting the main peak fractions a-f as 
illustrated in HPLC chromatogram in Figure 2.9. Samples were analysed on PerSeptive Biosystems 
V oyager-D E  STR. The calculated mass o f  LK25AOAl was 5736.
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Comments:- Clear, clean sequence. There is a small amount or a lysine background 
towards the end.
Note* on the presentation o f  the  data -
? m ost probable ,issignmcm —  = nothing cfctocted at this position. xxx unknown component
W here several sequences arc observed  an Jttcmpc s m ade :o armnge them in descending order nf abundance at each 
residue. However because o f  d iffic iftifs inherent m  the sequencing process, this should be treated as a  guide only.
Approved by Date H /£ AS
F igu re  2.11 Amino acid sequencing report o f bifunctional peptide lK 25AOA1#2. The automatic amino 
acid sequencing o f the first 23 N-terminal amino acid residues (performed on ABI 470A protein 
sequencer) were requested and showed that a clean clear fusogenic sequence was obtained. The lysine 
background towards the end o f the sequence was as a result o f random  cleavage inherent within the 
process of Edman degradation reaction used.
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F igu re  2.12 Analytical high-pressure liquid chromatogram of crude K2sAOA1#3 showing the absorbance 
o f elute measured at a wavelength o f 277 nm, using the Jasco™  programmable ternary pump and UV 
detector. The peptide was eluted by running a varied gradient between 90% (v/v) solvent A (0.1% (v/v) 
aqueous TFA) and 65% (v/v) solvent B (5% (v/v) aqueous TFA (0.1% ), 95% (v/v) acetonitrile) as 
detailed in Table 2.3.
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Figure 2.13 Mass spectrum o f crude LK2sAOAl#3 performed on a VG Quattro™ triple quadruple 
instrument with electrospray ionisation. The calculated mass o f  LK25AOAI was 5736.
2.3.2.2 PURIFICATION AND ANALYSIS OFDK25AOAI
The first batch of the D- amino bifunctional peptide DK25AOAI was purified using the 
gradient detailed in Table 2.3. A representative chromatogram of the preparative HPLC 
is shown in Figure 2.14. Biological testing in transfection experiments (chapter 3) 
showed that the D analogue was over 100-fold less active than l K 2sA O A 1 # 1 . A s this 
was not expected, amino acid sequencing was performed and this revealed that an 
amino acid had been omitted from the sequence. The reason for this omission is 
believed to be due to steric hindrance by the bulky triphenylmethyl side chain protection 
of asparagine which prevented the coupling of asparagine to the growing peptide chain. 
This first batch of DK25AOAI with a deleted asparagine (Asn) was named 
dK25AOA1(N). When asparagine without a side chain protection was used as in the case 
of the previous L- amino peptide synthesis and subsequent DK25AOAI batches were 
synthesized, transfection activity was restored (Chapter 3). The second batch of 




F ig u re  2.14 Representative preparative high-pressure liquid chrom atogram  of crude DK25AOAI showing 
the absorbance o f the elute measured at a wavelength o f 214 and 277 nm, red and blue traces, 
respectively, using the W aters™  490E multiwavelength UV detector. The peptide (40 mg in 20 ml 
solvent A) was pumped (W aters™  600 multisolvent delivery system) at 20 ml/min unto a 10 x 25 cm 
Vydac™  C l8 column and eluted by running a varied gradient between 90% (v/v) solvent A (0.1%  (v/v) 
aqueous TFA) and 65% (v/v) solvent B (5% (v/v) aqueous TFA (0.1%), 95% (v/v) acetonitrile) as 




'  tH K M I M iim i '
A l t a
B i o s c i e n c e
i s if i  i im w b ii .  Protein sequence report 29July. 1998
Alla Bioscicncc code: • S1511





3 p h e
4 g lu
5 a l a
6 i l e
7 a l a
8 g ly
9 p h e
10 i l a
II g lu
12 g ly
13 t r p
14 g lu
15 A  .
Residue
16 met:
17 i l e
18 a s p
19 g ly
20 t r p
21 t y r
22 g ly








Comments:- Clean sequence with only a trace o f an \ - l  sequence. There is an unusual 
steadily rising lysine background towards the end of the run.
Notes on the presentation o f  The daia;-
? -  most probable assignm ent — - nothing detected at this position xxx -  unknow n component
W here several sequences arc observed, an attempt is made to  aminuc them in descending urdcr o f  abundance at each 
residue. H ow ever because o f  difficulties inherent in I lie sequencing process, this should be treated as a guide only
Approved by V  ^  Date .'^S
F igu re  2.15 Amino acid sequencing report of bifunctional peptide dK25AOA1(N). The automatic amino 
acid sequencing o f the first 23 N-terminal amino acid residues (performed on ABI 470A protein 
sequencer) were requested and showed that asparagine (Asn) was omitted from the sequence at position 
number 12. The lysine background towards the end of the sequence was as a result of random  cleavage 
inherent within the process o f Edman degradation reaction used.
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2.3 .2 .3  PUR1FICA TION AND/OR ANALYSIS OF LK ioIN F 7
The bifunctional peptide lKioINF7 was purified by pumping (Waters™ 600 
multisolvent delivery system) the peptide (40 mg in 20 ml solvent A) at 20 ml/min unto 
a 10 x 25 cm Vydac™ C l8  column and eluted by running a linear gradient between 
95% (v/v) solvent A (0.1% (v/v) aqueous TFA) and 95% (v/v) solvent B (5% (v/v) 
aqueous TFA (0.1%), 95% (v/v) acetonitrile) in 120 minutes. The main peak was eluted 
between 53% (v/v) and 57% (v/v) of solvent B after 69 minutes and the pooled fractions 
that were lyophilised were analysed by automatic amino acid sequencing and MALDI- 
TOF mass spectrometry. The sequencing results showed that the main peak collected 
contained approximately 1% of an N-l sequence and about 3% of another unrelated 
sequence (Figure 2.17). MALDI-TOF analysis spectra confirmed that the main peak had 
a molecular mass of 3873, which was the calculated mass. The spectra also show the 
presence of impurities, consisting of deletion peptide sequences, accounting for the high 
level of background peaks before and after the main peak.
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Main peak
F igure  2.16 Representative preparative high-pressure liquid chromatogram of crude lKioINF7 showing 
the absorbance o f the elute measured at a wavelength o f 214 and 277 nm, red and blue traces, 
respectively, using the W aters™  490E multiwavelength UV detector. The peptide (40 mg in 20 ml 
solvent A) was pumped (W aters™  600 multisolvent delivery system) at a rate o f 20 ml/min unto a 10 x 
25 cm Vydac™  C18 column and eluted by running a variable linear gradient between 95% (v/v) solvent 
A (0.1% (v/v) aqueous TFA) and 95% (v/v) solvent B (5% (v/v) aqueous TFA (0.1%), 95% (v/v) 
acetonitrile) in 120 minutes.
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Comments:- Clear sequence. There is approximately 1% of an \ - l  sequence present and 
about 3% o f another, unrelated sequence.
Notes on the p resen tation  o f  tlx-' ilala:- 
?  * m ost probable assignm ent.
W here several sequences arc  o t 
residue. H ow ever because oCdifTiciyrtcs inherent in the sequencing process, th is  should  be treated as a  guide only.
—  -  no th ing  detected  at this position. 
jCd. an jitcm pt is m ade to  arrange them  in descending  order o f  abundance at each
= unknow n com ponent
Approved by
Figure 2.17 Amino acid sequencing report o f bifunctional peptide lK i0INF7. The automatic amino acid 
sequencing o f the first 23 N-terminal amino acid residues (performed on ABI 470A protein sequencer) 
were requested and showed that a clean clear fusogenic sequence was obtained. The lysine background 
towards the end o f the sequence was as a result o f random  cleavage inherent within the process of 
Edman degradation reaction used.
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Figure 2.18 MALDI-TOF mass spectrum o f lK i0INF7, purified by collecting the main peak in HPLC 
chromatogram in Figure 2.16. Samples were analysed on PerSeptive Biosystems Voyager-DE STR. The 
calculated mass o f  K 10INF7 was 3873.
A batch ofKioAOAl was synthesized by Dr. Graham Bloomberg using Fmoc chemistry 
on a PerSynthesizer 9050 plus™ automatic peptide synthesiser and was supplied as the 
crude peptide cleaved from the resin. The mass spectra of KioAOAl suggested that the 
target compound was about 80% of the crude product (see Figure 2.19). Analysis of 
KioAOAl by HPLC (Figure 2.20) using the solvent gradient in Table 2.3 showed the 
absence of a single main peak to isolate by preparative HPLC. Ideally, the various peaks 
present in the HPLC trace could have been collected and further analysed to find which 
fraction contained the target peptide, but such considerations were not possible due to 
financial constraints.
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F igu re  2.19 Mass spectrum of crude KioAOAl perform ed on a VG Quattro™ triple quadruple 
instrument with electrospray ionisation. The calculated mass o f K10AOA1 was 3815.
F igu re  2.20 Analytical high-pressure liquid chromatogram of crude KioAOAl showing the absorbance 
o f elute measured at a wavelength of 277 nm, using the Jasco™  programmable ternary pump and UV 
detector. The peptide was eluted by running a varied gradient between 90% (v/v) solvent A (0.1% (v/v) 
aqueous TFA) and 65% (v/v) solvent B (5% (v/v) aqueous TFA (0.1%), 95% (v/v) acetonitrile) as 
detailed in Table 2.3.
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2.3.2.4 P u r if ic a t io n  a n d  a n a l y s is  ofAOAI,  oleoyl-AOAl and INF7
In the absence of a low-pressure pumping and detection equipment required for use in 
ion-exchange separation method to purify the fusogenic peptides, the decision was taken 
to use reverse-phase HPLC separation method. The reverse-phase HPLC separation of 
fusogenic peptides was attempted by using a POROS™ 20 column (self-pack 
POROS™ 20 media was obtained from PerSeptive Biosystems (Framingham, MA, 
USA) and used to pack a 2.5x25 cm steel liquid chromatography column in the 
laboratory). The use of POROS™ column had the advantage of enabling HPLC to be 
performed at pH of 10 without risk of degradation of the solid phase, an occurrence 
associated with conventional C l8  columns. Unfortunately, the fusogenic peptides 
degraded at high pH (sodium hydroxide or ammonia 0.3%), evidenced by the emergence 
of multiple peaks after purification (Figure 2.21). MALDI-TOF mass spectra of INF7 
and oleoyl-AOAl showed that the compounds were highly impure (Figure 2.22). Due to 
the fact that the purity of the first batches of AOA1 and INF7 synthesized were 
questionable according to mass spectra analysis, this batch of AOA1 is marked with 
asterisks (*) in this report to differentiate it from a later batch of crude AOA1 
(synthesized by Dr. Graham Bloomberg) with an estimated purity of 90% (Figure 2.25). 
The expected molecular masses of INF7 and oleoyl-AOAl were 2590 and 3000 
respectively. In the absence of pure AOA1, another synthetic fusogenic sequence JTS1 
was obtained from GeneMedicine, Texas, USA, to use as a comparison in transfection 
experiments involving bifunctional peptides. An analytical HPLC of JTS1, showed that 
it was pure and a single species (Figure 2.23) and MALDI-TOF mass spectra analysis 
showed that the main species present had a mass of 2340, a potassium adduct of JTS1, 
molecular mass 2301 (Figure 2.24).
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F ig u re  2.21 Analytical high-pressure liquid chromatogram of (A) crude and (B) purified AOA1*. 
Purified AOA1* was obtained by collecting the main peak, arrowed in (A). Chromatogram shows the 
absorbance o f the elute measured at a wavelength o f 217 and 277 nm, red and blue traces, respectively, 
using the LDC Analytical SpectroM onitor 5000 photodiode array detector. Peptides (0.5 mg) were 
dissolved in 0.3% (v/v) aqueous ammonia (in 0.5 ml) and pumped (ConstaM etric™  4100 solvent 
delivery system) unto a POROS™  column and eluted between a variable linear gradient o f solvent A: 
0.3% (v/v) aqueous ammonia, pH 10, and solvent B: 0.3% (v/v) aqueous ammonia, 50% (v/v) 







Figure 2.22 MALDI-TOF mass spectra o f (A) INF7* and (B) oleoyl-AO Al, purified by collecting the 
main peak in HPLC chromatogram in Figure 2.21 Samples were analysed on PerSeptive Biosystems 
V oyager-D E STR. The calculated mass o f INF7 and oleoyl-AOAl are 2590 and 3000 respectively.
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F ig u re  2.23 Analytical high-pressure liquid chromatogram of JTS1 (a gift from GeneM edicine, Texas, 
USA) showing the absorbance of the elute m easured at a wavelength o f 217 and 277 nm, red and blue 
traces, respectively, using the LDC Analytical SpectroM onitor 5000 photodiode array detector. Peptides 
(0.5 mg) were dissolved in 0.3% (v/v) aqueous ammonia (in 0.5 ml) and pumped (ConstaM etric™  4100 
solvent delivery system) unto a POROS™  column and eluted between a linear gradient o f solvent A: 
0.3% (v/v) aqueous ammonia, pH 10, and solvent B: 0.3% (v/v) aqueous ammonia, 50% (v/v) 
acetonitrile, pH 10, for 15 minutes at a rate o f 5 ml/min.
F ig u re  2.24 M ALDI-TOF mass spectrum  of JTS1 (a gift from GeneM edicine, Texas, USA), with 
analytical HPLC chromatogram shown in Figure 2.23. Samples were analysed on PerSeptive Biosystems 
Voyager-D E STR. The expected molecular mass o f JTS1 is 2301.
GLF1 *ve mode
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Figure 2.25 Mass spectrum o f crude AOA1 performed on a VG Quattro™ triple quadruple instrument 
with electrospray ionisation.
2 .3 .2 .5  P u r i f ic a t io n  a n d  a n a ly s is  o f  K j0, K 25, K 25HI0a n d  K 25H 20
The analytical HPLC of crude oligolysine peptides K 10 and K25 were revealed that they 
were >90% pure by HPLC analysis but they purified by HPLC essentially to remove any 
traces of scavengers that may have been present. Peptides K 10 and K25 had very high 
hydrophilicity at pH 2 (0.1% (v/v) TFA) and eluted with the solvent front, making any 
attempt at separation from the scavengers impossible. In order to increase the 
hydrophobicity of K 10 and K25, peptides were dissolved in 0.3% (v/v) aqueous ammonia 
and pumped unto a 2.5x25 cm POROS™ column and eluted between a variable linear 
gradient of solvent A: 0.3% (v/v) aqueous ammonia, pH 10, and solvent B: 0.3% (v/v) 
aqueous ammonia, 90% (v/v) acetonitrile, pH 10. The solvent gradient used is shown in 
Table 2.4. This allowed the removal of scavengers from crude K jo and K25. MALDI- 
TOF mass spectrometry on Kjo showed that the main peak had a mass of 1300 
(expected molecular mass) and 1312 ( 1 0 0 %), and these peaks had sodium and 
potassium adducts with masses of 1322 and 1338 respectively. MALDI-TOF mass
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spectrum of K25 showed the calculated mass of 3223 and sodium adduct of mass 3245. 
The mass spectrum of K8 , a gift from GeneMedicine, Texas, USA, showed the expected 
molecular mass peak of 1720 and potassium adduct with a mass of 1758. There is also 
an unexpected peak at 1734. Another batch of K 10 and K25 synthesized by Dr. Graham 
Bloomberg, Department of Biochemistry, University of Bristol were not purified by 
HPLC, but each crude oligolysine had a high estimated purity of 95% of the target 
peptide present as evidenced by the mass spectra in Figure 2.28.
Time (minutes) % (v/v) solvent A 
(aqueous)







2 1 95 5
Table 2.4 Table o f gradient o f  solvents used in HPLC purification and analysis: solvent A: 0.3% (v/v) 
aqueous ammonia; solvent B: 0.3% (v/v) aqueous ammonia, 90% (v/v) acetonitrile.
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F ig u re  2.26 Representative preparative high-pressure liquid chromatogram of (A) crude K 10, (B) K25 and 
(C) K25H20 showing the absorbance o f the elute measured at a wavelength of 217 and 277 nm, red and 
blue traces, respectively, using the LDC Analytical SpectroM onitor 5000 photodiode array detector. 
Peptides (5-10 mg) were dissolved in 0.3% (v/v) aqueous am monia (in 2.5 ml) and pumped 
(ConstaM etric™  4100 solvent delivery system) unto a POROS™  column and eluted between a variable 
linear gradient o f solvent A: 0.3% (v/v) aqueous ammonia, pH 10, and solvent B: 0.3% (v/v) aqueous 




Figure 2.27 MALDI-TOF mass spectra o f  the oligolysine (A) K 10, (B) K25 and (C) K8. K I0, K25 and (D) 
K2sH20 purified by collecting the main peak in reverse phase HPLC, representative in Figure 2.26. K8 was 
a gift from GeneMedicine, Texas, USA. Samples were analysed on PerSeptive Biosystems Voyager-DE 
STR. The expected molecular mass o f  K )0, K25 and K8, and K25H20 are 1300, 3221, 1720 and 5962 
respectively.
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F igure 2.28 Mass spectra o f  crude K 10 (A) and K25 (B) performed on a VG Quattro™ triple quadruple 
instrument with electrospray ionisation. The calculated masses o f  K 10 and K25 were 1300 and 3221 
respectively.
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2.3.2.6 P u r i f i c a t i o n  a n d  a n a ly s is  o fK 2 5H1 0AOA1  a n d  K2 5H2 0 AOAI
Initial attempts to purify crude peptides K25H10AOAI and K25H20AOAI by reverse 
phase HPLC using a variable linear gradient between 95% (v/v) solvent A (0.1% (v/v) 
aqueous TFA) and 95% (v/v) solvent B (5% (v/v) aqueous TFA (0.1%), 95% (v/v) 
acetonitrile) in 80 minutes showed that separation of the mixture could not be achieved 
(Figure 2.29A). Other organic solvents that were tried in place of acetonitrile, using 
similar gradients mentioned above included isopropyl alcohol and ethanol. When TFA 
was replaced with ammonia in the above-mentioned gradient, again separation could not 
be achieved. Since the histidyl side chain has a protonable nitrogen with a pKa of about 
6.0, it was thought that a variation in pH of the solvent system could bring about a 
resolution of the mixture. A three-solvent acidic-to-basic variable linear gradient system 
from pH 2 (0.1% (v/v) aqueous TFA, solvent A) to pH 10 (0.1% (v/v) aqueous 
ammonia, solvent B) gradient was run in the presence of a 10% (v/v) acetonitrile 
(solvent C). Attempts at separation of the mixture using acidic-to-basic gradient (Table 
2.5) was unsuccessful (Figure 2.29B), but when the gradient was reversed to a basic-to- 
acidic gradient (Table 2.6), signs separation began to appear (Figure 2.29C). Increasing 
the percentage of acetonitrile from 1 0 % (v/v) to 15% (v/v) appeared to be sufficient to 
bring about the separation of K25H10AOAI from impurities (Figure 2.29D), but not 
sufficient for K25H20AOAI. A further increase of the percentage of acetonitrile to 20% 
(v/v) appeared sufficient to bring about resolution of the components of K25H20AOAI. 
Two main peaks could be observed at approximately 11 minutes and 28 minutes, 
corresponding to 40% (v/v) and 0% (v/v) solvent B (0.1% (v/v) aqueous ammonia) 
during the purification of K25H10AOAI. The peak at 28 minutes was collected and 
lyophilised based on the assumption that the target peptide would have the sharpest and 
largest peak. The chromatogram of K25H20AOAI was similar to those of K25H10AOAI, 
so only representative traces of the latter are shown (Figure 2.29).
According to the MALDI-TOF mass spectrometry results of target compounds 
K25H10AOAI and K25H20AOAI obtained at the end of the project (Figure 2.30A and B), 
respectively, attempts to purify these two compounds were unsuccessful. Due to lack of 
access to mass spectroscopy equipment, the scientifically compromised approach of 
assuming that the sharpest and largest peak during HPLC was the target peptide, proved
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to be flawed in this instance. Ideally, once a solvent system had been developed to 
separate the components of the mixture, various fractions should have been identified by 
MALDI-TOF mass spectrometry to determine which fraction contained the desired 
peptide, before proceeding with the purification process for such long peptides.
Time (minutes) % (v/v) Solvent A 
(pH2)
% (v/v) Solvent B 
(pH 10)
% (v/v) Solvent C 
(acetonitrile)
0 90 0 10
2 90 0 10
21 0 90 10
31 0 90 10
51 90 0 10
60 90 0 10
70 90 0 10
T able 2.5 Acidic-to-basic HPLC gradient Table o f  gradient o f  solvents used in HPLC purification and 
analysis: solvent A: 0.1% (v/v) aqueous TFA; solvent B: 0.1% (v/v) aqueous ammonia, solvent C: 
acetonitrile.
Time (minutes) % (v/v) Solvent A 
(pH2)
% (v/v) Solvent B 
(pH 10)
% (v/v) Solvent C 
(acetonitrile)
0 0 85 15
1 0 85 15
21 85 0 15
31 85 0 15
51 0 85 15
60 0 85 15
70 0 85 15
T able 2.6 Basic-to-acidic HPLC gradient: Table o f  gradient o f  solvents used in HPLC purification and 
analysis: solvent A: 0.1% (v/v) aqueous TFA; solvent B: 0.1% (v/v) aqueous ammonia, solvent C: 
acetonitrile.
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F igure  2.29 High-pressure liquid chromatogram of crude K25H 10AOAI showing the absorbance o f the 
elute measured at a wavelength of 217 and 277 nm, red and blue traces, respectively, using the LDC 
Analytical SpectroM onitor 5000 photodiode array detector. Solvents systems were pumped 
(ConstaM etric™  4100 solvent delivery system) solvents through a POROS™  column at various linear 
gradients summarised below: Trace (A) was obtained running a gradient between 95% (v/v) solvent A 
(0.1% (v/v) aqueous TFA) and 95% (v/v) solvent B (5% (v/v) aqueous TFA (0.1%), 95% (v/v) 
acetonitrile) in 90 minutes, and trace (B) was obtained by running a pH gradient three-solvent acidic-to- 
basic linear gradient system from pH 2 (0.1% (v/v) aqueous TFA, solvent A) to pH 10 (0.3% (v/v) 
aqueous ammonia, solvent B) gradient was run in the presence of 10% (v/v) acetonitrile (solvent C), see 
Table 2.5 for details. Chromatogram (C) and (D) was obtained by running a basic-to-acidic three solvent 
system in the presence of 10% (v/v) and 15% (v/v) acetonitrile (solvent C) respectively, see Table 2.6 for 
details o f gradient.
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Figure 2.30 MALDI-TOF mass spectra o f  (A) K25H 10AOAI (B) K25H20AOAI purified by collecting the 
main peak in reverse phase HPLC, representative in Figure 2.29. Samples were analysed on PerSeptive 
Biosystems V oyager-D E STR. The expected molecular masses o f K25H 10AOAI and K25H20AOAI were 
7106 and 8477 respectively.
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2 .4  D is c u s s io n
Solid-phase peptide synthesis can be employed routinely to create oligopeptides up to 
20-25 residues in length. When larger peptides are synthesised the purity decreases 
because each subsequent coupling gives an incomplete yield, so that when synthesis of 
peptides greater than 50 residues is attempted, the yield of target peptide becomes 
vanishingly small. Such peptides are very heterogeneous and purification is 
challenging. Assuming a 99% yield per coupling reaction, a 48-mer peptide sequence 
would potentially have a 0.9947 or 63% yield of target peptide before cleavage reactions 
were performed. To ensure a high yield of target peptide, it is important that coupling 
and cleavage reactions are optimised. A ready access to a protein sequencer and 
MALDI-TOF mass spectrometry are essential during the time of small-scale synthesis 
of long peptides as a back-up to, or in place of an on-line UV monitoring detector 
during automated peptide synthesis, to confirm that reactions are proceeding 
satisfactorily, before large scale synthesis is undertaken. The synthesiser used for this 
project lacked any form of on-line monitoring, and there was no access to analytical 
equipment at the time of synthesis. Synthesis and purification of the peptides had to be 
performed by observation of the appearance of the materials on HPLC. An attempt was 
made to purify each material to a single peak, and a sample collected was analysed by 
outside collaborators in due course.
These were challenging and expensive syntheses. The high cost of materials used 
limited the number of batches that could be prepared, so in some cases biological 
experiments were performed on partially purified materials, in the knowledge that the 
bulk of the material was the target peptide. The actual cost of each batch of 0.2 mmol 
of 48-mer peptide was about £1500.00 before purification. The availability of an 
instrument for small-scale peptide synthesis and analysis, followed by amino acid 
sequencing would have been beneficial, ensuring that difficult couplings could be 
identified and compensated for, before larger scale synthesis was undertaken. 
Unfortunately this resource was not available, so that medium-sized batches had to be 
prepared for each peptide under investigation. Thus optimisation of the syntheses with 
small-scale batches was not possible during this project. In an attempt to get the largest 
number of peptides in the least number of syntheses, thereby cutting the unit cost, in
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retrospect the batches of some compounds were too small leading to difficulties with 
HPLC purification. An early decision was taken to synthesize 6  peptide analogues in 
parallel, and tests for their in vitro efficacy in transfection before synthesizing larger 
batches. The initial peptides that were synthesised were K25AOAI, K25INF7 , KioINF7, 
AOA1, K25, and K10. The intention was that the synthesis of these peptides would allow 
the bifunctionality of K25AOAI and KioINF7 to be evaluated against the published 
literature of three-component mixtures (i.e. DNA + condensing peptide + fusogenic 
peptide). The yield after the first isolation of the largest and sharpest peak was typically 
40% but analytical HPLC revealed that the peptides were still impure. At this stage any 
attempt to further purify these small batches of fusogenic and bifunctional peptides 
would have resulted in insufficient peptide with which to perform biological 
experiments, so these peptides were used at 75-90% (?) purity (as determined by protein 
sequences) for the biologically active fusogenic moiety. The decision was then taken to 
synthesize a larger batch of the most active peptide, K25AOAI (as tested by ability to 
mediate gene delivery in vitro, Chapter 3), to enable a thorough purification, thus 
allowing sufficient biological experiments to be performed to determine that the 
observed activity was not due to a contaminant. At this later stage of this project, the 
PerSynthesizer 9050 plus™ became faulty: coupling reagents leaked considerably from 
the gasket of the on-line UV detectors of the PerSynthesizer 9050 plus™ during the 
coupling cycle. It was not possible to replace this gasket due to lack of funds, so the 
detectors were bypassed and subsequent synthesis had be performed without the benefit 
of on-line UV monitoring. It was possible to analyse the products retrospectively but 
the lack of access to a protein sequencer and MALDI-TOF mass spectrometer during the 
time of synthesis meant that it was not possible to confirm the identity of synthesized 
peptides until 2Vi years into the programme of synthesis. Prior to this the only means of 
analysis available were (i) HPLC, to isolate the largest and sharpest peak and (ii) in vitro 
testing for transfection activity.
In many cases, for preliminary examination, peptides are used without preparative liquid 
chromatography, to establish biological activity. Larger batches can then be purified to 
give higher levels of purity. This was the strategy used in this study. Given that the 
materials were not 99% pure it is important to discuss what the expected nature of the 
contaminants were and what their effect would be on biological activity.
During purification of the large second batch of K25AOAI (K2sAOA1 #2 ), 5 ml fractions 
of the main peak were collected from each run and samples from each fraction were 
analysed by analytical HPLC. The purest fractions were found to be those close to the 
tip of each main peak (i.e. fractions c and d in Figure 2.9). The pure fractions were 
considered to be those fractions from peak splicing which did not possess shoulders or 
multiple peak upon re-analysis by HPLC and these were pooled together and 
lyophilised, and called K2sAOA1 #2 . K2sAOA1 # 2  accounted for 6% of the crude 
peptide weight. The in vitro transfection activity of the pure peptide (K2sAOA1#2 ) was 
found to be 20% higher than the batch of K25AOAI in which the whole peak was used, 
named K2sAOA1 # 1 . However, the high cost of these peptides meant that synthesis of 
larger batches of AOA1 and INF7 to enable thorough purification for purposes of 
comparison to K25AOAI was regarded as an unaffordable expenditure. Such 
considerations may prevent the widespread use of bifunctional peptides such as 
K25AOAI, despite its excellent biological activity.
The analytical chromatogram of the bifunctional peptide K2sAOA1 # 2  indicated that the 
fractions pooled from the peak splicing had a sharp clean peak without shoulders. 
However this sharp peak emerged from a fairly high baseline representing the elution of 
related peptides that had absorbance at 277 nm. Considering that these bifunctional 
peptides were being purified using an exceptionally long duration of gradient over a 
wide solvent hydrophilicity-hydrophobicity range, the existence of the high baseline at 
277 nm was an indication of the difficulty associated with the purification of peptides of 
this size and composition by HPLC. On the basis of the traditional (area under the peak) 
interpretation of the chromatogram of K2sAOA1 #2 , the estimated purity was perhaps 
less than 10% by HPLC. The mass spectra analysis of K2sAOA1 # 2  gave a result that 
was in agreement with the HPLC results suggesting the presence of a high percentage of 
contaminating related peptides present in the batch. Protein sequencing analysis of the 
first 23 N-terminal amino acid residues of K2sAOA1 #2 , however, did not detect the 
presence of any related peptide in this batch obtained by peak-splicing. The mass 
spectra of K25 (Figure 2.27B) which was synthesized in parallel with the K25 moiety of 
K.25A0 A1 # 2  showed that there was a high degree of heterogeneity of oligolysine species 
of shorter lengths than the target 25 residues during that part of the synthesis. The 
inference from this evidence is that the fusogenic sequence with different lengths of
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oligolysine chains had been produced during the synthesis that were close in numerical 
value had not been successfully resolved by HPLC. Similar inferences can be drawn 
from the analysis of DK25AOAI, K25INF7  and KioINF7. HPLC analysis of the batch of 
K25A0A1#3 (which was synthesized by Dr. Graham Bloomberg and was not purified by 
HPLC (Figure 2.12)) showed that the three main peaks in the chromatogram emerged 
from and returned to a low baseline, suggesting that there was less heterogeneity in the 
lysine chain of this batch of K25AOAI and this was confirmed by the sharp peaks of the 
mass spectra of K2sAOA1 #3 . The mass spectra of the batch of K25 (Figure 2.28B), 
which was synthesized in parallel with the K25 moiety for K2sAOA1 # 3  showed a 
product with >95% of the of the target peptide, thus confirming the inference that the 
high absorbance baseline observed in the chromatogram of K2sAOA1 # 2  was due to the 
heterogeneity of the oligolysine moiety of K2sAOA1#2 . The mass spectra of 
K25A0A1#3 suggested that the crude product consisted of about 70% of the target 
compound, as determined by the ratio of the peak height of the target peptide as a 
proportion of the sum of all the major peaks in the spectra. The HPLC chromatogram of 
K25A0A1#3 however suggested that the proportion of the target peptide could be less 
than 70%. Ideally, it would have been preferable to isolate each of the three main peaks 
identified in the analytical HPLC trace of K2sAOA1 #3 , analysed each peak by protein 
sequencing or mass spectrometiy to identify the peak which contained the target peptide 
and then used that fraction in experiments. However such considerations were not 
possible as large quantities of K2sAOA1 # 3  were required for further erythrocyte lysis 
assays. The analytical chromatogram of K10AOAI showed the absence of a main peak 
and it suggested a very heterogeneous mixture of compounds, but the mass spectra 
showed that about 80% of the crude compound consisted of the target peptide in 
contradiction to inferences that could be made from the HPLC chromatogram. As 
analytical methods for such polypeptides, both HLPC and mass spectrometry have 
strengths as well as limitations. This disagreement between the levels of purity as 
determined by mass spectrometry and liquid chromatography of synthetic proteins of 
this composition was one which could only be resolved if there was substantial 
resources available to synthesize these peptides in large batches to enable peaks to be 
isolated by preparative liquid chromatography and the fractions analysed by protein 
sequencing and mass spectrometry.
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Fusogenic peptides have an overall negative charge and thus can only be solubilised in 
solutions with high pH or solutions containing a high concentration of a solubilising 
agent e.g. guanidinium hydrochloride (GnHCl). At a high pH, (pH greater than 8 ), C l8  
packing material used as the stationary phase in reverse-phase chromatography 
disintegrates. Reported methods of purification of fusogenic peptides include ion- 
exchange167 or solubilising the peptide in high concentration of GnHCl, pumping unto a 
C4 column and purifying by HPLC followed by desalting on a BioGel™ P-2 column76. 
Although there was an ion-exchange equipment within the department of Pharmacy and 
Pharmacology at the University of Bath, it was not available for use to purify the 
fusogenic peptides used in this project. The lack of ion exchange equipment (pump, 
column, detector) within the group to purify peptides with net negative charge meant 
finding alternative previously untested method to purify negatively charge peptides. The 
manufacturers of the POROS column had recommended the use of 0.3% ammonia (v/v) 
or sodium hydroxide (w/v) in the mobile phase, but this resulted in the degradation of 
the fusogenic peptides as evidenced by the appearance of new peaks after HPLC.
At a later stage of the project it was observed that the biological activity of bifunctional 
peptides were abrogated by the presence of 1 0 % (v/v) serum so a decision was taken to 
synthesize a D-amino analogue of K25AOAI (DK25AOAI) to investigate if resistance to 
enzymatic degradation will result in restoration of transfection activity in serum. The 
outcome of this investigation is discussed in Chapter 3. The first batch of DK25AOAI 
peptide that was synthesized had an Asn residue totally omitted from the sequence (as 
seen in protein sequencing report in Figure 2.15), most likely due to steric hindrance of 
the side chain-protecting group (triphenylmethyl) used. The resulting peptide (named 
dK25AOA1 (N)) was over 1 0 0 -fold less active in transfection experiments after 
complexation with DNA (see Chapter 3 section 3.3.13). A second batch of DK25AOAI 
synthesized used Asn with no side chain protection and the restoration of high 
transfection activity comparable to the L- amino acid analogue, suggests that the full 
sequence was present. Lack of funds did not permit a sequencing test to be performed 
on this second batch of DK25AOAI.
Although the synthesis of these peptides would be challenging under any circumstances, 
the difficulties encountered during purification of the fusogenic peptides and K25AOAI
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with oligohistidyl chains (K25H10AOAI and K25H20AOAI) were mainly due to lack of 
financial resources or lack of access to equipment. Nevertheless reasonable quantities 
of target peptides were obtained at purities, which enabled biological experiments to be 
conducted. It should be noted that in many instances biochemical activity is studied 
using crude peptides when the oligopeptide is above 30 residues in length.
Many of the peptides used in this study were of reasonable purity, but were not as pure 
as many analytical reagents used in scientific research. Typical purity for research 
materials of low molecular weight, which can be recrystallised several times without 
substantial loss of material, would be >95% and often >99%. This level of purity 
cannot be achieved with peptides of the size used in this study unless very large batches 
are available so that the peptides can be purified chromatographically and recovered 
from dilute solution.
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3 PHYSICAL AND NON-PHYSICAL CHARACTERISATION, IN VITRO 
AND IN VIVO TESTING OF BIFUNCTIONAL PEPTIDES
3.1 P h y s i c a l  c h a r a c t e r i s a t i o n  a n d  i n  v i t r o  t e s t i n g  o f  b i f u n c t i o n a l
PEPTIDES
3.1.1 I n t r o d u c t i o n
Although little concordance has been observed between in vitro and in vivo transfection 
efficiency of GDVs, the high expense of animal experiments makes the use of in vitro 
transfection experiments for screening and optimisation of potential/novel GDVs a 
common practice by researchers in the development of novel GDVs. Because dividing 
cells in culture are generally easier to transfect than cells in vivo, it is usually safe to 
assume that if a putative GDV can not promote gene delivery in vitro, then it is unlikely 
to be effective in vivo. Different cell lines respond differently to different GDVs so it is 
common practice for researchers to report the transfection efficacy of novel GDVs in a 
panel of different cell lines in vitro. In vitro transfection experiments can be useful as a 
tool to estimate of the quantity of GDV that may be required to complex a nominal 
quantity of DNA for in vivo transfection efficacy (i.e. the polycation:polyanion charge 
ratio). In vitro experiments can also be used to investigate possible obstacles to gene 
transfer in vivo such as the effect of serum proteins or enzymes on transfection. Fully 
confluent/differentiated cells cultured on filters can be used to simulate the effect of the 
absence of cell division on transfection efficiency of a GDV. The major limitation to 
using dividing cells as a model is that the nuclear membrane becomes discontinuous 
during cell division, which allows DNA to be incorporated into the daughter nuclei. 
However, dividing cells remain the primary test for new non-viral GDVs, due to the 
simplicity of the methods.
The synthetic peptides described in Chapter 2 were tested for their ability to promote 
transfection in vitro using dividing cells. Particular attention was paid to comparing the 
activity of binary complexes formed between novel bifunctional peptides and DNA with 
ternary complexes formed by sequential mixing of poly/oligolysine with DNA followed 
by addition of fusogenic peptides. This latter approach has previously described by
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Plank and colleagues and Gottschalk and collegues . In transfection studies, both the 
total level of gene expression in the culture as well as the proportion of cells transfected 
was determined. The effect of whole serum, serum albumin and chloroquine on the 
transfection efficiency of bifunctional peptides was also evaluated. Transfection studies 
using bifunctional peptides that both bind to DNA and provide membrane fusogens 
have not been previously reported. The work described here represents an attempt to 
produce a more reliable and reproducible endosome escape system than those that are 
currently available. As a positive control DNA complexes with the cationic lipid 
DOTAP or the cationic polymer polyethylenimine (PEI) were compared with peptide 
complexes. Preliminary in vivo testing of the novel bifunctional peptides, which 
involved intramuscular and intratumoural injection of bifunctional peptide/DNA 
particles were performed in mice.
Physical and non-physical characterisation studies of the novel bifunctional peptide(s) 
that were carried out in this project included particle sizing and zeta potential 
measurements of peptide/DNA complexes, DNA affinity studies of peptides using 
ethidium bromide exclusion assays and erythrocyte lysis assays which are an established 
method measuring the membrane disruptive potency of a fusogenic peptides.
3.2 M a t e r i a l s  a n d  m e t h o d s
3.2.1 C e l l  c u l t u r e  m a t e r i a l s
All biochemicals were of analytical grade and purchased from Sigma Chemicals, UK, 
except where indicated.
3.2 .1 .1  S o l u t io n s
3.2.1.1.1 Water
Freshly obtained Milli-Q water from a Milli-Q PF Plus system with ultrafiltration 
cartridge (Millipore UK Ltd.) was sterilised by autoclaving at 121 °C for 15 minutes
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before being used for the preparation of all culture media and solutions and was 
obtained.
3.2.1.1.2 Phosphate buffered saline
Phosphate buffered saline (PBS) tablets, without magnesium or calcium ions was 
obtained from Oxoid Ltd, UK. One tablet was dissolved in 100 ml of double-distilled, 
deionised water (DDDW) or Milli-Q water with a final pH of 7.3. Solutions were 
sterilised by autoclaving.
3.2.1.1.3 Sodium bicarbonate and sodium hydroxide
Solutions of 7.5% (w/v) sodium bicarbonate (NaHCOs) and 1 M sodium hydroxide 
(NaOH) were prepared individually using Milli-Q water and sterilised by autoclaving.
3.2.1.1.4 Ethylene diamine tetraacetic acid (EDTA)
A 0.02% (w/v) solution of EDTA was prepared in PBS and sterilised by autoclaving.
3.2.1.1.5 Trypan blue
Trypan blue, used for assessing cell viability, was obtained from BDH Laboratory 
Reagents Ltd and was prepared as a 0.1% (w/v) solution in PBS.
3.2.1.2 C u l t u r e  m e d ia  a n d  a d d it iv e s
All solutions used for the preparation of culture medium for mammalian cells were 
obtained from Gibco BRL, Paisley, UK, unless prepared as described above. Eagle’s 
Minimum Essential Medium - Eagle’s (MEM) with Earle’s salts and Dulbecco’s 
Modified Eagle’s Medium (DMEM) were obtained as lOx concentrates. The media 
were supplied without sodium bicarbonate and L-glutamine but contained phenol red as 
an indicator. MEM non-essential amino acids solution (MEM-NEAA), L-glutamine
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(200 mM), and penicillin (10000 IU/ml)/streptomycin (10000 pg/ml) were obtained as 
lOOx concentrates. Foetal calf serum (FCS) from various suppliers was batch tested to 
determine which provided optimum growth of cells. Batches 30F3031S, 40Q1841F and 
06Q7554F from Gibco were found to support growth of all cells and were thus used. 
Growth media were prepared aseptically according to the formulae shown below and 
stored at 4°C and used within three weeks of preparation. The quantities of the various 
media additives used for preparation of the culture media used in this project are 
summarised in Table 3.1.
Reagent MEM with 10% 
[v/v] FCS (ml)
MEM with 20% 
[v/v] FCS (ml)
DMEM with 10% 
[v/v] FCS (ml)
MEM lOx 50 50 -
DMEM lOx - - 50
FCS 50 100 50
MEM-NEAA 5 5 -




7.5% [w/v] NaHC03 15 15 25
Milli Q water to 500 to 500 to 500
1 M NaOH to pH 7.4 to pH 7.4 to pH 7.4
Table 3.1 Formulae for the preparation o f cell culture media.
3.2.1.3 E q u ip m en t
3.2.1.3.1 L abora tory  equipm ent
All aseptic techniques were carried out in a laminar flow cabinet (MDH Ltd) designed 
for vertical re-circulation of air. Cells were cultured in an LEEC PF2 anhydric 
incubator (Laboratory and Engineering Company).
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Growing cell cultures were viewed daily under an inverted light microscope (WILD M4, 
Wild Heerbrugg Ltd). For determination of cell concentration in suspension, 
appropriately diluted samples were counted on a standard double grid haemocytometer 
(Neubauer 0.1 mm Dept, Weber, UK).
3.2.1.3.2 Disposable items
Sterile 175 cm tissue culture flasks were obtained from Falcon, Becton and Dickinson 
and Co, UK. Six- and 96- well plates were obtained from Nunc, (Denmark). 24 mm 
diameter, 0.4 and 3 pm pore PTFE/collagen treated tissue culture inserts (Transwell- 
COL™) were obtained from Costar, UK. Cryopreservation ampoules used for storing 
frozen cells in liquid nitrogen were obtained from Nunc, (Denmark).
3.2 .2  Cell culture  m etho ds
3.2 .2 .1  Ce l l  l in e s
All cell lines were maintained at 37°C in a humidified atmosphere consisting of 95 % 
(v/v) air / 5% (v/v) CO2 . Cells were visually assessed on a daily basis for evidence of 
microbial contamination.
B16 cells, a murine melanoma cell line, were donated by L.R. Kelland, Institute of 
Cancer Research, Sutton. B16 cells were grown in Eagle’s MEM medium containing 
10% (v/v) FCS. For routine culture, cells were subcultured 1 in 10 twice weekly and the 
medium changed every 48 hours.
A549 cells, a human adenocarcinoma cell line derived from the alveolar region of the 
lungs (alveolar type II), were obtained from M. Watson, Department of Pharmacy and 
Pharmacology, University of Bath, UK. A549 cells were maintained in DMEM 
medium containing 10% (v/v) FCS. For routine culture, cells were subcultured 1 in 4 
twice weekly and the medium changed every 48 hours.
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COS-7 cells, a fibroblast-like cell line established by SV40 transformation of CV-1 
African green monkey kidney cells, were obtained from the European Collection of 
Animal Cell Cultures (ECACC), UK. COS-7 cells were cultured in Eagle’s MEM 
containing 10% (v/v) FCS. For routine culture, cells were subcultured 1 in 5 twice 
weekly.
HeLa cells, human carcinoma cells, were obtained from the European Collection of 
Animal Cell Cultures (ECACC), UK. HeLa cells were cultured in Eagle’s MEM 
containing 10% (v/v) FCS. For routine culture, cells were subcultured 1 in 3 twice 
weekly.
Primary human fibroblasts from newborn human foreskin (FEK4) were obtained from 
Professor R.Tyrrell, Department of Pharmacy and Pharmacology, University of Bath, 
UK, were cultured in DMEM supplemented with 15% (v/v) foetal calf serum.
The human fibroblast cell line NIH3T3, and the human emboynal kidney line HEK293 
were obtained from the European Collection of Animal Cell Cultures (ECACC). 
NIH3T3 cells were cultured in Eagle’s MEM containing 10% (v/v) FCS. For routine 
culture, cells were subcultured 1 in 5 twice weekly.
Caco-2 cells (a human colonic adenocarcinoma cell line) were obtained from J. Bennett, 
Pfizer Central Research, Sandwich, UK. These cells were maintained in Eagle’s MEM 
containing 20% (v/v) FCS (heat inactivated at 56°C for 30 minutes). In order to obtain 
differentiated monolayers, Caco-2 cells were cultured on semi-permeable membranes 
with a mean pore size of 0.4 pm which enabled feeding from both apical and basolateral 
surfaces. Cells were seeded at a density of 3 x 105 cells per 24 mm diameter collagen- 
coated tissue culture insert (Transwell-COL™, Costar). Cells were maintained on the 
filter for up to 30 days with a change of the culture medium every 48 hours.
All cells lines were grown as monolayer cultures and subcultured at 80-100% 
confluence. For subculture, 175 cm2 flasks containing attached monolayers of FEK4 
cells were rinsed three times with 10 ml aliquots of PBS and then incubated at 37°C 
with 2 ml of 0.02% (w/v) EDTA solution for approximately 5 minutes. Detached cells
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were diluted to 10 ml with complete culture medium, counted on a haemocytometer and 
an appropriate aliquot of suspension transferred to a sterile 175 cm flask containing 50 
ml of fresh culture medium.
3 .2 .2 .2  D e te r m in a  t io n  o f  c e l l  c o n c e n t r a  t io n
Following detachment of cells from flasks, the cell suspension was briefly vortexed to 
break-up clumps of cells. To a 100 pi aliquot of cell suspension was added 200 pi of 
PBS and 200 pi of 0.1 % (w/v) Trypan blue solution. This sample was loaded on to a 
grid haemocytometer overlaid with a coverslip. Viable cells were detected by a bright 
‘halo’ light around their cell membrane whereas dead cells were permeabilised by the 
dye and stained blue. The viable cell number in the four squares surrounding the central 
square were counted and this was repeated for the other side of the haemocytometer 
grid, using an inverted light microscope. The viable cell concentration in the original 
suspension was calculated using the following equation:
_ „ , Total cell count in 8 chambers x dilution factor xlO4Cells per ml = ------------------------------- --------------------------------
Equation 3.1
3 .2 .2 .3  C e l l  s t o r a g e  a n d  r e c o v e r y
Cells were prepared for storage by detachment of a confluent monolayer according to 
the standard protocol (section 3.2.2.1) followed by centrifugation at 1000 rpm for 8 
minutes. The supernatant was then discarded and the cells resuspended in filter 
sterilised (0.2 pm Acrodisc) solution of culture medium supplemented with 10% (v/v) 
dimethyl sulphoxide (spectrophotometric grade, Aldrich, UK) as a cryopreservative. 
Cell suspensions were then dispensed in 1.8 ml aliquots into Coming tubes and 
transferred to a Union Carbide BF6 biological freezer unit plug, which fitted into a 
Union Carbide LR-40 liquid nitrogen freezer. This permitted the cells to be cooled 
down to -70°C at a rate of approximately 1°C per minute. The cells were then
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transferred to a Union Carbide LR-40 liquid nitrogen freezer where they were stored at 
approximately -148°C. For cell recovery, the contents of an ampoule were thawed 
rapidly by brief incubation in a 37°C water bath followed by dilution with 10 ml of fresh 
medium added dropwise. Cells were centrifuged for 8 minutes at 1000 rpm and the 
supernatant was discarded. The cells were then resuspended in 10 ml of fresh medium 
and then transferred into a 175 cm flask containing 50 ml of medium and then 
incubated under standard culture conditions. Cells were cultured for at least two 
passages in order to establish them before any experiments were carried out.
3.2.3 M o lecular  biolog y  m eth o ds
3.2 .3 .1  B a c t e r ia l  S t r a in
Escherichia coli strain XL 1-Blue (Stratagene, UK), which has resistance to tetracycline, 
was used for propagation of plasmids. Competent E.coli XL 1-Blue cells were prepared 
as described in Appendix A and transformed with the appropriate plasmid using the heat 
shock technique (Appendix Bl) as described by Sambrook et a l254.
3 .2 .3 .2  D e o x y r ib o n u c l e ic  A c id  (D N A)
Two types of DNA plasmids, pRSV/acZ and pCMVluc, were used during the course of 
this project for transfection studies. pRSV/acZ contains the E.coli lacZ gene which 
encodes the p-galactosidase enzyme. pRSV/acZ was obtained from Dr. Ogilvie (Zeneca 
Pharmaceuticals, UK) and is a 7.8 Kb plasmid with the E.coli lacL gene under the 
transcriptional control of the Rous sarcoma virus (RSV) long terminal repeat 
promoter/enhancer sequence. The RSV promoter is a moderate to high strength 
promoter causing moderate levels of transgene expression in mammalian cells. 
pCMVluc contains the firefly luciferase gene driven under the transcriptional control of 
the human cytomegalovirus (CMV) immediate early promoter/enhancer element. The 
CMV promoter is a strong viral promoter causing high levels of transgene expression in 
mammalian cells. pCMVluc was constructed by Dr. D. Milroy (formerly of Bath 
University), by ligating the luciferase gene into the backbone of pCMVp (Clonetech),
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after removal of the lacZ gene.
3 .2 .3 .3  P l a s m id  P r o p a g a t io n , Is o l a t io n  a n d  P u r if ic a t io n
A single colony of E.coli XL 1-Blue containing the appropriate plasmid was isolated 
from an LB agar plate (Appendix C) supplemented with ampicillin and tetracycline (50 
pg/ml and 12.5 pg/ml respectively - see Appendix D) and inoculated into 10 ml of LB 
broth containing the same antibiotics (primary culture). This primary culture was grown 
for 8 hours at 37°C on a shaking incubator at 300 rpm (New Brunswick Scientific, UK) 
and then a 5 ml aliquot was expanded in 500 ml of LB broth, also containing the 
appropriate antibiotics, and grown overnight. The plasmid was isolated by the alkaline 
lysis method and the cell lysate purified by anion exchange chromatography using the 
Plasmid Maxi Kit (Qiagen Inc., USA) in accordance with the manufacturer’s 
instructions. The isolated DNA was dissolved in TE buffer (Tris 10 mM, EDTA, 1 
mM), pH 8 and stored at -20°C.
3 .2 .3 .4  Sa m p l e  P u r it y  a n d  Q u a n tif ic a  t io n
For quantification of plasmid DNA, a 10-20 pi aliquot of sample was diluted to 1 ml 
with distilled water and the absorbance of the solution measured at 260 nm (A260) and 
280 nm (A28o)- The concentration of DNA in the original solution was calculated as 
follows:
Concentration of DNA (pg/ml) = Dilution factor x 501 x A260  
Equation 3.2





Ratios between 1.8 and 2.0 were consistently obtained.
1 Based on the assumption that a 50 pg/m l solution o f  double stranded DNA has an absorbance o f  1 at
260 nm.254
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3 .2 .3 .5  S a m p l e  Id e n t if ic a  t i o n
A sample of purified DNA was linearised with a restriction endonuclease (usually Xba I 
or Sma I for pRSV/acZ (enzyme from New England Biolabs, UK) for one hour at 37°C 
and then loaded on to a 1% (w/v) agarose (Ultrapure grade, Gibco, UK) gel in lx TAE 
(0.04 M Tris-acetate, 0.001M EDTA). Controls of undigested DNA and molecular 
weight markers (Appendix E) were run alongside digested plasmid to verify the 
presence of other contaminating nucleic acids (genomic DNA or RNA) and to confirm 
the size.
3 .2 .4  Retention  of peptide functionality
The ability of the bifunctional peptides such as K25AOAI to bind to DNA and lyse 
erythrocytes simultaneously was investigated using gel mobility shift assay, ethidium 
bromide exclusion assay and erythrocyte lysis assay as described below.
3 .2 .4 .1  G e l  m o b il it y  s h if t  A ssa  y
Agarose gels were produced by dissolving electrophoresis grade agarose 1% (w/v), 
(Gibco BRL) in lx TAE at 100°C. The solution was cooled to about 60°C, poured into 
the gel tray and allowed to set to room temperature. The gels were then mounted in an 
electrophoresis tank (Bio-Rad mini-sub DNA cell) and submersed in lx TAE buffer.
Plasmid DNA, (3 pg pRSV/acZ) was diluted to 125 pi with HBS in a sterile micro- 
centrifuge tube. Various quantities of the peptides (K25AOAI and K25) were separately 
diluted to 125 pi in sterile micro-centrifuge tubes and were subsequently pulse 
centrifuged (Jouan microfuge, France) to concentrate samples to the bottom of the tube. 
The GDV solution was then added to an equal volume of DNA solution by gentle 
mixing (pipetting up and down five times). Mixtures were incubated for 30 minutes 
under ambient conditions. After this time, 40 pi of solution were diluted to 50 pi with 
electrophoresis loading buffer. Six pi of this sample was loaded on to a 1% (w/v) 
agarose gel in lx TAE and subjected to electrophoresis at 80 volts for one hour in lx
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TAE. The gels were stained with ethidium bromide in water at a concentration of 0.5 
pg/ml for 10 minutes. The agarose gel was then viewed under a ultra-violet 
transilluminator and photographed using a Polaroid 55 film fitted into a Polaroid CU-5 
camera.
3 .2 .4 .2  E t h id iu m  B r o m id e  Ex c l  u s io n A ssa  y
Six pg of pRSVfacZ was diluted to 125 pi with HBS in a sterile micro-centrifuge tube. 
Various quantities of the GDV were separately diluted to 125 pi in sterile micro- 
centrifuge tubes. The samples of DNA and GDV were mixed by pipetting up and down 
five times, incubated for 30 minutes and then diluted to 3 ml with 20 mM sodium 
chloride solution. The fluorescence was monitored at Excitation 260 nm and Emission 600 
nm immediately following the addition of 3 pi of a 0.5 mg/ml solution of ethidium 
bromide (final concentration of 0.5 pg/ml), on a RF-540 spectrofluorimeter (Shimadzu, 
UK) using 1 cm cells with slit settings of 5 nm for both the excitation and emission 
monochromators.
3 .2 .4 .3  E r y t h r o c y t e  l y s is  a s s a  y
Erythrocyte lysis capabilities of the peptides were tested using the method described by 
Plank et al.161. Freshly prepared human erythrocytes were washed with HEPES buffered 
saline (HBS: 20 mM HEPES, 150 mM sodium chloride, pH 7.4) and resuspended in a 2 
x assay buffer of the appropriate pH (300 mM NaCl, 30 mM sodium citrate) at a 
concentration of approximately 5 x 107 cells/ml. An aliquot of 80 pi of the erythrocyte 
suspension was added to 80 pi of a serial dilution of the peptide in water (concentration 
of peptides ranged from 0.078125 to 5 pg/pl) in a 96-well microtitre plate and incubated 
for 1 h at 37°C with constant shaking. After removal of the unlysed erythrocytes by 
centrifugation (1000 x g, 5 min), 55 pi of the supernatant was transferred to a new 
microtitre plate and haemoglobin absorption determined at 490 nm (background 
correction at 750 nm). 100% lysis was determined by adding 1 pi of a 10% (v/v) Triton 
X-100 solution prior to centrifugation. The haemolytic units were calculated as the 
reciprocal value of the peptide concentration, where 50% leakage was observed (i.e. the
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volume (pi) of erythrocyte solution which is 50% lysed, per jug of peptide). The 
experiment was performed in triplicates for each peptide concentration.
3.2.5 In v estig a tio n  of toxicity  u sin g  M TT a s s a y
B16 cells were plated in a 96-well plate at a density of approximately 4000 cells per 
well in 100 pi media. Peptides to be tested were made up at twice the required 
concentration in 100 pi of PBS and added to the wells. The first column had no cells, 
the sixth column had cells incubated with 100 pi PBS (no cytotoxic agent). Ten serial 
dilutions were prepared such that expected 50% cell kill was straddled evenly by 
maximum and minimum concentrations. The cells and agents were incubated at 37°C 
for 3 days. The medium was then removed and the plates washed twice with 200 pi 
PBS. A 10 mg/ml stock solution of MTT (2-(4,5-dimethylthiazol-2-yl)-2,5- 
diphenyltetrazolium bromide, from Sigma Chemicals Ltd, Louis MO USA) was made in 
PBS and diluted with serum free media (no FCS, no amino acids) to produce a 1 mg/ml 
solution. The cells were then incubated with 200 pi of 1 mg/ml MTT in serum free 
medium for 3 hours at 37°C. The medium was then removed by quick overturn of the 
96-well plate. Two hundred microlitres DMSO was added to each well and the plate 
was placed on an orbit mixer moving at medium speed for 5 minutes to dissolve the 
formazan. Absorbance was read at 540 nm (background readings at 690 nm). A graph of 
absorbance versus log concentration of cytotoxic agent was plotted. The extracellular 
concentration of cytotoxic agent which kills 50% of cells compared to control ( E C 5 0 )  
was determined.
3 .2 .6  Transfectio n  of m a m m a lia n  cells
For transfection of exponentially growing cultures, cells were seeded at a density such 
that at the time of transfection monolayers were 40-50% confluent. For the various cells 
types studied, seeding densities on 35 mm well plates (6 -well plates) were as shown in 
Table 3.2. Following seeding, cells were grown for 16-20 hours under standard 
conditions in the appropriate culture medium prior to transfection. Transfections were 
carried out in the presence of Opti-MEM™, which is a serum-free medium specifically 
designed for transfection experiments.
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Cell Line Cell Number per 6- 
well Plate
B16 1 X 105
NIH3T3 4 x  105
HEK293 2 x  105
COS-7 2 x  105
A549 2 x  105
HeLa X O
Caco-2 3 x  105
CHO 1 x 105
FEK4 5 x  10s
Table 3.2 Seeding densities on 6-well plates for the transfection o f  various mammalian cells lines.
3 .2 .7  P r o t e in  a s s a y
The protein content in cell extracts was measured using the Bio-Rad protein 
assay kit. Samples were prepared according to the manufacturer’s protocol (macro 
assay) and calibration curves were constructed using bovine serum albumin as a 
standard. Spectrophotometric measurements were made at 595 nm. A typical standard 
curve is shown in Appendix F.
3 .2 .8  P e p t id e - D N A  c o m p l e x  f o r m a t io n
Three batches of L K 2 5 A O A I  were used in this project. The first batch (K2sAOA1#1) 
consisted of the whole main peak collected during HPLC and had an estimated purity of 
70-80%. This batch of peptide was used for erythrocyte lysis assay, ethidium bromide 
assay and initial transfection experiments. The second batch (K2sAOA1#2) consisted of 
peak splicing of the main peak (Figure 2.9) and has an estimated purity of 75-90% 
(based protein sequencing and analytical HPLC results). The yield of this batch after 
purification was 6 %  and was used only for transfection. A third batch of K 2 5 A O A I
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(K25A0A1#3) was crude peptide, which did not undergo any HPLC purification 
process. K2sAOA1 # 3  has an estimated purity of 70% according to MALDI-TOF mass 
spectrometry (Figure 2.13) analysis. This batch was used for the second erythrocyte lysis 
assay in section 0, and experiments with Bafilomycin Ai (section 3.3.7).
A solution containing 6.4 pg DNA was made up to 800 pi with HBS in a sterile 
microcentrifuge tube. For single-step complex formation, aliquots of appropriate 
quantities of peptide solutions taken from a 1 mg/ml stock solution were placed in 
separate microcentrifuge tubes and made up to 800 pi with HBS. The peptide and DNA 
solutions were mixed by pipetting up and down 5 times. This method was found to be 
the optimum mixing method for polycation/DNA complexes . For two-step complex 
formation, 6.4 pg of DNA in 400 pi HBS was mixed with an appropriate quantity of K25 
or K8  in 400 pi HBS and left for 30 minutes before mixing with appropriate quantity of 
fusion peptide in 800 pi HBS and incubating for a further 30 minutes.
An hour prior to transfection, monolayers of rapidly dividing cells were washed twice 
with warm transfection medium and then 1.5 ml of this medium was added to each well. 
Five hundred microlitres of complex containing 2 pg of DNA and variable quantities of 
gene transfer agent were added to each well. Transfection was carried out for 4 hours at 
37°C after which time the transfection medium was replaced with fresh complete 
culture medium and cells were cultured for a further 44 hours for RSVlacZ plasmid or 
20 hours for CMVluc plasmid before harvesting for analysis. For all transfection 
studies, each data point represents the mean ± standard error of the mean (SEM) of 
triplicate samples and each experiment was performed on at least two occasions to 
ensure reproducibility of results.
3.2.9 O l e o y l - f u s o g e n i c  p e p t i d e / D O T AP/DNA c o m p l e x  f o r m a t i o n
DOTAP/oleoyl-fusogenic liposomes were prepared by an adaptation of the reverse 
phase evaporation method previously described by Szoka and Papahadjopolous . 
DOTAP powder was dissolved in chloroform to produce a 2 mM stock solution. An 
appropriate volume of solution was transferred to a clean amber sample vial. Oleoyl- 
AOA1 peptide solution was prepared by dissolving in 0.1% (v/v) aqueous ammonia. An
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appropriate amount of ethanol (approximately 1:1 v/v) was added to both the 
chloroform layer and aqueous layer before mixing the two layers to form a clear 
homogenous solution containing various molar proportions of DOTAP/oleoyl-AOAl. 
The clear homogeneous mixtures containing DOTAP/oleoyl-AOAl were evaporated by 
bubbling nitrogen gas, eventually leaving a thin film on the glass wall. Residual 
amounts of liquid were removed by placing vials under high vacuum (Edwards) 
overnight. The lipidic film was subsequently re-dispersed in sterile water. The aqueous 
dispersion was vortexed for 1 minute at full speed under ambient conditions to generate 
large multilamellar vesicles. Following preparation, the lipidic fusogenic peptides were 
stored at 4°C and used within 7 days.
3.2.10 A n a l y t i c a l  m e t h o d s
3.2 .10 .1  P r e p a r a t io n  o f  c e l l  e x t r a c t s  f o r  a n a l y s is  o f  g e n e  e x p r e s s io n
Solutions used during analysis are listed below. Their composition is found in section
3.2.1.1 above.
Phosphate buffered saline (PBS)
0.02% (w/v) EDTA solution
0.1M sodium phosphate buffer (pH 7.3)
Lysis buffer (0.1% [w/v] Triton X-100 in 250 mM Tris buffer pH 8)
Washed cell monolayers were treated with 250 pi of lysis buffer per well and plates 
were frozen at - 70°C. After thawing at room temperature, the cell extracts were 
collected and transferred into sterile micro-centrifuge tubes and centrifuged for 10 
minutes at 1000 rpm and the supernatant used for analysis.
3 .2 .10 .2  A ssa  y  m e t h o d s
3.2.10.2.1 4- methylumbelliferyl -fi-D-galactoside (MUG) method
300 mM MUG in DMSO
100
Buffer Z 0.1 M sodium phosphate buffer (pH 7.3) 
10 mM potassium chloride 
1 mM Magnesium sulphate
STOP buffer 300 mM Glycine
15 mM EDTA
adjusted to pH 11.2 with concentrated solution or pellets 
of sodium hydroxide
A 300 mM stock solution of MUG was prepared in DMSO (10 mg/ml) and stored at 
4°C for up to one month. When required, this solution was diluted 1:100 to a 3 mM 
working solution in buffer Z (reducing the DMSO concentration to » 1% [v/v]) and 
heated in a boiling water bath to aid solubilisation when necessary.
An appropriate volume of cell extract (maximum of 105 pi) was diluted to 120 pi with 
buffer Z in a 96-well plate to which 30 pi of 3 mM MUG solution was added. The 
contents in each well were mixed and the plate was incubated at 37°C for 60 minutes 
after which time the reaction was terminated by the addition of 75 pi of STOP buffer. 
Fluorescence was measured using a multiwell plate scanning spectrofluorimeter 
(Titretek Fluoroskan II) at Agitation 350 nm and Admission 460 nm. A typical calibration 
curve is shown in Appendix Gl.
3.2.10.2.2 Luciferase assay
Luciferase levels within cells were quantified using the Promega luciferase assay system 
(Promega, UK) according to the manufacturer's instructions. As little as 0.001 pg of 
firefly luciferase can be measured using this kit. A standard curve of light units versus 
relative enzyme concentration was produced using purified firefly luciferase (Appendix 
G2 and G3). The lysis protocol detailed above was followed, substituting the Promega 
lysis buffer (25 mM Tris-phosphate, pH 7.8; 2 mM DTT 2 mM
l,2-diaminocyclohexane-N,N,N',N'-tetraacetic acid; 10% (v/v) glycerol; 1% (v/v) Triton 
X-100 and BSAI mg/ml) for the phosphate buffer. Supplementation with 1 mg/ml BSA
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ensured that luciferase was not lost from solution by adsorption onto container walls. 
After centrifugation of the cell lysate, 20 pi of room temperature cell extract 
(supernatant) was mixed with 1 0 0  pi of luciferase assay reagent (luciferase assay 
substrate plus 10 ml of assay buffer) at room temperature. The disposable test tube 
containing the reaction was then immediately placed into the luminometer (TD-20/20). 
The instrument settings were as follows: sensitivity 25.1, delay 2 seconds and the 
integration 1 0  seconds.
3.2.10.2.3 Cytochemical staining for p~galactosidase activity
Solutions used:
Phosphate buffered saline (pH 7.3)
Fixative solution 1% (v/v) glutaraldehyde
1 mM magnesium chloride 
0.1M sodium phosphate pH 7.3
X-gal solution 0.2% (w/v) 5-bromo-4-chloro-3-indolyl-p-
galactoside (X-gal) in dimethylformamide 
1 mM magnesium chloride 
150 mM sodium chloride
3.3 mM potassium ferrocyanide, K4Fe(CN) 6
3.3 mM potassium ferricyanide, K3Fe(CN) 6 
0.1M sodium phosphate
Forty-four hours post transfection, cell monolayers were rinsed twice with 2 ml of PBS 
and then permeabilised by overlaying with 2  ml of the fixative solution followed by 
incubation at 4°C for 5 minutes. The fixative solution was aspirated, the cells rinsed 
once with PBS and then overlaid with 1 ml of X-gal solution, followed by incubation 
overnight at 37°C. Cells were then washed twice with PBS and viewed under an 
inverted light microscope. Cells expressing the p-galactosidase enzyme were stained 
blue against a background of unstained cells. Where appropriate, photographs were 
taken using a Nikon F-301 camera with Fujichrome 200 or 400 DX film.
102
3.2.10.2.4 Fluorescence Cytometry
Cells were transfected as usual in 6 -well plates with DNA/peptide complexes with 
plasmid DNA encoding for the enhanced green fluorescent protein (EGFP) complexed 
with either DK25AOAI, lK 2sAOA1 #2 , K8+JTS1, PEI, or PL219 in the presence or 
absence of chloroquine at a concentration of 100 pM at their respective optimum charge 
ratios for the respective cell lines. Twenty-four hours after initiation of transfection, the 
culture medium was aspirated and the cells were washed twice with 2  ml aliquots of 
PBS. Transfected cells were detached by incubating cells with 250 pi of 0.02% (w/v) 
EDTA solution per well at 37°C for 2 minutes. In order to remove EDTA from the cells, 
the cell suspension was transferred into a 1.5 ml microcentrifuge tube and centrifuged at 
13000 rpm for 1 minute. The supernatant was removed and the cells were resuspended 
in 1 ml Opti-MEM® supplemented with 10% (v/v) foetal calf serum (FCS), centrifuged 
at 13000 rpm for 1 minute and the supernatant removed. This last process was repeated 
once. Cells were then resuspended in 1 ml Opti-MEM supplemented with 10% (v/v) 
FCS and placed on ice, ready for fluorescence cytometry analysis. Samples were 
analysed on a Becton Dickinson fluorescence cytometry Vantage with optics optimised 
for detecting EGFP.
3.2.11 C a l c u l a t i o n s
3 .2 .11 .1  Tr a n s f e c t io n  A c t iv it y
P - gal/luc activity per well = 250 (pi) x p  - gal/luc activity per sample 
Sample volume (pi)
E q u a tio n  3.4
Protein content per well = 250 (pi) x protein content per sample 
Sample volume (pi)
E q u a tio n  3.5
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„ ... _ ... . . Total B - gal/luc activity per well (uU or mU)Specific p - gal/luc per activity = --------- —- ------------- —--------- —---------- -
Total protein per well (mg)
E q u a tio n  3.6
3 .2 .1 1 .2  C h a r g e  r a t io s
» . .  . .  . Mass of GDV x No. of positively charged groupsNo. of mols of positive charges = ---------------------------- ----------------- 2— -— —
Molecular weight of GDV
E q u a tio n  3.7
No. of mols of negative charges = Mass of DNA 2
330 
Equation 3.8
. . . No. of mols of positive charges+ / -  charge ratio = -------------------£-------------- —
No. of mols of negative charges
Equation 3.9
Calculation of charge ratios
. . . Molarity of positive charges+/- charge ratio = --------- ------ ---------------2—
Molarity of negative charges
Equation 3.10
w  mass of DNAMolarity of negative charges = molarity of nucleotides = -----------------
E q u a tio n  3.11
RMM (relative molecular mass) = 330, based on an average molecular weight of a 
nucleotide monomer. There is one negative charge per DNA.
2 Based on the assumption that the average m olecular w eight o f  a nucleotide is 3304
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2 x 1 0  x 1 (-ve charge)Molarity of negative charge in 2 pg of DNA = ----------------------------
E q u a tio n  3.12
Molarity of positive charges = molarity of positive charges supplied by the cationic 
molecule. There is one positive charge per lysine residue. For peptide molecules with 
both positive and negative charges e.g. K25AOAI, the net charge between positive and 
negative residues was used as the overall charge to calculate the quantity required to 
complex with DNA to provide the desired charge ratio for the complex. K25AOAI has 
25 positive charges from lysine and 4 negative charges from glutamic acid and aspartic 
acid. Hence the net positive charge is 21.
„ . .  . mass x net positive charge mass x 2 1Molarity of positive charges = ----------------------   =--
RMMKjjAOA] 5736
E q u a tio n  3.13
For compounds with histidyl chains ( K ^ s H i o A O A l a n d  K 2 5 H 2 0 A O A I ) ,  the histidine side 
chain (pKa =6.0) was estimated to be uncharged at pH 7.0 and hence not included in the 
calculation of positive charges.
3.2.12 I n  v iv o  t r a n s f e c t i o n  m e t h o d s
Dr. Pauline Wood, the Home Office licence holder, assisted in animal studies and her 
considerable input into this study is gratefully acknowledged. Female C3H mice were 
obtained from Charles River at 6-7 weeks of age and then allowed to acclimatise for a 
further week prior to experiments. Murine fibrosarcoma RIF-I cells258 were cultured in 
RPMI 1640 medium supplemented with 15% (v/v) foetal calf serum, penicillin and 
streptomycin, and were not passaged more than 7 times prior to trypsinisation for 
implantation. The mice were lightly anaesthetised using intraperitoneal Hypnorm (a mix 
of fentanyl citrate 0.315 mg/ml and fluanisone 10 mg/ml, 0.05 ml per mouse) about 2 
hours before implantation. An injection of 0.05 ml PBS containing 2xl05 RIF-1 cells 
was made intradermally mid way along the back of the mouse after shaving off the fur
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with clippers. Tumours were ready for gene delivery experiments 7-10 days 
post-implantation. The mice were weighed and the dimensions of the tumour recorded, 
one day before muscle injection with DNA/peptide complexes. The mice were then 
randomly assigned to the different treatment cages.
On day zero, a 20 pi suspension/solution containing DNA complexed with or without 
K25AOAI was made into the right hind leg muscle of each mouse. To facilitate 
intramuscular injection the mice were anaesthetised using a combination of Hypnovel 
(midazolam 5 mg/ml) and Hypnorm (1 ml of Hypnovel + 1 ml of Hypnorm + 2 ml 
sterile water, inject 0 . 1  ml intraperiotoneally) and the right hind thigh shaved with an 
electric shaver. On day five, the mice were each injected with a 20 pi 
suspension/solution containing DNA complexed with or without K25AOAI into each 
tumour. Muscle and tumour injections were made using a graduated 0.3 ml sterile B-D 
syringe (Becton and Dickinson and Co, UK) fitted with 8  mm, 30 gauge needle. 
Following each injection, the needle was left in place for a short period to prevent 
formulation being expelled by the back pressure in the tissue. The mice were killed by 
cervical dislocation on day seven. Tumours and right hind leg muscle tissues were 
excised and placed in 2 ml cryotubes (NUNC, Denmark) and snap frozen in liquid 
nitrogen and stored in a Union Carbide BF6  biological freezer unit plug which fitted 
into a Union Carbide LR-40 liquid nitrogen freezer until ready to be analysed.
3.2.13 A n a l y s i s  o f  in  v iv o  g e n e  e x p r e s s i o n
Excised tissues were weighed then homogenised for 30 seconds in a screw cap sterile 
tube containing 5-fold v/w of lysis buffer/weight of tissue (0.1 M potassium phosphate 
buffer pH 7.8, 0.2% (v/v) Triton X-100) using an ultraturax homogeniser. The tissue 
suspension was then spun at 12000 g for 15min at 4°C to remove the cellular debris. 
Luciferase was quantified using the Promega luciferase assay system (Promega, UK) as 
described in chapter 3 (section 3.2.10.2.2). The protein content of this supernatant was 
analysed using the Bio-Rad Protein assay kit (section 3.2.7). Expression was normalised 
with respect to total muscle or tumour protein.
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3 .3  R e s u l t s  a n d  d is c u s s io n s
3.3.1 Re su lts  a n d  d isc u ssio n : Inv estig a tio n  of retention  of bifunctionality
In ternary complexes consisting of plasmid DNA, cationic polymers and fusogenic 
peptide sequences, the presence and individual activity of the constituent reagents are
7 f\ i fnrecognised as important for the mediation of gene delivery ’ . Novel peptides
consisting oligolysine chains of 10 and 25 residues linked covalently to fusogenic 
sequence were synthesized in this project. The following sections describe studies 
performed to determine if the two moieties of the novel peptide retained their functions 
after being synthesized as a single linear peptide and discuss the effect of low pH on the 
activity of the fusogenic sequence within the bifunctional peptide.
3.3.1.1 R e te n tio n  o fD N A -b in d in g  a c t iv i ty
The purpose of this study was to ascertain if the presence of the fusogenic component of 
the bifunctional peptide inhibited the ability of the peptide to bind and condense DNA, a 
prerequisite for any in vitro transfection activity94. The bifunctional peptide K25AOAI 
(batch # 1 ) was compared with K25 using gel retardation assay and ethidium bromide 
exclusion assay, to investigate the effect of the presence of the fusogenic moiety and 
study the ability of bifunctional peptides to bind and condense DNA.
3.3.1.1.1 Gel mobility assay
To compare the complexation of K25AOAI and K25 with DNA, various quantities of 
either peptides were mixed with 3 pg of pCMVluc in HBS, as described in section 
3.2.4.1. Following incubation, the migration of complexes on a 1% (w/v) agarose gel in 
lx TAE buffer was examined after staining with ethidium bromide. DNA neutralisation 
was assumed to have occurred at the lowest charge ratio (+/-) where the DNA was 
completely immobilised within the well origin. Figure 3.1 shows the results of the effect 
of charge ratio of K25AOAI/DNA or K25/DNA complexes on the pattern of migration 
of these complexes on 1 % (w/v) agarose gel when a potential difference of 80 volts was 
applied for 1 hour. In lane 1, which had plasmid DNA only, there was a small degree of
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smearing but a predominant proportion of the DNA formed a single band pertaining to 
supercoiled DNA (refer to Figure 3.27, which shows a supercoiled DNA band and a 
nick-circular DNA band appearing under different incubation conditions). When DNA 
was complexed with K25AOAI at a charge ratio of 0.96, (lane 2) there was a 
considerable amount of smearing, indicating that DNA had been partly neutralised and 
was moving at varying speeds through the gel depending on the extent of neutralisation. 
It was observed that some amount of DNA barely migrated out of the well, indicated by 
the dark band below the well (towards the positive end of the gel); this band represented 
the proportion of plasmid DNA which was fully neutralised. The dark band of DNA 
observed furthest from the well (in line with the DNA band in lane 1) represented the 
proportion of DNA that was not complexed with K25AOAI. A similar observation was 
made for K25/DNA complexes formed at a charge ratio of 0.5. At charge ratios above 
neutral, that is 1.9, 3.8, 7.6 and 15.2 in lanes 3, 4, 5 and 6  respectively, no DNA/peptide 
migration was observed, indicating that the fully neutralised complexes were 
immobilized within the wells; the excess proportion of peptide not complexed with 
DNA would have drifted into the electrophoresis buffer towards the cathode. Lanes 8 , 9 
and 10 containing K25/DNA complexes at charge ratios of 1.0, 2.0 and 4.0 also showed 
that fully neutralised DNA complexes did not migrate much further beyond the 
boundary of the wells (Figure 3.1). This result provided evidence that the presence of 
the fusogenic moiety in K25AOAI did not inhibit the DNA binding function of the K25 
component at the charged ratios used for transfection.
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F igu re  3.1 Agarose gel displaying the retardation of DNA/peptide complexes with increasing amounts 
o f either K25A0 A 1#2 (lanes 2-6) or K25 (lanes 7-10), free DNA is in lane 1. K25A 0A 1/D N A  complexes 
were formed at charge ratios o f 0.96, 1.9, 3.8, 7.6, and 15.2 (lanes 2 to 6 respectively) by adding 
increasing amounts o f K25A 0A 1#2 to 3 pg DNA in 125 pi HBS. K25/DNA complexes were formed at 
charge ratios o f 0.5, 1.0, 2.0 and 4.0 (lanes 7 to 10). The complexes were prepared in HBS as detailed in 
section 3.2.8, and incubated for 30 minutes before loading onto a \%  (w/v) agarose gel and running at 80 
Volts for one hour.
3 .3 .1 .1 .2  E th id ium  B rom ide exc lusion  A ssa y
The ability of the oligolysyl peptides and bifunctional peptides to interact and form 
complexes with plasmid DNA was also studied using the ethidium bromide (EtBr) 
exclusion assay. The binding of compounds to DNA prevents ethidium bromide from 
intercalating with DNA resulting in a quenching of florescence. The complexation of 
DNA was measured as a decrease in fluorescence intensity of ethidium bromide and the 
results expressed as a percentage of control (naked DNA) fluorescence, normalised to 
100%. The quantity of each peptide used to complex DNA was expressed in terms of 
calculated charge ratios of peptide/DNA complexes to simplify comparisons. The 
results showed that increasing the amounts of oligolysine or bifunctional peptides 
complexing with a fixed quantity of DNA resulted in a decrease in fluorescence of 
DNA/EtBr complexes (Figure 3.2). The results also showed that the binding affinity of 
oligolysine K10 and K25 to DNA to the exclusion of ethidium bromide compared 
favourably with high molecular mass polylysine2i4 . Linking of fusion peptide sequences 
did not prevent binding if the oligolysine moiety was long enough. The quenching of 
EtBr florescence to minimal level occurred with p L L ^  at a charge ratio of about 2.5
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compared to the charge ratio of 3 to 4 for the bifunctional peptides K25INF7 and 
K25A O A l#l. Also, peptides K10 and K25AOAl#l or K25INF7 bound to DNA more 
effectively than K10INF7. Although K10 was efficient at condensing DNA, when the 
HA-2 analogue, INF7, was coupled covalently to K10 (to form K10INF7) it was 
necessary to add a large charge excess to achieve condensation. This explains the 
undetectable transfection activity using the (3-gal reporter plasmid, which is reported 
later in this chapter.
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F igu re  3.2 Ethidium bromide exclusion by various peptides at various charge ratios. Six pg of 
pRSV/acZ was diluted to 125 pi with HBS in a sterile micro-centrifuge tube. Variable quantities o f the 
GDV were separately diluted to 125 pi HBS in sterile micro-centrifuge tubes to give the charge ratios 
indicated in the graph. Samples were mixed, incubated for 15-30 minutes and then diluted to 3 ml with
20 mM sodium chloride solution. The fluorescence was monitored at A,exCitation 260 nm and Emission 600 
nm immediately following the addition o f 3 pi o f a 0.5 mg/ml solution o f ethidium bromide (final 
concentration o f 0.5 Jig/ml), on a RF-540 spectrofluorimeter (Shimadzu, UK) using 1 cm cells with slit 
settings o f 5 nm for both the excitation and emission monochromators.
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The ability of K2 sAOA1 # 1  to bind to DNA was demonstrated by ethidium bromide 
exclusion assay and gel retardation assay. The results demonstrated that the presence of 
fusogenic peptides did not inhibit the DNA binding activity once the number of lysine 
residues exceeded a certain threshold. The data suggested that the bifunctional peptides 
with 10 lysine residues had a lower binding affinity for DNA than bifunctional peptides 
with 25 residues of lysine. Given that Kio was able to bind to DNA (and exclude 
ethidium bromide) to practically the same degree as K25AOAI and K25INF7 , the 
inability of K i o I N F 7 to effectively bind to DNA can be explained by the fact that the 
relatively larger fusogenic moiety with negative charges interferes sterically and 
ionically with the binding of the positive lysine residues in K i o I N F 7. The inability of 
K i o I N F 7 to effectively condense DNA explains its lack of transfection activity (Figure 
3.12). It will be of interest to determine the minimum length of the lysine chain required 
within a bifunctional peptide to restore DNA-binding activity to the level of Kio or K25, 
because as it was shown in Chapter 2, the greater the number of residues in the peptide 
sequence, the more heterogeneous and expensive the product.
3 .3 .1 .2  R e t e n t io n  o f  f u s o g e n ic  a c t iv it y
The ability of synthetic fusogenic peptides to disrupt membranes is central to its 
capacity to improve in vitro transfection of cells167. Two established methods for 
ascertaining the fusogenic properties of peptide sequences are liposome leakage assay 
and erythrocyte lysis assay. The haemolytic activity of a fusogenic peptide as 
determined by the erythrocyte lysis assay had been shown by Plank and colleagues to 
have a better correlation with transfection activity than the liposome leakage activity of
1 fnpeptide sequences . Peptide sequences that had liposome leakage activity but did not 
possess haemolytic activity were found not to augment transfection in a quaternary gene
1 fntransfer system . It was considered necessary to investigate if fusogenic activity was 
retained after the inclusion of oligolysine residues to the carboxyl terminal of the 
fusogenic peptide sequences. In view of the fact that these biophysical analytical studies 
required a considerable quantity of peptide material (20-60 mg) and there was a limited 
quantity of peptide material available, the erythrocyte lysis assay was chosen as the only 
method to show the fusogenic property of the bifunctional peptide. Erythrocyte lysis 
assay was performed at pH 5 and 7 to determine if the membrane-disruptive ability of
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fusogenic peptides and bifunctional used in this project were pH- dependent. Peptides 
with a high degree of selective lytic activity at pH 5 compared to pH 7 have been shown 
to be better transfecting agents . The data from this first erythrocyte lysis study, 
represented in Figure 3.3, showed that AOA1*, INF7* and their oligolysyl derivatives 
K25A0A1#1 and K25INF7 , all had the ability to disrupt membranes of erythrocytes. 
Both fusogenic peptides AOA1* and INF7* and their K25 derivatives had 1.5-3-fola 
greater lytic activity at pH 5 than at pH7 as determined by comparing the concentration 
at which 50% of erythrocytes are lysed. Peptides K25, K25H20 and the target sequence of 
K25H20AOAI (data not shown) did not have any erythrocyte lytic activity.
In a repeat of the erythrocyte lysis study to confirm the previous data, the concentration 
of the peptides were calculated and compared in terms of molarity (M) to compensate 
for the large differences in relative molecular weights between AOA1 and the 
bifunctional peptides K10AOAI and K25AOAI. The data from this second erythrocyte 
lysis study is represented collectively in Figure 3.4 and for individual peptides AOA1, 
K10AOAI and K2 sAOA1 # 3  in Figure 3.5, Figure 3.6 and Figure 3.7 respectively. A 
detailed comparison of the haemolytic potencies of AOA1, K10AOAI and K2sAOA1 # 3  
is described later and represented in Table 3.3.
The data showed that Kio and K25 did not have any haemolytic activity greater than 
water, the negative control. The visual appearance of the erythrocyte suspension in the 
assay buffer of pH 5 (but not pH 7) darkened with time (after about 1 hour), even in the 
absence of any test compound. Subsequently, the absorbance readings (at a wavelength 
of 490 nm) of the supernatant of the negative control, as well as the haemolytically 
inactive Kio and K25 were higher at pH 5 (ranging between 0.116 and 0.152) than at pH 
7 (ranging between 0.051 and 0.062).
It was visually observed that on addition of erythrocyte suspension at pH 5 to a high 
concentration (6.25x1 O'4 to 5x10*2 M) of peptide with fusogenic activity, the suspension 
turned into a clear red solution almost instantly, whereas, at pH 7, there was a delay 
from about 1 minute at the highest concentration to about 5-10 minutes at peptide 
concentration of 1.5 6x1 O'4 M. This observation suggests that the fusogenic sequence 
AOA1 is kinetically more haemolytic at pH 5 that at pH 7 and that at low
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concentrations, the difference in speed of membrane disruption could be important in its 
activity as an adjunct in gene delivery. Allowing for the differences in background 
readings at pH 5 and 7, haemolytic activity of peptides A O A 1,  K i o A O A l  and K 2 5 A O A I  
was higher at pH 5 than at pH 7.
For comparison, adding 1 pi of a 10% (v/v) solution of triton X-100, which effects 
100% lysis167, gave average absorbance readings of 0.864±0.053 at pH 5 and 
0.760±0.041 at pH 7. Based on this premise, both A O A 1 and K i o A O A l  caused 100% 
lysis of erythrocytes from a peptide concentration of 1.56x1 O'4 M and above, at pH 5, 
but K 2 5 A O A I  required a higher concentration, between 3.125x1 O'4 and 6.25x1 O'4 M 
(between 2- and 4-fold higher concentration) to cause 100% lysis at pH 5. At pH 7, 
A O A 1 required 1.25x10' M (an 8 -fold higher concentration compared to pH 5) to cause 
100% lysis, whilst K i o A O A l  required 6x1 O'4 M (a 4-fold increase in concentration 
compared to pH 5) and K 2 5 A O A I  required 2.5-5.0x10' M (a 4 to l6 -fold increase in 
concentration compared to pH 5) to cause 100% lysis. It therefore appears that the 
attachment of the oligolysyl chain reduces the haemolytic activity of the fusogenic 
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Figure 3 .3  Haemolytic activity o f synthetic fusogenic peptides at pH 5 and pH 7. Assay at pH 5 (A) 
and pH 7 (B) were perform ed as described in methods section 3.2.4.3. (C): The haemolytic units were 
calculated as the reciprocal value o f the peptide concentration, where 50% leakage was observed (i.e. the 
volume (|il) o f erythrocyte solution, which is 50%, lysed, per fig o f peptide).
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F igu re  3.4 Haemolytic activity o f synthetic fusogenic peptides at pH 5 and pH 7. Assays perform ed at 
pH 5 are represented as thick lines in the graph and marked with asterisks (*) in the legend.
It was observed that AOA1 was only partially soluble in water. A suspension of AOA1 
in deionised water at a concentration of 5x1 O'2 M was visualised as a white, cloudy but 
uniform dispersion. The white haze of the suspension of AOA1 was present till the 9th 
serial dilution. From purification attempts of AOA1 (Chapter 2), it was known that 
AOA1 was not soluble at low pH, therefore it was suspected that the addition of 
erythrocyte suspension at pH 5 would further reduce the solubility of AOA1. Indeed, 
when erythrocyte suspensions were centrifuged after incubation, suspensions 
containing AOA1 had precipitates present from the highest concentration to the 5th 
serial dilution; the precipitates were visually greater in volume at pH 5 than at pH 7, 
thus supporting the notion that AOA1 solubility was further reduced after the addition 
of erythrocyte suspension at pH 5. This observation is important because it suggests 
that the haemolytic potency of AOA1 at pH 5 is reduced by its low solubility at pH 5. 
In other words, the attachment of lysine 10 residues to form K10AOA1, increases the 
solubility of the compound and offsets any reduction in fusogenic effect as a result of 
the attachment of fusogenically inactive K10. Increasing the lysine chain length to 25
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residues (to form K25AOAI), however, began to cause some reduction in the fusogenic 
activity, compared to that of AOA1.
Plank and colleagues167 used the concept of haemolytic units to compare haemolytic 
activity of various peptides at pH 5 and 7. This method provided a snap shot comparison 
of haemolytic potency for peptides and was useful for demonstrating the specificity or 
selectivity of the haemolytic activity of peptides at different pHs. This method of 
analysis (haemolytic values) was used in the first erythrocyte lysis assay, results of 
which are shown in Figure 3.3, but the information it provided was limited because the 
peptides being compared were not specific or even selective at pH 5 but merely had a 
higher haemolytic activity at pH 5 compared to pH 7. A modified concept of haemolytic 
units has been applied below, for each peptide with a fusogenic component, at multiple 
concentration points where the graph of absorbance versus concentration exists in the 
same absorbance range, to produce a more comprehensive picture of the effect of pH on 
the activity of A O A 1,  K i o A O A l  and K 2 5 A O A I ,  based on the data represented in Figure 
3.4. The data in Table 3.3 shows that the ratio of peptide concentration at pH 5 to pH 7, 
required to cause the same degree of haemolysis varies considerably with respect to the 
concentration of peptide incubated with erythrocyte suspension. The influence of low 
pH on the haemolytic potency of A O A 1,  K i o A O A l  and K2sAOA1 # 3  was highest at the 
top range of the concentrations of peptides tested. From a peptide concentration of 
1.25x1 O'3 M and above, A O A 1,  K i o A O A l  and K2sAOA1 # 3  were about 10-fold more 
potent at causing haemolysis at pH 5 compared to pH 7. At a peptide concentration of 
about 3.125x1 O'4 M, the influence of pH on the haemolytic potency of the peptides 
A O A 1 and K i o A O A l  had been reduced to 4.5-fold, and about 2-fold for K 2 5 A O A I .  The 
haemolytic activity of A O A 1 exhibited the highest preference for pH 5 (against pH 7), 
as the haemolytic potency ratio at pH 5 compared to pH 7 did not decrease below 4-fold 
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F igu re  3.5 Haemolytic activity o f AOA1 at pH 5 (red line and marked with asterisk (*) in legend) and 
pH 7 (blue line) at low peptide concentrations (A) and across the whole concentration range o f 1.22 |iM  
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F igu re  3.6 Haemolytic activity o f KioAOAl at pH  5 (red line and marked with asterisk (*) in legend) and 
pH 7 (blue line) at low peptide concentrations (A) and across the whole concentration range o f 1.22 pM  
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F igu re  3.7 Haemolytic activity o f K25AOAI at pH 5 (red line and marked with asterisk (*) in legend) and 
pH 7 (blue line) at low peptide concentrations (A) and across the whole concentration range of 1.22 pM  






Concentration o f 
peptide at pH 5 (M)
Concentration o f 
peptide at pH 7 (M)
Ratio o f concentration o f 
peptide at pH 7 to pH 5 which 
caused the same average 
extent o f haemolysis
AOA1 0.737 1.250E-04 1.250E-03 10.000
0.579 9.000E-05 6.250E-04 6.944
0.444 6.000E-05 3.125E-04 5.208
0.339 3.906E-05 1.800E-04 4.608
0.32 3.500E-05 1.563E-04 4.464
0.23 9.766E-06 1.000E-04 10.240
K10AOA1 0.799 1.200E-04 1.250E-03 10.417
0.735 9.000E-05 6.250E-04 6.944
0.627 7.000E-05 3.125E-04 4.464
0.478 5.000E-05 7.813E-05 1.563
0.332 3.050E-05 3.906E-05 1.281
0.193 6.750E-06 1.953E-05 2.894
K25AOAl 0.887 5.500E-04 5.000E-03 9.091
0.637 2.500E-04 2.500E-03 10.000
0.599 2.200E-04 1.250E-03 5.682
0.489 1.400E-04 3.125E-04 2.232
0.363 7.813E-05 7.813E-05 1.000
0.276 6.000E-05 3.906E-05 0.651
T able 3.3 Showing a comparison o f the concentration o f  peptides AOA1, KioAOAl and K25A 0A 1#3 at 
pH 5 and pH 7, which was required to cause the same extent o f  haemolysis.
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The influence of lower pH (pH 5 versus pH 7) on the haemolytic potency of K i o A O A l  
was lowered to 1.3-fold, as the concentration of peptide being tested was decreased. To 
complete the trend, the haemolytic potency of K 2 5 A O A I  started with a high preference 
for pH 5 against pH 7, but at a peptide concentration of 7.813x1 O' 5 M, K 2 5 A O A I  was 
equipotent at pH 5 and pH 7. A further reduction of concentration showed K 2 5 A O A I  
being more haemolytic (about 1.5-fold) at pH 7 than pH 5. These results suggest that the 
attachment of the lysyl chain to form bifunctional peptides reduces the fusogenic 
potency and pH-selectivity at lower peptide concentrations. This result is not 
unexpected because the attachment of a sequence with no fusogenic activity reduces the 
chance of close interaction (steric hindrance) of the fusogenic sequence to interact with 
the lipid bilayer and disrupt the bilayer of erythrocytes.
• 1 fifiDestabilization of the target membrane bilayer is a prelude to membrane fusion . The 
ordered architecture of the viral surface and the organised conformational changes by 
which influenza HA mediates membrane fusion, culminating in the formation of a
| QQ #
fusion pore , is lacked in a synthetic complex consisting of DNA/polylysine/fusogenic 
peptide. Although fusogenic peptide sequences used in transfection experiments by 
Plank and colleagues were based in N-terminal sequences of the influenza HA-2, the 
only commonality between influenza HA-mediated fusion and fusogenic peptide 
mediated fusion, is the ability of either to destabilize the target lipid bilayer, a feature 
shared with amphipatic molecules such as detergents and cationic lipids. HA is a trimer 
of three identical subunits, each of which contains a fusion peptide, a conserved 
sequence containing many hydrophobic amino acids. The fusion peptides are tightly
1 Sfitucked into the subunit interface by a network of hydrogen bonds . In response to low 
pH, the tertiary structure of HA is altered, exposing the fusion peptides and other 
sequences buried in the stem ’ ’ . The exposed fusion peptides render the HA
*yf/y
ectodomain hydrophobic and foster its immediate attachment to the target membrane 
before significant lipid mixing occurs . Additional conformational changes as well as 
rotational and lateral motions of HA trimers in the plane of the viral membrane 
results in the aggregation of several HA trimers and formation of a fusion pore within 
the interior of the aggregate .
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The observation by Cotten and colleagues that inactivated adenovirus particles (psoralen 
and irradiation) could still mediate endosmolytic activity and improve in vitro 
transfection , led to the study of the use of fusogenic sequences in influenza HA-2 as
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adjuncts for gene transfer . The legacy of the method of forming ternary and 
quaternary complex originate from early studies in this field using modified polylysine 
as a means of condensing DNA and attaching inactivated viruses and receptor ligands to 
them1. Studies by Plank and colleagues had showed a high correlation between pH- 
specific (as opposed to pH-sensitive) erythrocyte lysis activity and gene transfer
1 f\lefficiency using ternary complexes that included fusogenic peptide sequences.
The bifunctional peptides K25AOAI and K25INF7  retained pH-sensitive lytic activity 
(Figure 3.3) in the erythrocyte lysis assay. However, the erythrocyte lytic activity of the 
bifunctional peptides was not highly selective at pH 5. At lower molar concentrations of 
K25AOAI, the data from the second erythrocyte lysis assay showed that there was no 
measurable difference between haemolytic activity at pH 5 compared to pH 7. The 
significance of this observation is discussed later in section 3.3.9 when the lack of effect 
of the endosomal proton pump inhibitor on the transfection efficiency of K25AOAI is 
discussed. The erythrocyte lysis activity of the bifunctional peptides in these 
experiments were over 100-fold lower than the levels for INF6 , as reported by Plank and 
colleagues167. Plank and colleagues also reported that INF6  had a high erythrocyte lysis 
activity but was not pH specific (about 2-fold higher at pH 5 compared to pH 7). Plank 
and colleagues also observed that fusogenic peptides that had a high haemolytic 
potential but did not display the strong specificity for low pH showed only a moderate
1 ftT!augmentation of gene expression . Therefore, on the basis of the findings by Plank and 
colleagues, bifunctional peptides K25AOAI and K25INF7 , which had a comparatively 
low haemolytic activity and weak pH specificity, would not be expected to augment 
gene expression. However, as it will be seen in section 3.3.3, in vitro transfection was 
very strongly improved using these bifunctional peptides. The peptide K25, which did 
not have any erythrocyte lysis activity, did not show augmentation of gene expression, 
demonstrating that both DNA binding and fusogenic activity are required for in vitro 
transfection activity of bifunctional peptides.
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These data on retention of functionality in conjunction with in vitro transfection studies 
data presented later in this thesis, suggest that, for augmentation of gene expression, the 
advantage of ensuring co-localisation of DNA/polylysine/fusogenic peptide in a 
peptide/DNA complex, outweigh the advantage of high haemolytic potency and pH 
specificity of the fusogenic peptide used. It is apparent that the structural integrity of 
viruses, which are being emulated in the construction of these virus-like particles, is 
crucial to success of viruses in transferring genetic material to host cells for expression. 
It is likely that the ionic interactions that are being relied upon to form the speculative 
ternary or quaternary complexes produce delivery systems that are less efficient and 
unreliable.
3.3 .2  Zeta  potential  a n d  particle size m ea su r em en ts
3.3 .2 .1  In t r o d u c t io n
The surface charge of colloidal particles in solution has a considerable effect on 
flocculation of primary particles to form larger aggregates, and consequently on the 
apparent size of the secondary aggregates. Flocculation may explain why some 
peptide/DNA formulations are ineffective at in vitro transfection experiments. 
Therefore characterisation of zeta potential and size are important formulation 
parameters, and are useful to interpret the results of biological experiments.
3 .3 .2 .2  P a r t ic l e  s iz in g  b y  p h o t o n  c o r r e l a t io n  s p e c t r o s c o p y
Photon correlation spectroscopy (PCS) is a technique used for measuring the dynamic 
changes in light scattering associated with macromolecular and colloidal systems. 
Particles in solution undergo the random movement of Brownian motion, which occurs 
due to collisions with the smaller molecules of the continuous phase. The suspended 
particles are constantly in a state of motion, and hence undergo diffusion. Diffusion is 
governed by the average distance of travel before collision with another molecule, 
which causes a diversion from the original path of motion. When a solution of
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macromolecules is illuminated, the light is scattered by the particles in Brownian 
motion, and the intensity of this light yields information regarding the molecular weight.
PCS analyses the constantly changing patterns of laser light scattered or diffracted by 
particles in solution, exhibiting Brownian motion. The rate of change of the scattered 
light during diffusion is monitored. The scattered light displays a spectrum of 
frequencies due to the Doppler effect. Fluctuations in the intensity arise because the 
centres of light scattering are constantly moving, producing different extents of 
interference. An autocorrelation function allows the intensity fluctuations to be 
characterised. The intensities are measured at short time intervals (5-10 ps) over a 
longer time period of several minutes, and recorded digitally. PCS allows estimation of 
the translational diffusion coefficient (D). D is related to the equivalent hydrodynamic 
radius of the particle by the Stokes-Einstein equation:
6mrrh 
E q u atio n  3.14
where ke is the Boltzman constant, T is the absolute temperature (Kelvin), r\ is the 
viscosity of the solvent and Th is the hydrodynamic radius.
CONTIN analysis was used to fit the experimental intensity decay curve with a curve 
calculated assuming a distribution of decay rates. This method extracts a smoothed or 
regularised size distribution by matrix techniques. Larger particles produce a greater 
intensity of scattered light, and this may interfere with the intensity from smaller 
species. In extreme cases, the intensity of light scattered from small particles may be 
masked by the interference and intensity from only a tiny percentage of large particles 
within the population.
Solutions, which contain more than one species, require correction for the intensity 
interference problems. The correlation function contains the same number of terms as 
species in the sample, but each term is weighted by the intensity of light scattered from 
each species. The output from CONTIN analysis includes information about weight and 
number distribution within the sample.
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3 .3 .2 .3  Z e t a  P o t e n t ia l  M e a s u r e m e n t
The surface charge, more specifically the surface charge density, plays an active role in 
colloidal stability. A colloid may be simply defined as a particle or molecule with a least 
one dimension less than, approximately, 1 pm and all dimensions greater than, 
approximately, 1 nm. The surface area per gram of material for colloidal-sized particles 
is orders of magnitude larger than it is for particles approximately 10 pm. Therefore, 
surface effects, which are normally negligible, become dominant in the description of 
colloidal behaviour. Condensed DNA/peptide complexes form colloids, and therefore 
the measurement of surface charge is important in explaining observed behaviour of 
these complexes.
Without going into detail, the zeta potential is a good approximation of the surface 
charge density. Zeta potential for DNA/peptide complexes was measured using the 
ZetaPlus Zeta Potential Analyser, (Brookhaven Instruments Corporation, New York, 
USA). In the ZetaPlus, charged particles in a dilute suspension move between two 
oppositely charge electrodes. Zeta potential can be calculated from the measurement of 
average drift velocity of charged colloidal particles as they move towards the electrode 
of opposite charge. Due to the motion of the charged particles, a frequency shift, called 
the Doppler Shift, occurs in a focused laser beam light (wavelength A.=670 nm) 
scattered by the particles. The velocity is deduced from the shift in the laser beam 
frequency.
3 .3 .2 .4  R e s u l t s  o f  z e ta  p o t e n t ia l  a n d  p a r t ic l e  s iz e  m e a s u r e m e n t s
The effective diameter in nm of DNA/DK25AOAI complexes at charge ratios of 0.4, 
0.8, 1.6 and 3.2 shown in Figure 3.8 represents the complexes formed using 102.2 pg 
DNA (in 800 pi of 5% (w/v) glucose) complexed with 34.4 pg, 6 8 . 8  pg, 137.6 pg and
275.2 pg of DK25AOAI (in 5% (w/v) glucose) respectively. These quantities of DNA 
and peptide were used at 16-fold higher concentration than that used during in vitro 
transfection. The reason high concentrations were used is that lower concentrations did 
not generate enough scattered laser light with the available laser. One would need a
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very powerful (perhaps 2W argon laser) to allow lower concentrations of DNA to be 
examined. The results show that the effective diameter was fairly constant between 120 
and 140 nm for particles except at charge ratio of 1 . 6  when aggregation occurred to give 
particles with effective diameter 4-6 pm. Attempts to increase the charge ratio using
102.2 pg DNA beyond 3.2 resulted in precipitation of the sample. Previous work had 
established that precipitation can occur at concentrations of DNA above 40 pg/ml.
Complexes formed in HBS using the same amount of DNA (102.2 pg) complexed to 
varying amounts of DK25AOAI resulted in precipitation. A 25.6 pg DNA/6 8 . 8  pg 
DK25AOAI complex (representing a charge ratio of 3.2) produced particles with 
effective diameter of over 3 pm and a negative zeta potential of 58.78 (+/-8 .6 ). This zeta 
potential reading is most likely an artefact caused by the presence of neutralizing ions. 
A 6.4 pg DNA/17.2 pg DK25AOAI complex in HBS resulted in particles with effective 
diameter ranging between 890 nm and 1070 nm zeta potential of the main population 
being -0.24 and two smaller populations with zeta potential of - 8  mV and -16 mV.
For the purpose of comparison, 51.2 pg DNA was complexed with 92.16 pg PEI in 5% 
(w/v) glucose representing a nitrogen/phosphate ratio of 6  (approximate +/- charge ratio 
of 3) resulted in particle sizes between 136 and 156 nm and a mixed population of 
particles with zeta potential ranging from -2  to 13 mV. An attempt was made to reduce 
the chances of aggregation of particles by further decreasing the concentration 
complexes formed in HBS, but this was not possible as it resulted in poor sample 
quality (low count rates) for the instrument. A similar result was observed when K25 was 
used to complex DNA.
A tertiary complex sample consisting of 6.4 pg DNA (in 400 pi HBS)/ 9 pg K8  (in 400 
pi HBS) /16 pg JTS1 (in 800 pi HBS) gave a poor sample quality, with the instrument 
returning a value of 714 nm as a possible effective diameter and also, a very 
heterogeneous zeta potential result ranging from -47 to 217 mV due to the presence 
ions in HBS.
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3 .3 .2 .5  D is c u s s i o n : Z e t a  p o t e n t ia l  a n d  p a r t ic l e  s iz e  m e a s u r e m e n t s
Particle stability in ionic solutions is essential for the success of gene delivery in vivo. 
Injection of polyplexes systemically results in particle aggregation, thus limiting 
successful in vivo gene delivery. Although cationic polyplexes are stable in water, they 
aggregate in ionic solutions due to a decrease in the protective electrostatic double layer. 
Polyplexes aggregate rapidly in physiological salt concentration (~150 mM) . The 
advantage that single-step complex formation with bifunctional peptides has over two- 
step complex formation become important when particle stability and formulation 
difficulties associated with two-step complexes is considered. Complexes with 
K25AOAI can be formed at higher concentrations and are more stable from aggregation 
than K25/DNA complexes. Particle size measurements and zeta potential measurements 
showed that even in glucose, K25/DNA complexes were highly unstable and aggregated 
immediately at lower charge ratios. When K25AOAI complexes with DNA were 
formed in HBS, aggregation occurred but to a less extent than two-step complexes. It is 
not clear why the bifunctional peptide/DNA complexes are more stable in HBS than 
K25/DNA complexes. The presence of uncharged residues in the fusogenic moiety 
possibly reduces the zeta potential of K25AOAI/DNA particles. Another possible 
explanation is that the fusogenic moiety provides a steric stabilisation similar to the
o / r
effect of PEGylation of polylysine/DNA complexes .
Both the zeta potential and sizing experiments required large masses of DNA and 
peptides, which could not be recovered. It would have been useful to extend these 
studies to optimise the formulation of particles but this was prohibited by their cost. 
The cost of formulation studies will have considerable impact on the commercial 
development of non-viral gene delivery systems. These studies will require a 
substantial commitment.
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F igu re  3.8 Determination o f particle size and zeta potential o f K25AOAI/DNA complexes. The effective 
diam eter in nm of DNA/DK25AOAI complexes at charge ratios o f 0.4, 0.8, 1.6 and 3.2 shown in above 
represents the complexes formed using 102.2 pg DNA (in 800 pi of 5% (w/v) glucose) com plexed with
34.4 pg, 68.8 pg, 137.6 pg and 275.2 pg of DK25AOAI (in 5% (w/v) glucose) respectively. These 
quantities o f DNA and peptide represent a 16-fold increase in concentration compared to what is used 
during in vitro transfection. Zeta potential for DNA/peptide complexes was measured using the ZetaPlus 
Zeta Potential Analyser, (Brookhaven Instruments Corporation, New York, USA).
3.3.3 In  v it r o  t r a n s f e c t i o n  r e s u l t s
The transfection results presented in this thesis represent typical data from a single 
experiment. Experiments were carried out on at least two separate occasions to 
establish reproducibility of the data. Typically gene expression was variable from one 
batch of cultured cells to another, between replicate experiments. The data obtained 
from replicate wells was reproducible, and the relative effects of formulation 
parameters were reproducible.
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3 . 3. 3.1 INVESTIGA TION OF THE EFFECT OF CHARGE RA TIO ON TRANSFECTION EFFICIENCY
To determine the effect of charge ratio on transfection of dividing cells in vitro, 
increasing masses of each peptide were complexed with 2 pg of either pRSV/acZ or 
pCMV luciferase plasmid DNA and used to transfect B16, A549 or NIH3T3 cells 
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F igure 3.9 Effect o f charge ratios on transfection efficiency in B16 melanoma and A549 cells. 
Complexes formed between pRSVlacZ  (2 pg) and increasing quantities o f  LK25A0 A 1#1 were incubated 
with B16 melanoma and A549 cells for 37°C for 4 hours and cells harvested 48 hours post initiation o f 
transfection for analysis. DOTAP at a charge ratio o f  +/- 2.5 was used as positive control. Data represent 
the mean o f triplicate samples ± SEM, and is representative o f  two separate experiments.
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Calculation of p-gal expression Calculation of protein content Transfection efficiency
sample
P- Abs vol Trans. Trans.
CRof Measured Sample Vol gal/sample p-gal/plate ODS for prt.(p Prt/sample Prt/plate Efficiency efficiency
K25AOA1 light units For p-gal(pl) (pg) (pg) 595nm 1) (pg) (pg) Units/pg Prt (mU/mgPrt)
0.8 809 20 1.33E-05 0.0002 0.636 2 1.172 146.54 1.14E-06 1.14
0.8 1376 20 2.47E-05 0.0003 0.66 2 1.276 159.50 1.93E-06 1.93
0.8 1424 20 2.56E-05 0.0003 0.618 2 1.095 136.83 2.34E-06 2.34
1.6 2338 0.2 4.39E-05 0.0549 0.673 2 1.332 166.52 3.30E-04 329.72
1.6 2184 0.2 4.08E-05 0.0511 0.714 2 1.509 188.66 2.71 E-04 270.62
1.6 3540 0.2 6.80E-05 0.0850 0.631 2 1.151 143.84 5.91 E-04 590.61
2.6 4000 0.1 7.72E-05 0.1929 0.621 2 1.108 138.44 1.39E-03 1393.41
2.6 3500 0.1 6.72E-05 0.1679 0.584 2 0.948 118.47 1.42E-03 1417.37
2.6 5431 0.1 1.06E-04 0.2645 0.593 2 0.987 123.33 2.14E-03 2144.40
3.2 6798 0.1 1.33E-04 0.3328 0.608 2 1.051 131.43 2.53E-03 2532.32
3.2 9216 0.1 1.81 E-04 0.4537 0.632 2 1.155 144.38 3.14E-03 3142.38
3.2 6848 0.1 1.34E-04 0.3353 0.587 2 0.961 120.09 2.79E-03 2792.25
4.8 7151 0.1 1.40E-04 0.3505 0.586 2 0.956 119.55 2.93E-03 2931.59
4.8 6707 0.1 1.31 E-04 0.3283 0.56 2 0.844 105.51 3.11E-03 3111.26
4.8 8094 0.1 1.59E-04 0.3976 0.603 2 1.030 128.73 3.09E-03 3088.82
6.4 7557 0.4 1.48E-04 0.0927 0.576 4 0.913 57.07 1.62E-03 1624.05
6.4 7211 0.4 1.41 E-04 0.0884 0.625 4 1.125 70.30 1.26E-03 1256.93
6.4 7158 0.4 1.40E-04 0.0877 0.626 4 1.129 70.57 1 24E-03 1242.74
8 1523 0.4 2.76E-05 0.0173 0.57 4 0.887 55.45 3.11 E-04 311.35
8 1788 0.4 3.29E-05 0.0206 0.613 4 1.073 67.06 3.07E-04 306.84
8 1365 0.4 2.45E-05 0.0153 0.591 4 0.978 61.12 2.50E-04 250.15
9.6 1444 0.4 2.60E-05 0.0163 0.58 4 0.930 58.15 2.80E-04 279.91
9.6 1278 0.4 2.27E-05 0.0142 0.621 4 1.108 69.22 2.05E-04 205.18
9.6 1315 0.4 2.35E-05 0.0147 0.586 4 0.956 59.77 2.45E-04 245.35
16 4879 20 9.47E-05 0.0012 0.488 8 0.533 16.66 7.11 E-05 71.10
16 6198 20 1.21 E-04 0.0015 0.496 8 0.568 17.74 8.54E-05 85.36
16 6083 20 1.19E-04 0.0015 0.459 8 0.408 12.74 1.17E-04 116.56
19.2 4814 40 9.34E-05 0.0006 0.439 8 0.321 10.04 5.82E-05 58.15
19.2 3689 40 7.09E-05 0.0004 0.449 8 0.365 11.39 3.89E-05 38.92
19.2 3674 40 7.06E-05 0.0004 0.446 8 0.352 10.99 4.02E-05 40.18
22.4 5553 80 1.08E-04 0.0003 0.476 8 0.481 15.04 2.25E-05 22.49
22.4 3847 80 7.41 E-05 0.0002 0.428 8 0.274 8.56 2.71 E-05 27.06
22.4 5375 80 1.05E-04 0.0003 0.453 8 0.382 11.93 2.74E-05 27.41
25.6 3891 80 7.50E-05 0.0002 0.376 8 0.049 1.54 1.52E-04 152.27
25.6 1160 80 2.04E-05 0.0001 0.455 8 0.390 12.20 5.21 E-06 5.21
25.6 2995 80 5.71 E-05 0.0002 0.448 8 0.360 11.26 1.58E-05 15.84
DNA only 593 20 9.02E-06 0.0001 0.641 2 1.194 149.24 7.56E-07 0.76
DNA only 533 20 7.82E-06 0.0001 0.675 2 1.341 167.60 5.84E-07 0.58
DNA only 559 20 8.34E-06 0.0001 0.671 2 1.324 165.44 6.30E-07 0.63
DOTAP 3961 0.2 7.64E-05 0.0955 0.585 2 0.952 119.01 8.02E-04 802.31
DOTAP 3515 0.2 6.75E-05 0.0843 0.599 2 1.013 126.57 6.66E-04 666.30
DOTAP 4502 0.2 8.72E-05 0.1090 0.628 2 1.138 142.22 7.66E-04 766.43
T able 3.4 Investigation o f effect o f charge ratio on transfection efficiency in B16 cells (represented 
graphically in Figure 3.9. “Prt/plate” stands for protein quantity per 6-well plate.
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ofK 25AOAl#l/DNA complexes ranging from 0.8 to 25.6 after transfecting in B16 and 
A549 cells. Table 3.4 shows typical data describing the effect of charge ratio on cell 
protein content as well as the quantity of the reporter protein MUG expressed following 
in vitro transfection in B16 cells. These results show that below neutrality (at a charge 
ratio of 0.8) the transfection efficiency was only 2.7-fold above transfection with 
uncondensed ‘naked’ DNA (negative control) i.e. background activity. At a charge ratio 
of 1.6 (above neutrality), there was a 220-fold increase in transfection activity in B16 
cells, compared with complexes formed at a charge ratio of 0.8. A further increase in 
charge ratio of peptide/DNA complexes from 1. 6  to 2.6 resulted in a 4-fold increase in 
transfection efficiency. There were further improvements in transfection efficiency in 
B16 cells as the charge ratio of the peptide/DNA complexes was increased, to peak 
transfection efficiency at a charge ratio of about 4.8. Increasing the charge ratio of the 
peptide/DNA complexes beyond a charge ratio of 4.8 resulted in a decrease in 
transfection efficiency. Between the charge ratio of 4.8 and 6.4, there was over 2-fold 
decrease in transfection efficiency of B16 cells and nearly a 5-fold decrease in 
transfection efficiency between complexes at a charge ratio of 6.4 and 8 . Figure 3.9 and 
Table 3.4 show that in B16 cells, the decline in transfection efficiency continued 
steadily with increasing charge ratio of complexes above 4.8. Table 3.4 shows that the 
cell protein content (see column labelled “prt/plate” in Table 3.4) also declined as 
charge ratio increased above 4.8. This observation is corroborated by MTT assay results 
(see section 3.3.13 and Figure 3.25) in which the toxicity of various GDVs were 
studied. These two separate experiments confirm that increasing toxicity due to 
increasing excess of peptides in solution was responsible for the decrease in transfection 
efficiency at higher charge ratios above the optimum.
In A549 cells, a similar trend of increasing charge ratio of complexes resulting in an 
increase in transfection efficiency up to a peak activity at a charge ratio of 4.8, followed 
by a decline in transfection efficiency (described for B16 cells above) was observed 
(Figure 3.9).
In a separate transfection experiment in NIH3T3 cells, the effect of charge ratio of 
l K 25A O A 1# 1/ D N A  was compared to that of D K 2 5 A O A I  (estimated purity of 
>90%)/DNA complexes. A comparison between the transfection efficiency of the D -
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and L- isomers of the bifunctional peptide K25AOAI revealed that DK25AOAI was 
about 10-20% less active than LK25AOAI at charge ratios between 2.7 and 5.4 (Figure 
3.10). Plank and colleagues reported that transfection activity between ternary 
complexes formed with D- or L- isomers of fusogenic peptides were not significantly 
different167. The results obtained in this study were consistent with the observation that 
activity was independent of the isomeric form of the peptide.
3000 -
•c 2500 - ■©
2Q.a
|  2000 -
0.9 1.8 2.7 3.6 4.32 5.4 7.2 14.4 21.6
Charge ratios of peptides
F igure 3.10 Effect o f charge ratios on transfection efficiency in NIH3T3 cells. Complexes formed 
between pCMVluc (6.4 pg in 800 pi HBS) and increasing quantities o f  DK25AOAI and LK25AOAI (in 
800 pi HBS) were incubated for 30 minutes before adding a 500 pi aliquot (containing 2 pg per 6-well 
plate) to cells. NIH3T3 cells were incubated with complexes at 37°C for 4 hours and harvested 24 hours 
post initiation o f  transfection for analysis. Data represent the mean o f  triplicate samples ± SEM, and is 
representative o f two separate experiments.
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The difference in activity observed in this experiment may have been due to the 
different levels of purity in the compounds used, though such small differences could 
also have been due to problems with the accuracy of weighing small masses of peptide 
for stock solutions. A comparison between transfection efficiency of the two batches of 
LK25AOAIconfirmed this to be the case (Figure 3.11) The highly pure batch of 
LK25AOAI (K25A0A1#2), (purified using peak splicing of main peak) was about 20% 
more active than the batch where the whole main peak had been collected, suggesting 
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F igure 3.11 Comparison o f transfection activity between two batches o f  LK25AOAI with different levels 
o f purity: lK 25A O A 1#1 is estimated to be 70-80% pure, and lK 25A O A 1#2 is estimated to be 75-90% 
pure.
A comparison of the transfection activities of lK 2sAOA1# 1 , LK25INF7  and lKioINF7 
(estimated purity of 90%) complexed with DNA were studied in B16 cells at charge 
ratios of 0.8, 1.6, 3.2, 4.8, and 6.4. The results of this experiment shown in Figure 3.12 
showed that the transfection efficiency of LK25AOAI was between 2- and 6 -fold greater 
than LK25INF7  (Figure 3.12). The purity of LK25INF7  used in this experiment was 
similar to that of lK 2sAOA1 # 1  and therefore the difference in transfection efficiency 
between the two peptides is due to the effect of replacing the glutamic acid residue at
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position 7 from the N-terminus, with alanine (see Table 2.1 for sequence). The 
bifunctional peptide lK ioIN F7, with a shorter lysyl chain did not show any ability to 
transfect cells when complexed with DNA (Figure 3.12). The lack of ability of 
lK joIN F7 to promote detectable gene expression in B16 cells when complexed with 
DNA can be explained by the fact that lK ioIN F7 does not bind effectively to DNA, as 
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F igure 3.12 Comparison o f  transfection efficiency o f  various complexes in B16 cells. Complexes formed 
between (6.4 pg in 800 pi HBS) and various quantities o f  lK 25AOA1#1, LK25INF7, lK 10INF7 and 
DOTAP were incubated for 30 minutes before adding a 500 pi aliquot (containing 2 pg per 6-well plate) 
to cells. Cells were incubated with complexes at 37°C for 4 hours and harvested 24 hours post initiation o f 
transfection for analysis. Data represent the mean o f  triplicate samples ± SEM, and is representative o f 
two separate experiments.
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3 .3 .3 .2  In  v it r o  t r a n s f e c t io n  o f  a  p r im a r y  c e l l  l in e
The ability o f L K 2 5 A O A I/D N A  complexes to transfect primary cells in vitro was 
investigated using primary skin fibroblast, F E K 4  cells, obtained from the foreskin of 
newly bom males. These cells had been shown to be refractory to transfection by 
traditional methods including calcium precipitation and lipofection (personal 
communication, Dr. Charareh Pourzand, Pharmacy Department, University of Bath). 
Cells were seeded at a density of 5 x 105 cells per well. To determine the optimum 
amount of complex needed for transfection, increasing amounts of pCMV luciferase 
D N A  was complexed with K 25A O A I at a charge ratio of 3.2 and incubated with cells as 
described in methods section 3.2.8. Increasing quantities o f K 2 5 A O A I/D N A  complexes 
resulted in near linear increase in the levels of luciferase expression (Figure 3.13).
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F igure 3.13 Complexes formed between increasing quantities o f  pCM Vluc complexed with LK2sAOAl#2 
at a charge ratio o f  3.2 were incubated for 30 minutes before adding a 500 pi aliquot (containing 2, 4, 6, 8 
or 10 pg per 6-well plate) to cells covered with 1.5 ml o f  serum free OPTI-M EM ™ . FEK4 cells were 
incubated with complexes at 37°C for 4 hours and harvested 24 hours post initiation o f  transfection for 
analysis. Data represent the mean o f  triplicate samples ± SEM, and is representative o f  two separate 
experiments.
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Comparing levels of gene expression in FEK4 cells to immortal cell lines, this level of 
expression using 2 pg DNA at a charge ratio of 3.2 for example, was about 2-fold less 
than in A549 cells, 3-fold less than in NIH3T3 cells and over 5-fold less than in B16 
cells (Figure 3.9, Figure 3.10 and Figure 3.13).
3 .3 .4  D isc u ssio n : Effect of charge  ratio  o n  transfectio n  efficiency
The net charge of the complex formed with DNA significantly affects the transfection 
efficiency of a gene delivery vector264. The charge ratio is defined here as the molar 
ratio of positive charges provided by the gene delivery vector relative to negative 
charges from the DNA. An increase in the quantity of GDV (LK25AOAI and 
DK25AOAI and K25INF7 ) (and hence charge ratio) led to an increase in transfection 
activity until a maximum was reached. Further increases beyond this optimum resulted 
in a reduced transfection efficiency as a result of toxic effects mediated by free gene 
delivery vector. MTT assay results (section 3.3.13) demonstrated that there was 
increased cell death in the presence of excess GDV, accounting for the decrease in 
transfection efficiency at high charge ratios.
A direct comparison of K2sAOA1 # 2  and K25INF7  in B16 cells showed that they both 
had similar optimum charge ratios around 3.2 and that K25AOAI was between 2- and 6 - 
fold better than K25INF7  (Figure 3.12). In another experiment K2sAOA1 # 2  was 
compared to K25INF7  as part of an experiments comparing binary and ternary 
complexes systems (Figure 3.17) and K2sAOA1 # 2  was found to be about 1.6-, 1.4-, 1.5- 
and 4.8-fold better than K25INF7  in B16, NIH3T3, COS-7 and A549 cells, respectively. 
A comparison of the haemolytic activity between K25AOAI and K25INF7  showed that 
that point mutation in the sequence of the bifunctional peptide was responsible for a 
greater haemolytic activity of K25AOAI at both pH 5 and pH 7 (Figure 3.3). A possible 
explanation for this difference in activity is that following the replacement of the 
glutamic acid residue at position 7 with a neutral residue, alanine, the negatively 
charged residues become more concentrated in a narrower region (less spread) resulting 
in greater polarity in the alpha helical structure of LK25AOAI compared to K25INF7  (see 
Figure 3.14). This hypothesis is indirectly supported by work reported by Gottschalk 
and others who found that JTS1 was approximately 1000-fold more active than INF7 at
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transfection when they were separately included in the ternary system with DNA and 
K876. A comparison of sequence of amino acids in JTS1 compared to INF7, shows that 
the only functional change to the structure is the replacement of a charged residue 
(glutamic acid) with an uncharged leucine residue at position 7 (Figure 3.14).
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F igure 3.15 Amino-terminal fiisogenic peptide o f  influenza haemagglutinin subunit HA-2 showing 
conformation at neutral pH, according to data from x-ray analysis265 and a-helical conformation at low 
pH, consistent with references 266 and 267. Taken from reference 167.
Oligolysine/DNA complexes, K25/DNA, or fusogenic peptide/DNA complexes, 
AOA1/DNA, were not effective at transfection (data not shown). This is in contrast to a 
report by Gottschalk et al. who found that K8 /DNA complexes showed some 
transfection activity76. However, the ternary complex system K8/DNA/JTS1 was only 
marginally effective in this study. In our laboratory, polylysine2 M was only effective in
'yf.o
the presence of chloroquine at a charge ratio of 1.5 . This optimum charge ratio for
polylysine/DNA in the presence of chloroquine is lower than that of bifunctional 
peptide/DNA complexes and reflects the fact that long chain cationic polymers have a 
higher DNA condensation capacity than shorter chain polylysine. Endocytosed 
DNA/pLL complexes do not have a means of endosomal escape and require the 
concomitant use of lysomotropic agents or pH sensitive fusogenic peptides such as that 
derived from the influenza haemagglutinin HA-2 subunit167.
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3.3.5 C o m p a r i s o n  b e t w e e n  i n  vitro  t r a n s f e c t i o n  a c t i v i t y  o f  b i n a r y  a n d
TERNARY COMPLEXES
Previous efforts to deliver DNA into dividing cells in vitro using polylysine or similar
1 1 7 0polycations have focused on ternary or quaternary complexes 5 due to the
nr
dependence on commercially available polycations. Reports by Gottschalk et al. and 
Hart et al 170 were among the first published work to synthesize oligocations or 
bifunctional peptides respectively for use as adjuncts in gene delivery. Work by
nr
Gottschalk and colleagues was based on the ternary complex models using fusion
170  170peptides first described by Wagner et al . Studies done by Hart et al used 
oligolysyl chain as a means of anchoring an integrin targeting moiety to a lipid based 
gene delivery system, again a ternary system. The bifunctional peptide described in this 
work, which is a fusogenic peptide with an oligolysine chain is a novel non-lipid-based 
binary complex capable of transfecting dividing cells. This novel peptide-based system 
has two important advantages: 1 ) the relative ease of addition of different functional 
moieties, compared to lipid-based systems, during the initial synthesis without the risk 
of destroying the functions of other moieties and 2 ) the location/presence of each 
attached functional moiety is assured by design through the covalent peptide bond (as 
opposed to electrostatic interactions in a ternary or quaternary complex system). The 
transfection efficiency of the following novel bifunctional peptides LK25AOAI, 
DK25AOAI, lKioAOAI and LK25INF7  were compared to the cationic lipid system 
DOTAP/DNA and the ternary complex system K8/DNA/JTS1. The cationic lipid 
DOTAP/DNA charge ratio complex used in this work was previously optimised in our 
laboratory by Dr. Aima Uduehi and the charge ratio for the ternary system was as
nr
reported by Gottschalk et al .
A direct comparison between binary complexes (bifunctional peptides/DNA) and 
ternary complexes (K25/DNA/AOAI* or K8/DNA/JTS1) for in vitro transfection 
activity was investigated in six cell lines namely B16, HEK293, HeLa, A549, NIH3T3, 
and COS-7 cells. All complexes between bifunctional peptides and DNA (pRSV/acZ or 
pCMVluc DNA) were formed in HBS at charge ratios indicated in brackets of the x-axis 
label in Figure 3.16 and Figure 3.18. The bifunctional peptides studied were 
lK 25AOA1#2, LKioAOAI, lK 25INF7, dK25AOA1 and dK25AOA1(N) (dK25AOA1 
without asparagine residue).
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Figure 3.16A and B (linear and log scale representation of the same results) shows the 
results of a comparison of transfection ability between binary complexes formed with 
bifunctional peptides lK 2sAOA1 #2 , LK25INF7 , DK25AOAI, dK2sAOA1 (N) (with 
omitted asparagine residue) or DOTAP and ternary complexes formed with K8/JTS1 in 
HeLa cells. This experiment was also used to determine the optimum charge ratio for 
LK25AOAI/DNA complexes in HeLa cells. The results in Figure 3.16 show that, for 
LK25AOAI/DNA complexes, at the optimum charge ratio of 3.2 (same optimum charge 
ratio as in B16 cells), the binary complex was over 43-fold or 127-fold better than the 
ternary complex of K8/DNA/JTS1, at a JTS1 concentration of 7 nM or 38 nM 
respectively. The bifunctional peptide LK25AOAI complexed with DNA at the optimum 
charge ratio of 3.2 was only marginally (1.7-fold) better than the binary complex of 
DOTAP/DNA in HeLa cells. The other bifunctional peptides LK25INF7  and DK25AOAI 
were 14-fold and 37-fold better than the ternary complex of K8/DNA/JTS1 compared 
with 7 nM concentration of JTS1. The bifunctional peptide dK2sAOA1 (N) (with 
omitted asparagine residue) had similar transfection efficiency to that of the ternary 
complexes; the reason for the low transfection activity of dK2sAOA1 (N) is discussed in 
section 3.3.13.
In a separate experiment, the transfection efficiency of bifunctional peptides 
l K .2 5 A O A 1 # 2 , DK25AOAI (N), LK25INF7  and l K ioA O A I  formulated as binary 
complexes with DNA at a charge ratio of 3.2 was compared to the lipid based binary 
complex of DOTAP/DNA and peptide based ternary complex of K8/DNA/JTS1 or 
K25/A0A1*/DNA in four cell lines, namely B16, NIH3T3, COS-7 and A549 cells and 
the results are showed in Figure 3.17. As expected, there were variations in the 
responsiveness of different cell lines to transfection by the same gene delivery agent in 
transfection experiment performed on the same day and under the same experimental 
conditions; but the differences in transfection efficiencies between various gene delivery 
agents can be clearly noticed in the results showed in Figure 3.17. The binary complex 
of bifunctional peptide LK25 AO A1 #2/DN A was over 12000-fold, 5700-fold, over 
74000-fold and over 8000-fold better than the ternary complex of K8/DNA/JTS1 in 
B16, NIH3T3, COS-7 and A549 cells respectively. Similar orders of magnitude 
differences in transfection efficiencies were previously observed in B16 cells when 
lK25AOA1#1 was compared to the ternary complex system of K25/A0A1*/DNA prior
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to obtaining pure K8  and JTS1 from Gottschalk et al.16, but because the purity of the 
fusogenic peptide AOA1* was not known at this stage, the superiority of the binary 
complex involving the bifunctional peptide over the ternary complex system was 
uncertain. It now seems likely that AOA1 performed with similar efficient to JTS1. An 
explanation for the relative lack of transfection activity for the ternary complex systems 
reported in this work may be found from results of experiments to study the particle size 
(hence complex stability) in HBS of K2 5 /D N A  complexes in HBS described in section 
3.3.2. The large complexes formed are symptomatic of the sensitivity of the product, 
which may vary according to local differences in the nature of the mixing protocol.
The fold differences between transfection efficiencies of the bifunctional peptide 
LK25AOAI and DOTAP were relatively marginal: 1.6-, 1.2- and 2.3-fold in B16, 
NIH3T3 and A549 cells respectively and in COS-7 cells DOTAP was slightly better 
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F igure 3.16 A and B: Linear and logarithmic scale representation o f  the comparison o f transfection 
efficiency o f  various complexes in HeLa cells. For K8-DNA/JTS1 complexes, K8 (9 pg in 400 pi HBS) 
and pCM Vluc (6.4 pg in 400 pi HBS) were mixed and incubated for 30 minutes followed by mixing with 
either 7 nM or 38 nM JTS1 or AOA1* (in 800 pi HBS) and a further incubation for 30 minutes before 
adding a 500 pi aliquot (containing 2 pg per 6-well plate) to cells. Bifunctional peptide/DNA complexes 
formed between pCMVluc (6.4 pg in 800 pi) and various quantities o f  lK 25AOA1#2 (batch #2, estimated 
purity 95%), LK25INF7 (estimated purity 80%), DK25A0A1 (estimated purity: 95%) and DOTAP were 
incubated for 30 minutes before adding to cells. Cells were incubated with GDV for 4 hours 37°C for 4 
hours harvested 24 hours post initiation o f  transfection for analysis. Data represent the mean o f  triplicate 
samples ± SEM, and is representative o f  two separate experiments.
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Another distinctive result in this experiment was the total lack of transfection activity by 
bifunctional peptide with a shorter lysyl chain l K ioA O A I  in all four cell lines. The 
reason for this observation was that l K ioA O A I  did not effectively bind to DNA as 
inferred from ethidium bromide exclusion assay results in section 3.3.1.1.2. A fuller 
explanation has been provided in the discussion of the ethidium bromide exclusion 
assay and gel retardation assay results in section 3.3.1.
Figure 3.18 shows the results of the comparison between binary and ternary complexes 
for transfection efficiency in B16 and HEK293 cells performed in the early stages of this 
project when pRSVlacZ P-gal was used as the reporter gene. The results showed that the 
binary system of K2sAOA1 # 1 /DNA was between 1.4 x 103 and 2.6 x 103-fold better at 
mediating transfection in B16 cells than the ternary system of K25/DNA/AOA1* at 
identical charge ratios. In HEK293 cells, K25 AO A1 # 1 /DNA system was between 87- 
fold and 630-fold better than K25/DNA/AOAI* ternary system. While using the P- 
galactosidase reporter gene assay method, the low transfection activity of the ternary 
complex systems were being concealed by the high background readings of the negative 
controls, represented by “no DNA” and “DNA only” columns: thus the real fold 
difference in transfection efficiency between the binary and ternary complex systems 
could not be accurately determined, and hence there was the need to change to the use of 
firefly luciferase reporter gene assay method.
Comparison of luminometer readings, a common practice with many researchers, 
indicated that the difference in between the two types of complexes was actually greater 
(>106-fold, per pg protein). The apparent discrepancy stems from the fact that it is not 
possible to obtain one standard curve of luciferase activity, which spans more than 5 
orders of magnitude. The lack of linearity over 7-8 orders of magnitude of luciferase 
activity meant it was inaccurate to directly compare light unit readings from the lower 
end of the scale to the top part of the scale (Appendix G). Comparison of binary 
complexes with K8/DNA/JTS1 ternary complexes (using reported concentrations of 7
Hfiand 38 nM of JTS1) again revealed the same level of superiority of bifunctional 
peptide/DNA complexes over the K8/DNA/JTS1 system (Figure 3.16). The purity of 
K8 , JTS1 and K25AOAI were confirmed by MALDI-TOF mass spectrometry and 















F ig u re  3.17 Comparison o f transfection efficiency o f various complexes in A549, COS-7, NIH3T3 and 
B16 cells. For K8 or K25-DNA/JTSI complexes, K8 or K25 (9 pg in 400 pi HBS) and pCMV luciferase 
(6.4 pg in 400 pi HBS) were mixed and incubated for 30 minutes followed by mixing with JTS1 at 38 
nM (in 800 pi HBS) and a further incubation for 30 minutes before adding to cells. Complexes formed 
between pCM V luciferase (6.4 pg in 800 pi HBS) and previously determined optimised quantities of 
LK25AOAI, lK 25INF7, dK 25AOA1(N) and DOTAP (in 800 pi HBS) were incubated for 30 minutes 
before adding a 500 pi aliquot (containing 2 pg per 6-well plate) to cells. Cells were incubated with 
com plexes at 37°C for 4 hours and harvested 24 hours post initiation o f transfection for analysis. Data 
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Figure 3.18 Comparison o f transfection efficiency o f  various complexes in B16 and HEK293 cells. For 
K25-DNA/AOAI complexes, K25 (9 pg in 400 pi HBS) and pRSV/acZ (6.4 pg in 400 pi HBS) were 
mixed and incubated for 30 minutes followed by mixing with 800 pi HBS containing various quantities o f 
AOA1 (to produce the charge ratios stated in brackets) and further incubation for 30 minutes before 
adding a 500 pi aliquot (containing 2 pg per 6-well plate) to cells. Complexes formed between pRSV/acZ 
(6.4 pg in 800 pi HBS) and various quantities o f  peptides (in 800 pi HBS) were incubated for 30 minutes 
before adding a 500 pi aliquot (containing 2 pg per 6-well plate) to cells. Cells were incubated with 
complexes for 4 hours at 37°C and harvested 48 hours post initiation o f transfection for analysis. Charge 
ratios o f  DNA/peptide complexes are shown in brackets. Data represent the mean o f triplicate samples ± 
SEM, and is representative o f  two separate experiments.
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To help answer the question of why the ternary complex of K25/DNA/AOAI* system 
did not work and extrapolate the results to account for the lack of transfection activity of 
K8/DNA/JTS1 systems, particle size and zeta potential measurements (see section
7A3.3.2) were performed in 5% (w/v) glucose (solution used by Gottschalk et al ) and in
1A7 1 70HBS (buffer system used by Wagner and colleagues ’ , the pioneering researchers in
the use of fusogenic peptides in ternary/quaternary gene delivery systems).
3.3.6 d i s c u s s i o n :  c o m p a r i s o n  b e t w e e n  i n  v it r o  t r a n s f e c t i o n  a c t i v i t y  o f  b i n a r y
AND TERNARY COMPLEXES
1 f\ 7Plank and colleagues synthesized and studied the gene transfer enhancement ability 
of several sequences of peptides based on the 23 amino-terminal sequence of influenza 
virus X-31 in a self-assembled quaternary complexes dependent on ionic interactions. 
Of the sequences tested, INF7 and dimeric influenza peptides INF5, INF3DI and 
INF4DI were found to promote the highest gene expression (more than 5000-fold higher 
than in the absence of peptide) when formulated as quaternary complex using 
DNA/polylysine/ transferrin-polylysine/fusogenic peptide. The mechanism by which 
these peptide sequences were improving transfection was determined to be through 
endosomal escape of complexes: this inference was drawn from the observation that 
when cells in culture internalised FITC-dextran in endosomes through fluid-phase 
endocytosis, the presence of an endosomolytic peptide in the culture medium resulted in 
absence of bright vesicles, and the fluorescence spread over the cell: indicating the 
release of FITC-dextran into the cytoplasm. The presence of bafilomycin Ai, an
76Qinhibitor of vacuolar ATPase that specifically blocks the endosomal proton pump, 
also blocked the peptide-mediated release of FITC-dextran from vesicles and gene 
expression. It had been observed that the peptide-mediated endosome disruption and 
gene expression were dependent on the concentration of the fusogenic peptide, but the 
question of whether ionically bound (to DNA/polylysine) or unbound fusogenic peptide 
was mediating gene expression was neither asked nor answered by the authors. The idea 
of self-assembly of a quaternary particle: that a DNA/transferrin-polylysine/polylysine 
particle with an overall positive charge could be formed, to which negatively charged 
fusogenic peptide could be ionically bound to the surface, was not demonstrated by 
Plank and colleagues . It was very possible that it was unbound fusogenic peptide
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present in the medium that was responsible for mediating gene transfer. If unbound 
fusogenic peptide was responsible for enhancing gene delivery, then could ensuring that 
the fusogenic peptide was associated with the DNA/polylysine particle to be released 
from the endosome further enhance gene expression? The hypothesised model for self- 
assembly of particle suggests that the negative residues of the fusogenic peptide interact 
ionically with the excess positive charges on the exterior of a DNA/polylysine particle. 
Since these complexes are formulated at pH 7, the acid residues (pKa 4 to 5) in the 
fusogenic peptide would be ionised, and the lysyl s-amino groups (pKa 9) will also be 
partially protonated and therefore the binding of the fusogenic peptide to the surface of a 
“positively charged” DNA/polylysine particle can be assumed, but this can not be 
guaranteed in the presence of other ions present in solution, for example HBS. In a 
mixture containing DNA, polylysine and fusogenic peptide, the possible species present 
(depending on the relative quantities of each component added) are: DNA/polylysine, 
unbound polylysine, unbound fusogenic peptide, polylysine/fusogenic peptide, and 
perhaps the ternary complex, DNA/polylysine/fusogenic peptide. Contrary to the 
impression given by diagrams presented by proponents of self-assembled ternary or 
quaternary complexes, the fusogenic peptide should not exist as a sided alpha helix 
molecule at pH 7, because at pH 7, the glutamic and aspartic acid residues will be 
charged and oppose the formation of an alpha-helical structure (Figure 3.15). If on the 
other hand, bound fusogenic peptide was responsible for enhanced gene expression, was 
the ionic interaction between the fusogenic peptide and polylysine not hindering the 
fusogenic peptide from forming the alpha helix conformation (at the lower endosomal 
pH of 5.5) necessary for endosomal escape? The notion at the beginning of this project 
was that the peptide-mediated gene expression could be improved if the entire 3-D 
structure of the fusogenic peptide, complexed to DNA via oligolysine/polylysine was 
available to interact with the endosomal membrane. In order to achieve this aim, it was 
necessary to synthesize a peptide with both DNA binding and fusogenic moieties, a 
bifunctional peptide.
In this project, in all 6  cell lines tested, results showed that the binary complexes of 
DNA/bifunctional peptide D- or LK25AOAI were 43- to 74000-fold more effective than 
the ternary complex of DNA/K25 / AOA1* or K8/DNA/JTS1 (Figure 3.16, Figure 3.17, 
Figure 3.18 and Figure 3.21). One possible reason why the ternary complexes were
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almost ineffective is that the complexes were formulated in HBS rather than 250 mM 
sucrose which may have resulted in flocculation of particles producing aggregates 
which were not capable of transfecting cells. Attempts to formulate and measure zeta 
potential and particle size of ternary complexes (K8 /DNA) in HBS at peptide 
concentrations used during transfection resulted in a poor sample quality, which made 
the accurate determination of zeta potential impossible. In contrast, when formulated in 
HBS, the sample quality of DK25AOAI/DNA complexes was sufficiently good for 
particle size and zeta potential measurements to be made at usual concentrations used 
for transfection, although not at higher concentrations. Thus, K25/DNA complexes had a 
much lower solubility and stability in the presence of ions and could account for the low 
transfection efficiency of the overall ternary complex.
The challenge of instability of complexes to salts in vitro and in vivo must be overcome 
by designing more robust GDVs. The decision to formulate K8/DNA/JTS1 complexes 
in HBS was taken in order to maintain formulation consistency with extensive 
optimisation experiments performed with K25AOAI/DNA complexes formulated in
1 fSlHBS. This buffer was also used in work published by Plank and colleagues and was 
prior to the publication of work by Gottschalk and colleagues with K8/DNA/JTS1 
complexes76. The fact that DNA/K8/JTS1 complexes were reported to be highly 
effective by one group of researchers but not in our laboratory highlights the lack of 
robustness of this type of gene delivery formulation. The bifunctional peptide K25AOAI 
is an example of how a single multifunctional peptide can be constructed to overcome 
solubility problems and ensure that the required functional components of a successful 
gene delivery agent are present in the desired location within the complex. The 
advantage of a single multifunctional peptide is evident: the co-localisation of the 
required moieties in the desired relative positions to DNA can be achieved without the 
risk of compromising the functionality of the constituent moieties.
3.3.7 E f f e c t  o f  d i l u t in g  b if u n c t io n a l  p e p t i d e  w it h  o l i g o l y s in e
In a study to elucidate the importance of the DNA-binding moiety of K 2 5 A O A I ,  a 
transfection experiment was performed in which the relative quantity of the fusogenic 
moiety present in a complex was diluted out. To achieve this dilution, optimum and
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sub-optimum quantities (75%, 50% and 25% of optimum weight) of K25AOAI were 
complexed with DNA and their transfection efficiency compared with a parallel 
experiment in which the molar proportion of the DNA-binding moiety (K25-) had been 
pre-incubated with DNA by addition of K25 30 minutes before adding K25AOAI. The 
data from this experiment represented in Figure 3.19, showed that in complexes where 
only 50% and 25% of K25AOAI was present in the complexes (i.e. 50% and 75% 
reduction in K25AOAI), there was approximately 3700-fold and 21600-fold reduction in 
transfection efficiency. However, when a quantity of K25 equivalent to 50% and 75% of 
the mass of K25 in K25AOAI (i.e. replacing the 50% and 75% of K25 removed, which is 
equal to 4.5 pg and 6.9 pg respectively) was incubated with DNA 30 minutes prior to 
the addition of 50% and 25%, respectively, of the optimal quantity of K25AOAI, the 
fold reduction in transfection efficiency (for complexes containing 50% and 25% of 
optimum weight of K25AOAI) were 4-fold and 10-fold respectively. The result of this 
study also showed that the pre-incubation of DNA with K25 before adding the optimum 
or near optimum amount of K25AOAI was inhibitory, possibly because the amount of 
K25AOAI directly bound to DNA was reduced.
These results highlight two important issues: Firstly the plasmid DNA must be 
sufficiently condensed by the bifunctional peptide for transfection to take place. 
Effective DNA condensation by pre-incubating with K25 without fusogenic moiety 
restored some transfection activity. Secondly, synthesizing both components as a single 
peptide guarantees a high concentration and co-localisation of the fusogenic moiety on 
the surface of the DNA/peptide particle; both of these factors appear to be important for 
high gene expression mediated by fusogenic peptides in dividing cells.
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Figure 3.19 Transfection experiment showing the effect o f  diluting K25A O A l#3 with K25 in HeLa cells. 
Quantities o f  K25AOAl and K25 added to DNA are shown in the first row o f the data table and 
transfection efficiency is shown in the second row o f  the data table. Different quantities o f K25 (in 400 pi 
HBS) were mixed with pCM Vluc (6.4 pg in 400 pi HBS) and incubated for 30 minutes followed by 
mixing with different stated quantities o f  K25A0A1 (in 800 pi HBS) and a further incubation for 30 
minutes before adding a 500 pi aliquot (containing 2 pg per 6-well plate) to cells. Cells were incubated 
with GDV for 4 hours 37°C for 4 hours harvested 24 hours post initiation o f transfection for analysis. 
Data represent the mean o f  triplicate samples ± SEM, and is representative o f  two separate experiments.
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3.3 .8  St u d y  of the m ec h a n ism  of a c tio n  of bifu n c tio n a l  peptides u sin g
ENDOSOMAL PROTON PUMP INHIBITOR
Transfections of HeLa cells were performed in the presence or absence of bafilomycin 
Ai. Transfection experiments in the presence of bafilomycin Ai were performed as 
described in section 3.2.2 with the exception that the transfection medium contained 
200 nM bafilomycin Ai (achieved by adding 10 pi of 40 mM stock solution of 
Bafilomycin Ai in dimethyl sulfoxide (DMSO) to 6 -well plates containing cells covered 
with 1.5 ml of Opti-MEM™ and 0.5 ml transfection complexes in HBS). Binary and 
ternary complexes were formed at a charge ratio of +/-3.2, and PEI/DNA complexes 
were formed at a mass ratio of 3.6 pg PEI per 2 pg DNA per well as done throughout 
this project.
The results (Figure 3.20) showed that with K2sAOA1 #3 /DNA complexes, luciferase 
readings were 1.9-fold less in the presence of bafilomycin Ai and cell lysate protein 
content was also reduced by nearly 1.5-fold in samples containing bafilomycin Ai; 
therefore the net effect of bafilomycin Ai was a 1.3-fold reduction in the transfection 
efficiency of K2sAOA1 #3 /DNA complexes. The toxicity of bafilomycin Ai in DMSO 
was visually observed under the microscope as a higher number of detached cells from 
wells containing bafilomycin Ai at 4-hours and 24-hours post transfection. The 
transfection efficiency of PEI decreased by 190-fold in the presence of bafilomycin A\. 
The toxicity of PEI/DNA complexes to cells was evidenced by the observation that the 
cell lysate protein content of wells containing “PEI only” were low and similar to those 
which contained both PEI and bafilomycin Ai. The transfection efficiency of ternary 
complexes composed of Kio or K25/DNA/AOAI and the binary complex of 
K10AOAI/DNA were similar to that of the negative control of “DNA only” and the 
effect of the presence of bafilomycin Ai was insignificant due to the very low 
transfection activities of these complexes.
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Figure 3.20 Transfection o f  HeLa cells in the presence or absence o f  200 nM bafilomycin Aj. Complexes 
formed between pCMVluc and peptides lK 25AOA1#3, K10AOA1 (binary complexes) K25 + AOA1 and 
K 10 + AOA1 (ternary complexes) were all at a charge ratio o f  3.2. Cells were incubated with complexes 
for 4 hours at 37°C and harvested 24 hours post initiation o f  transfection for analysis. Data represent the 
mean o f  triplicate samples ± SEM, and is representative o f  two separate experiments.
3 .3 .9  D is c u s s io n : S t u d y  o f  t h e  m e c h a n is m  o f  a c t io n  o f  b if u n c t io n a l  p e p t id e s
USING ENDOSOMAL PROTON PUMP INHIBITOR
Fusogenic peptide sequences related to the N-terminal HA-2 sequence of the influenza 
virus which possess a low pH-selective haemolytic activity had been shown by a 
number of researchers to enhance gene transfer when added to DNA and oligolysine or 
polylysine complexes76,167,236. Plank et al. found a strong correlation of gene transfer 
efficiency of quaternary complexes that included fusogenic peptides with the capacity of 
the fusogenic peptides to lyse erythrocytes in an acidic environment. Crucially, Plank 
and colleagues observed that peptides that possessed a high haemolytic potential but did 
not display the strong specificity for low pH showed only moderate to insignificant 
augmentation of gene expression in quaternary DNA/TfpLys/pLys/fusogenic peptide 
complexes. Plank and colleagues also found that inhibition of endosomal acidification
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by blocking the endosomal proton pump with bafilomycin Ai considerably reduced 
peptide-mediated gene expression in quaternary DNA/TfpLys/pLys/fusogenic peptide 
complexes. The above observations, in conjunction with the observation that 
bafilomycin Ai blocked fusogenic peptide-mediated release of FITC-dextran from 
endosomes formed the basis for the explanation of the mechanism of action of 
fusogenic peptides in quaternary complexes.
The above-mentioned observations by researchers have supported the theory that the 
fusogenic peptide sequences used in ternary or quaternary complexes undergo a 
conformational change at the low pH in the endosome to an alpha-helical structure in 
order to exert its endosomal escape properties; this mechanism is similar to the
1 QSconformational change that occurs during influenza HA-mediated membrane fusion . 
Based on this theory, other fusogenic peptide sequences with low pH-dependent 
haemolytic activity have been synthesised and tested for their ability to augment gene
1 fk 7 7Adelivery by Plank et al and Gottschalk et al ’ . Plank and colleagues had not 
provided an explanation as to why synthetic peptides that possessed high haemolytic 
activity but lacked the low pH-selectivity, caused insignificant augmentation of gene 
expression. Perhaps, if and attempt had been made to address the question of why 
peptide sequences which do not need a low pH to be endosomolytically active, did not 
significantly improve gene delivery, this might have raised questions about the validity 
of the concept of step-wise complex formation of quaternary complexes involving 
fusogenic peptides. The question that needed to be answered was: if a peptide sequence 
had membrane disruptive activity at pH 7 and was endocytosed as part of a quaternary 
gene delivery complex, why did it not cause enhancement of gene delivery through 
endosomal escape in much the same way as a peptide which needed a low pH to be 
endosomolytically active? In other words, why should a non pH-selective membrane 
active peptide appear to lose its membrane-disruptive ability at a low pH? There seems 
to be no obvious reason for such an observation by Plank et al. In this project, ternary 
complexes consisting of K10 or K25/DNA/AOAI had very low transfection efficiency to 
the extent that the presence of bafilomycin Ai did not cause a distinguishable difference.
The observation in this research project was that, the non pH-selective haemolytically 
active peptide K25AOAI, was able enhance gene delivery. From erythrocyte lysis assay
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results, K 2 5 AO AI had a higher haemolytic potency at pH 5 compared to pH 7, but this 
difference in potency varied depending on the concentration (see Table 3.3). At low 
peptide concentrations (below 7.8 x 10‘5 M), the differences in the haemolytic potency 
of K2 5 AO AI at pH 5 and pH 7 were not measurably different. Given that the trend 
pointed to a diminishing of pH-dependent haemolytic potency at lower concentrations, it 
is reasonable to assume that, at peptide concentrations used in transfection experiments 
(4.65 x 10' M or 5.3 pg in 2 ml), the difference in measurable haemolytic potency will 
be negligible at pH 5 compared to pH 7. Therefore the observation that the presence of 
the vacuolar proton pump inhibitor bafilomycin Ai caused only a marginal reduction 
(1.3-fold reduction) in transfection efficiency of K2 5 A O AI is consistent with 
conclusions which can be drawn from erythrocyte lysis assay results. The slight 
reduction in transfection efficiency of K2 5 AO AI in the presence bafilomycin Ai (in 
DMSO) may be due to other effects exerted by DMSO or bafilomycin Ai, which were 
sufficient to disrupt the cellular functions but not enough to result in cell detachment or 
cell death. The difference may also be attributed to the possibility that, at pH 5, there 
was a subtle increased effect on the lytic potency or lytic rate of K 2 5 AO AI that could 
not be detected by erythrocyte lysis assay method.
Plank and colleagues had observed a 6.5-fold reduction in measured light units in the 
presence of bafilomycin Ai for the dimeric peptide IMF5 that had a low pH (pH 5) 
specific haemolytic potency but it appeared that this reported result did not take the
1 fntoxicity of bafilomycin Ai into account . It is therefore reasonable to speculate that 
had the protein lysate measurements been taken into account, this fold difference 
(between the presence and absence of bafilomycin Ai) would have been even less. For a 
peptide that depends entirely on activation at the low pH within the endosome to 
enhance gene delivery, a less than 6.5-fold reduction in the presence of bafilomycin Ai 
raises more questions about the proposed mechanism of action of pH-dependent 
fusogenic peptides in quaternary complexes, than the experiment was meant to answer. 
A possible partial explanation for the relatively low effect of bafilomycin Ai on the 
transfection activity of quaternary complexes that included INF5 could be that, the 
bafilomycin Ai concentration (200 nM) was not high enough to reduce the transfection 
activity of INF5, and thus prove beyond doubt the dependence of INF5 on acidic 
environment for activation. However, in this project, the presence of 200 nM
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bafilomycin Ai resulted in a 190-fold reduction in transfection efficiency of PEI. The 
explanation for this significant reduction in the transfection efficiency of PEI is that, PEI 
needed a low pH to be protonated. The “proton sponge” effect of PEI at low pH 
contributed largely to its ability to act as an endosomolytic agent. The observation that 
the transfection activity of PEI was not completely abrogated in the presence of 
bafilomycin Ai can be explained by the fact that PEI had a sufficiently high residual 
buffering capacity at pH 7 (the buffering capacity of PEI at around pH 7 could be 
observed during the preparation of PEI stock solution for transfection, which involved 
neutralizing PEI with hydrochloric acid) to exert an endosomolytic effect through 
osmolytic pressure. This result confirmed that the concentration of bafilomycin Ai (200 
nM) used in this study and in the study by Plank et al was sufficient to block endosomal 
proton pump and significantly affect the transfection efficiency of gene delivery agents 
that were dependent on acidification of the endosomal compartment for activation.
The erythrocyte lysis results in section 3.2.4.3 and the transfection experiment in the 
presence of endosomal proton pump inhibition reported in this section provide a clear 
and consistent experimental evidence for the mechanism of action of binary complexes 
composed of K25AOAI and DNA. The mechanism of action is as follows: the 
bifunctional peptide K25AOAI binds to DNA by ionic bond of the K25 moiety with 
DNA and forms particles that have DNA and K25 in the core of the particle and the 
fusogenic moiety on the surface of the particle. However because these complexes are 
formed at high positive charge ratios (+/-3.2), there are likely to be extra concentric
9 7 0layers of K25AOAI on the surface of core K25AOAI/DNA particles , as well as excess 
K25AOAI present in solution. During in vitro transfection studies, K25AOAI/DNA 
particles become concentrated on the surface of cells by gravitational precipitation and 
would be taken up by cation-mediated endocytosis into endosomes. Due to the fact that 
the bifunctional peptides do not need the low pH environment of the endosome to be 
membrane disruptive, the disruption of the cell surface prior to uptake through cation- 
mediated endocytosis is also possible. Within the endosome, the concentration of the 
peptide/DNA complex would be high enough to cause endosomal lysis, independent of 
the acidification process. Endosomal acidification can be significantly reduced by the 
presence of bafilomycin Ai but because the fusogenic activity of K25AOAI does not 
depend on low pH, the presence of bafilomycin Ai in the transfection medium did not
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significantly reduce the transfection activity of K25AOAI. In the erythrocyte lysis assay 
results in section 3.2.4.3, it was stated that lytic activity of AOA1, K10AOAI and 
K25A0A1#3 were visibly faster at pH 5 compared to pH 7, but this could not be 
investigated due to the limitation of the equipment and the compounds used in this 
study. It is therefore possible that the acidification process within the endosome may 
speed up the endosomolytic activity mediated by the fusogenic moiety of the 
bifunctional peptide resulting in the faster release of K25AOAI/DNA complexes into the 
cytoplasm. Regardless of the functioning of the proton pumps however, K25AOAI is 
able to mediate the escape of the peptide/DNA complex from the endosome and hence 
escape lysosomal degradation. The mechanism by which the bifunctional peptide/DNA 
complex is transported towards the nucleus is not know but it is not likely to be 
dissimilar to the mechanism by which most particles with excess positive charge are 
transported through the cell. As mentioned in section 3.3.13, the process of mitosis of 
the cells in culture is vital to the gene transfer activity of bifunctional peptides and other 
polyplexes, not least because the barrier of the nuclear membrane is considerably 
reduced during mitosis.
3 .3 .1 0  E f f e c t  o f  c h l o r o q u in e  o n  t r a n s f e c t i o n  e f f i c i e n c y  a n d  p r o p o r t io n  o f
TRANSFECTED CELLS MEDIATED BY BINARY AND TERNARY COMPLEXES
The possible effect of chloroquine on the transfection efficiency and proportion of 
transfected cells was studied by assaying the quantity of expressed reporter protein or 
determining the percentage of positively expressing cells by means of florescence 
cytometry.
3.3.10.1 E f f e c t  o f  c h l o r o q u i n e  o n  t r a n s f e c t io n  e f f i c i e n c y
Addition of chloroquine at a concentration of 100 pM to the transfection medium 
resulted in a 3- to 20-fold increase in transfection efficiency for DK25AOAI/DNA 
complexes in COS-7, CHO, A549 and B16 cells and 1.2- to 15-fold increase in 
transfection efficiency for LK25AOAI/DNA complexes in COS-7, CHO and A549 cells 
(Figure 3.21). The increases in transfection efficiency were greater in CHO cells than in 
other cell lines. The increases in transfection efficiency of bifunctional peptides due to
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chloroquine in A549 and CHO cells were 1.5- to 2-fold higher than with increases in 
percentage of cells positively expressing the reporter gene (Figure 3.21 and Figure 
3.23). This infers that chloroquine increased not only the number of cells expressing the 
reporter gene but also the amount of gene expression per cell. Disappointingly, 
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F ig u re  3.21 Effect o f chloroquine on transfection efficiency of binary and ternary complexes in COS-7, 
CHO, B16 and A549 cells. For K8/DNA/JTS1 complexes, K8 (9 pg in 400 pi HBS) and pCMV 
luciferase (6.4 pg in 400 pi HBS) were mixed and incubated for 30 minutes followed by mixing with 
JTS1 at 38 nM (in 800 pi HBS) and a further incubation for 30 minutes before adding to cells. 
Complexes formed between pCM V luciferase (6.4 pg in 800 pi HBS) and previously optimised 
quantities o f lK25AOA1, d K25AOA1, PLL219 and PEI (in 800 pi HBS) were incubated for 30 minutes 
before adding a 500 pi aliquot (containing 2 pg per 6-well plate) to cells in the presence or absence of 
100 pM  chloroquine. Cells were incubated with com plexes at 37°C for 4 hours and harvested 24 hours 
post initiation o f transfection for analysis. Data represent the mean o f triplicate samples ± SEM, and is 
representative o f two separate experiments.
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3.3.10.2 E f f e c t  o f  c h l o r o q u i n e  o n  p r o p o r t i o n  o f  t r a n s f e c t e d  c e l l s  d e t e r m in e d  
u s in g  F l u o r e s c e n c e  C y t o m e t r y
Fluorescence cytometry is a process, which counts cells in accordance with their 
fluorescent properties. HeLa, HEK293, CHO and A549 cells were transfected with 
plasmid D N A  encoding for the enhanced green fluorescent (EGFP) protein complexed 
with either D & L K 2 5 A O A I ,  K8+JTS1, PEI, or PL219 in the presence or absence of 
chloroquine at a concentration of 100 pM at their respective optimum charge ratios for 
the respective cell lines. Transfected cells were harvested after 24 hours for analysis. 
There was a wide variation in the percentage of cells expressing EGFP as determined by 
using fluorescence cytometry depending on the cell line and the results are shown in 
Figure 3.23. In all four cell lines used in this experiment, addition of chloroquine to the 
transfection media before adding L K 2 5 A O A I / D N A  complexes resulted in an increase in 
the percentage of cells expressing EGFP. The consistent trend that could be observed 
regarding the effect chloroquine on L K 2 5 A O A I -mediated gene expression was that the 
higher the percentage of positive expressing cells, the lower the enhancement due to 
addition of chloroquine: for example in HeLa cells in which 28% of cells were counted 
positive for L K 2 5 A O A I -mediated gene expression, the increase as a result of adding 
chloroquine to the media was marginal (1.1-fold), whereas in CHO cells there was 
nearly a 1 0 -fold increase in the percentage of cells counted positive for gene expression. 
In A549 cells, addition of chloroquine resulted in a 2-fold increase in percentage of 
positively expressing cells from 5.5% to 11.3%. Using D K 2 5 A O A I ,  chloroquine 
generally resulted in an increase in the percentage of positively expressing cells except 
in HeLa cells in which there was a decrease. Similar to L K 2 5 A O A I  -mediated 
transfection in CHO cells, the percentage of positively expressing CHO cells increase by 
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F igu re  3.22 F lo rescence  cy tom etry  ana lysis o f  HeLa, A549, HEK293 and CHO after transfection with 
D- and LK25AOAI, K8+JTS1, PEI, PL219 com plexed with plasmid DNA encoding for EGFP protein, in 
the presence or absence o f chloroquine at a concentration o f 100 pM , as described in methods section 
3.2.10.2.4. (FLl-H eight on the x-axis represents the fluorescence intensity at 530 nm and Events on the 
y-axis represents the number o f cells counted).
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The effect of chloroquine in PEI-mediated transfection was mixed: addition of 
chloroquine to the media resulted in a decrease in the percentage of HeLa and HEK293 
cells positively expressing EGFP but an increase in the percentage of CHO and A549 
cells expressing EGFP. In HeLa cells for example, there was over 5-fold decrease in the 
percentage of positively expressing cells from 75.4% to 14.4% and approximately 10- 
fold decrease in HEK293 cells (from 34.7% to 3.6%) following the addition of 
chloroquine to the transfection medium.CHO cells were totally resistant to PEI- 
mediated transfection but addition of chloroquine to the media resulted in about 3.5% of 
cells positively expressing EGFP, in contrast to the trend observed in HeLa and 
HEK293 cells for the effect of chloroquine in PEI-mediated transfection. In A549 cells, 
there was a 1.4-fold increase in the percentage of PEI-mediated cells expressing EGFP 
as a result of adding chloroquine.
Polylysine (PL2 i9)/DNA complexes mediated low gene expression in HeLa, HEK293 
and A549 cells resulting in 3.6%, 0.6% and 0.9% of cells positively expressing EGFP 
respectively, but as with PEI, CHO cells were resistant to transfection. Addition of 
chloroquine resulted in a 2-fold increase in the percentage of HeLa cells but a 2-fold 
decrease in the percentage of HEK293 and A549 cells expressing EGFP mediated by 
PL2 19. Almost consistently, K8/DNA/JTS1 complexes failed to promote the expression 
of EGFP, in some cases making it inferior to just polylysine2 i4 as a gene delivery 
vehicle.
Two consistent trends can be observed from these results: (i) single-step complexes with 
bifunctional peptides were more effective than the two-step K8/JTS1 system, (ii) the 
presence of chloroquine increased the proportion of cells positively expressing the 
reporter protein transfected with DK25AOAI, LK25AOAI and polylysine but the effect 
on PEI-mediated transfection was mixed. As it was observed earlier, these modest 
increases in the percentage of expressing cells due to the presence of chloroquine did 
not always correspond with the larger increases in transfection efficiency as determined 







































F ig u re  3.23 Percentage o f various cells (HeLa, A549, HEK293 and CHO) expressing enhanced green 
fluorescent protein (EGFP) as determ ined by fluorescence cytometry after transfection with D- and 
LK25AOAI, K8+JTS1, PEI, PL219 com plexed with plasmid DNA encoding for EGFP protein, in the 
presence or absence o f chloroquine at a concentration o f 100 pM , as described in methods section
3.2.10.2.4
3.3.11 D is c u s s io n : E f f e c t  o f  c h l o r o q u in e  o n  t r a n s f e c f e c t io n  e f f ic ie n c y  o f
BINARY AND TERNARY COMPLEXES
The effect of chloroquine on the transfection efficiency of D & L K 25A O A I  varied 
according to cell line, but generally, in the presence of chloroquine, there was an 
increase in transfection efficiency of between 3- and 20-fold. For endosomolytic effects, 
the lysomotropic agent chloroquine was used at a concentration of 100 pM. The 
mechanism of action of chloroquine is not well defined although it is generally assumed 
that its accumulation within acidic compartments of the cell, notably the endosome and 
lysosome prevents acidification and hence activation of hydrolase enzymes contained 
therein . However, a simple buffering effect, resulting in the inhibition of transfer to 
the lysosomes cannot provide a complete explanation since there is no innate 
mechanism for transfer to the cytoplasm . Hence endosomal bursting (a consequence 
of raised endosomal osmotic pressure) is an alternative mechanism that has been
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postulated . Wolfert and Seymour reported synergistic transfection activity between 
INF7-SGSC (INF7-serine-glycine-serine-cysteine) and chloroquine and postulated that a 
post-endosomal disruption of polylysine/DNA complex by INF7-SCSC could account 
for the observed synergy226. Under this hypothesis, it is suggested that INF7-SGSC may 
facilitate transcription by negative charge-mediated destabilisation of the pLL/DNA 
complexes. Despite similar synergism being observed between chloroquine and 
bifimctional peptide, the hypothesized mechanism of destabilisation for a ternary 
complex, post endosomal release, can not be possible with a binary complex of 
DNA/bifunctional peptide where the oligolysine moiety is covalently attached to the 
fusogenic moiety. The more plausible explanation is that the two agents (K25AOAI and 
chloroquine) mediate lytic activities on different subpopulations of intracellular vesicles 
or both agents have an additive lytic activity within the same endosome.
Wagner and colleagues also observed the synergistic effect of chloroquine on HA-2 
sequences during transfection and suggested three mechanisms by which this effect may 
have occurred, namely: protection of conjugates from lysosomal degradation, osmotic 
destabilization of endocytic vesicles by internal accumulation of chloroquine, and/or by 
the observation that the influenza peptide conjugates display some residual leakage 
activity at neutral pH179. In this project, it was observed that the membrane disruptive 
activity of the bifimctional peptide K 2 5 A O A I  occurred at neutral pH (see section
3.3.1.2), therefore the action of chloroquine to raise the pH of endosomes would not 
interfere with the fusogenic effect of K 2 5 A O A I .  The synergism between chloroquine 
and K 2 5 A O A I  can thus be explained by a combination of all three mechanisms
1 70postulated by Wagner et al.
In the presence of chloroquine, gene expression mediated by bifimctional peptide per 
cell was increased. The increase in the proportion of cells expressing the enhanced green 
fluorescence protein, as determined by fluorescence cytometry, is possibly due increased 
expression within a subpopulation of cells that hitherto had too low an expression to be 
sorted as positively expressing cells that now had high enough expression in the 
presence of chloroquine.
162
In terms of harnessing the effects of chloroquine in a putative gene delivery vector in 
vivo, it will be worth studying the effect of including an amino acid derivative of 
chloroquine into a multifunctional GDV although the resulting molecule will not be 
freely diffusible. An amino acid derivative with side chain containing nitrogen atoms of 
pKa values (10.2 and 8.1) similar to that of chloroquine could confer acid buffering 
capabilities to the multifunctional molecule. PEI is an example of a reagent whose 
endosomolytic properties depend on osmolytic lytic effect due to acid buffering of the 
endosomal vesicle (see section 3.3.7). However, PEI is quiet toxic to cells at 
concentrations used to promote gene transfer (see section 3.3.7). The main advantage of 
synthesizing relatively smaller peptidic molecules for use as adjuncts for gene delivery 
is that of reduced toxicity. Gottschalk et al.16 showed that K8  was at least 104 times less 
toxic than polylysine in HepG2 cells. Although polymers are inexpensive and some 
degree of control can be achieved in the attachment of ligands to polymers, it is still a 
relatively rudimentary process in terms of understanding the structural features of the 
end product34. The difficulty with modulating a polymeric reagent such as PEI with 
ligands to improve gene delivery (for example inclusion of targeting capability or 
nuclear localisation signal) is that efforts are hampered by the lack of control in the 
positioning of functional moieties due to the presence of multiple reactive sites on PEI. 
PEI was found to be 1.5 to 4-fold better than K25AOAI in B16 and CHO cells but 
K25AOAI was about 1.3-fold better than PEI in A549 cells and over 5-fold better than 
PEI in COS-7 cells. These results demonstrate that there is a high degree of cell-specific 
variations in transfection experiments in vitro and it is important for a putative gene 
delivery agent to be more amenable to specific and subtle changes for the purpose of 
improving them as gene transfer agents in vivo.
3 .3 .1 2  D e t e r m i n a t i o n  o f  p r o p o r t io n  o f  t r a n s f e c t e d  c e l l s  u s in g  c y t o c h e m ic a l
STAINING FOR P-GALACTOSIDASE ACTIVITY
In order to visualize the proportion of cells expressing the reporter protein after 
transfection with the bifunctional peptide LK25AOAI or lipid DOTAP, the method of 
cytochemical staining for p-galactosidase activity was used. Cytochemical staining of 
cells with the substrate 5-bromo-4-chloro-3-indoly-P-D-galactoside (X-gal) is one of 
two methods available for evaluating p-galactosidase expression in single cells. Cells
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expressing p-galactosidase hydrolyse this substrate to galactose and soluble indolyl 
compounds, which in turn are oxidised (by ferricyanide and ferrocyanide ions) to 
insoluble indigo coloured species273. Hence, the development of a deep blue colour 
following incubation with X-gal enables identification of P-galactosidase expressing 
cells. When cells were stained with X-gal, it was noted that there were more lacZ+ve 
cells on transfection with K25AOAI compared with DOTAP i.e. the number of and the 
intensity of blue staining in cells transfected with K25AOAI was higher than observed 
with DOTAP (Figure 3.24). Estimation of the proportion of cells stained blue is very 
subjective, but it is safe to conclude that more than 50% lacZ+ve cells were present after 
transfection with K25AOAI, whereas the figure for DOTAP is less than 40%. The use of 
rapidly dividing cells for many gene delivery studies has been met with criticism since 
the many target organs for in vivo gene therapy comprise non-dividing/terminally 
differentiated cells. The lack of suitable in vitro cell culture models is now well 
recognised and requires the rapid development of intermediate in vitro systems with 
functional and morphological characteristics similar to the in vivo targets. Although it is 
impossible to emulate identically the conditions in vivo, studies with differentiated cell 
cultures should serve as a short-term compromise, making it possible for better 
correlation’s to be made between in vitro and in vivo transfection data.
When cultured on membranes (PTFE or nitrocellulose), Caco-2 grow to confluence and 
undergo differentiation, ultimately exhibiting morphological characteristics (tight 
junctions, microvilli), brush border enzymes (various glycosidases, alkaline 
phosphatase, aminopeptidase N) and drug metabolising enzymes found in gastric
* \ n  a  97£ 977 970enterocytes ’ Differentiated Caco-2 cells thus represent a good in vitro
model of the small intestinal mucosa and has been used extensively for elucidating the
770 7RH 9K1mechanism of drug transport and predicting the intestinal absorption of drugs *
As a result of these properties, differentiated Caco-2 cells were used as a model for 
evaluating LK25AOAI plasmid DNA delivery to the gut epithelium and to other 
epithelial monolayers. The human origin of this cell line makes it ideal for evaluating 
the feasibility of gene therapy to the colon for conditions such as cancer and irritable 
bowel disease. Cytochemical staining of 14- day old differentiated Caco-2 cells 
(cultured on semi-permeable membranes with a mean pore size of 0.4 pm on filter, see 
section 3.2.2.1) X-gal staining results showed that less than 0.5% of cells were
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transfected using a LK2 5 AOAI/DNA complex at a charge ratio of 3.2 (data not shown).
F igu re  3.24 Cytochemical staining o f B16 cells with X-gal. Cells transfected with com plexes formed 
between pRSV/acZ (2 pg in 800 pi HBS) and various quantities o f LK25AOAI at a charge ratio o f 2.6 
(A), 3.2 (B) and (C) same as (B) except the wells were overlayed with 3 ml of culture m edium instead of 
the normal 2 ml, post transfection for 44 hours) or 4.8 (D) DOTAP (E) (in 800 pi HBS) or naked DNA 
(F) were incubated for 30 minutes before adding to cells. Cells were incubated with GDVs for 4 hours at 
37°C. Cells were then washed and stained 48 hours post transfection as described in section 3.2.10.2.3. 
Cells positive for P-galactosidase activity stain blue with X-gal treatment. Cells were photographed at 
magnification x300. The fields shown are representative o f the expression levels detected over the plates, 
with three wells transfected per formulation.
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3.3.13 In v e s t ig a t io n  o f  t o x ic it y  u s in g  MTT a s s a y
The comparative toxicities of the uncomplexed peptides ( D- & L K 25A O A I), polylysine, 
PEI (in the presence or absence of chloroquine) and D O T A P  were determined using the 
MTT assay over concentration ranges relative amounts required for optimum 
transfection in vitro (Table 3.5).
Gene delivery agent Concentration range
D&lK25AOA1 1.3 - 334 pg/ml
PL214 1.2 - 149.2 pg/ml
PEI 1.05 -230.4 pg/ml
DOTAP 1.56-400  pg/ml
T able 3.5 Concentration range for GDVs used in M TT assay in toxicity studies.
There were wide variations in absorbance readings (10-30%) making interpretation of 
toxicity results less certain at GDV concentrations below 10 pg/ml, however it clear that 
D O T A P  was the least toxic of the five GDVs tested (Figure 3.25). Between GDV 
concentrations of 1 0  and 1 0 0  pg/ml, the order of toxicity from the most to the least toxic 
was PI214, PEI, D K 25A O A I, LK25AOAI and D O T A P . The presence of chloroquine at a 
concentration of 100 mM with PLL214 was highly toxic to the cells. The significance of 
these results relate to complexes between D N A  and GDVs formed at positive charge 
ratios. All the GDVs tested for toxicity have positive charge ratio for optimum 
transfection activity in vitro. At positive charge ratios, it is inevitable there will be free 
GDV present in the formulation and these toxicity results reflect the effect of free GDV 
on cell survival during transfection.
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F igu re  3.25 Comparison o f toxicity of free L K 25A O AI, D K 25A O A I, PEI, polylysine 214, and DOTAP on 
B16 melanoma cells was determined by M TT assay as described in section 3.2.4 B16 cells were plated in 
a 96-well plate at a density o f approximately 4000 cells per well in 100 p i media. Peptides to be tested 
were made up at twice the required concentration in lOOpl o f PBS and added to the wells. Ten serial 
dilutions were prepared such that expected 50% cell kill was straddled evenly by maximum and 
minimum concentrations. The cells and agents were incubated at 37°C for 3 days. The media was then 
removed and washed twice with 200 pi PBS. The cells were then incubated with 200 pi o f 1 mg/ml MTT 
in serum  free media for 3 hours at 37°C. The media was then removed and 200 pi DMSO added to each 
well to dissolve the formazan. Absorbance was read at 540 nm (background readings at 690 nm). A 
graph of absorbance versus log concentration o f cytotoxic agent was plotted. The extracellular 
concentration o f cytotoxic agent which, kills 50% of cells com pared to control (EC50) was determined. 
Data represent the mean o f four samples ± SEM, and is representative o f two separate experiments.
3.3.14 D is c u s s io n : In v e s t ig a t io n  o f  p r o p o r t io n  o f  t r a n s f e c t e d  c e l l s
The cytochemical staining of B16 cells suggested that over 80% of cells were 
transfected by K25AOAI at a charge ratio of 4.2. However the cytochemical staining of 
cells also revealed that there was a high degree of toxicity resulting in cells being 
detached from the plates (compared to transfection with DNA only). The total 
proportion of blue cells is not known because the proportion of blue cells that detached 
could not be estimated and this situation probably resulted in misleadingly high 
percentage transfected cells. Data from studies performed to investigate the toxicity of
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the various GDV using the MTT assay (section 3.3.13) confirmed that the formulations 
were toxic to cells. The aim had been to corroborate the cytochemical staining method 
of determining the proportion of transfected B16 cells with the use of fluorescence 
cytometry method, but this was not possible within the time available on the cytometer. 
However data from both cytometry and cytochemical staining methods independently 
confirm the ability of the novel bifimctional peptide K25AOAI to augment gene delivery 
in dividing cells in vitro.
Differentiated and non-dividing Caco-2 cells were very resistant to transfection with 
less than 1% of cells staining blue as lacZ+ve because of the lack of mitotic and perhaps 
endocytotic activity (data not shown). The requirement for mitotic activity for
17^transfection has been reported by Wilke et al. . During cell division, the nuclear 
membrane becomes discontinuous allowing entry of plasmid DNA into the nucleus. The 
lack of mitotic activity in differentiated Caco-2 cells and the consequent resistance to 
transfection led Uduehi and colleagues to conclude, rightly, that differentiated Caco-2 
are a better in vitro model for in vivo transfection than dividing cells95. Therefore a 
greater use of differentiated Caco-2 should be made in future work to optimise these 
new bifunctional peptides as a more economical but realistic model for in vivo activity. 
The ability of bifimctional peptides to lyse cells suggest that they may have the ability to 
disrupt cell membranes and this ability may be exploited to enhance its entry into non­
dividing cells by formulating complexes at sub-toxic charge ratios.
In conclusion, K25AOAI readily transfected dividing cells but not non-dividing cells, 
therefore the use of non-dividing cells will be a better in vitro transfection model for in 
vivo activity when testing novel multifunctional peptides.
3.3.15 E f f e c t  o f  f o e t a l  c a l f  s e r u m  o r  s e r u m  a l b u m in  o n  t r a n s f e c t i o n
Addition of 10% (v/v) foetal calf serum to the transfection medium resulted almost 
total loss of transfection using LK25AOAI or DK25AOAI complexes (Figure 3.26) but 
did not abrogate the activity of DOTAP (data not shown). The presence of 10% (w/v) 
bovine serum albumin (BSA) resulted in a 3-4-fold decrease in transfection efficiency 
(Figure 3.26).
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Figure 3.26 Investigating the effect o f  FCS or BSA on transfection efficiency in vitro. Complexes 
formed between pCMV luciferase (6.4 pg in 800 pi HBS) and previously optimised quantities o f 
lK 25A O A 1#2 and DK25AOAI (in 800 pi HBS) were incubated for 30 minutes before adding a 500 pi 
aliquot (containing 2 pg per 6-well plate) to cells in the presence or absence o f  10%  (v/v) foetal calf 
serum (FCS) or 10% (v/v) bovine serum albumin (BSA). Cells were incubated with complexes at 37°C for 
4 hours and harvested 24 hours post initiation o f transfection for analysis. Data represent the mean o f 
triplicate samples ± SEM, and is representative o f  two separate experiments.
To investigate the reason for the loss of transfection activity in the presence of serum, 
K25AOAI/DNA complexes were incubated in Opti-MEM supplemented with 10% (v/v) 
FCS at 37°C for 4 hours and then run on a horizontal electrophoresis gel. 
K25AOAI/DNA complexes were formed at charge ratios below neutrality (+/- 0.5), at 
neutrality (+/- 1 .0 ) and at the optimum charge ratio for usual in vitro transfection 
experiments (+/- 3.2). This was compared to K25/DNA complexes at the same charge 
ratios because both K25AOAI and K25 had previously been shown to condense DNA in 
ethidium bromide exclusion assay (section 3.2.4.2) and retard electrophoretic migration 
of DNA (section 3.2.4.1). The various negative controls for this experiment were: 
absence of FCS, or absence of DNA or absence of peptide and are detailed in the table 
in Figure 3.27 below. The first of two general observations from the results of this 
experiment is that the presence of FCS resulted in the disappearance of the supercoiled
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D N A  band and the appearance of the nick-circular D N A  band. Secondly, smearing of 
D N A  bands occurred mainly when D N A  was complexed with K 2 5  or K 2 5 A O A I  at a 
charge ratio below neutrality (+/- 0.5) (lanes 1 and 4, when no FCS was present, and 
lanes 9 and 10, when FCS was present). The result showed that for both K 2 5 A O A I  and 
K 2 5 ,  at a charge ratio below neutral (+/- 0.5), in the presence of FCS, lanes 9 and 12 
respectively, there was some smearing of D N A  bands, the disappearance of the 
supercoiled band and the appearance of the nick-circular band. At neutral charge ratio, 
there was complete retardation of D N A  and no smearing for K 2 5 / D N A  (lane 10) but 
some smearing and migration of D N A  for K 2 5 A O A I / D N A  complexes (lane 12). At the 
charge ratio of +/- 3.2 (the optimum in vitro transfection for K 2 5 A O A I / D N A  
complexes), for both K 2 5  and K 2 5 A O A I  complexes with D N A ,  there was complete 
retardation (lanes 3 and 6  for K 2 5 A O A I  and K 2 5 ,  respectively, when no FCS was 
present; and lanes 11 and 14, for K 2 5 A O A I  and K 2 5  respectively, when FCS was 
present). Comparison between naked D N A  in the presence and absence of 10% (v/v) 
FCS (lanes 7 and 15 respectively) showed that the presence of FCS with D N A  results in 
the disappearance of the band corresponding to supercoiled D N A  and the appearance of 
the linear/nick-circular D N A  band, however, there was not significant smearing. Thus, 
smearing of bands observed in this experiment was not due to fragmentation of D N A  
but rather due to partially complexed D N A  moving at different speeds through the gel.
The lack of evidence of DNA degradation in the presence of FCS when K25AOAI/DNA 
complexes were formed at a charge ratio of +/- 3.2, combined with the observation that 
the presence of BSA reduced transfection efficiency in vitro, suggests that binding of 
serum protein to complexes, and not enzymatic degradation, is responsible for the loss 




Lanes 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
KjjAOAl 0.5 1.0 3.2 0.5 1.0 3.2 - - - -
K25 - - - 0.5 1.0 3.2 - - - - - 0.5 1.0 3.2 -
DNA + + + + + + + - + + + + + + +
F C S + + + + + + + +
F igure 3.27 Investigation o f  the effect o f  serum on peptide/DNA complexes. Agarose gel displaying the 
retardation o f  DNA/peptide complexes with increasing amounts o f  either LK25AOAI or K25. 
LK25A OAI/DNA and LK25/DNA complexes were formed at charge ratios o f  0.5, 1.0 and 3.2 as indicated 
in the table above, by adding increasing amounts o f  LK25AOAI in 125 pi KBS to 3 pg DNA in 125 pi 
HBS. The complexes were incubated for 30 minutes as detailed in section 3.2.8, and incubated in 1.0 ml 
Opti-MEM in the presence (+) or absence (-) o f 10% (v/v) serum (FCS) for 4 hours at 37°C before 
loading onto a 1% (w/v) agarose gel and running at 80 Volts for one hour and prepared for viewing and 
photographing as detailed in 3.2.4.1.
3 .3 .1 6  D i s c u s s io n : E f f e c t  o f  f o e t a l  c a l f  s e r u m  o r  s e r u m  a l b u m in  o n
TRANSFECTION EFFICIENCY OF BINARY COMPLEXES
The presence of 10% (v/v) heat-inactivated foetal calf serum (Gibco Inc., UK) in MEM
medium (see Table 3.1) during the 4-hour incubation period of K25AOAI/DNA
complex with in vitro cells was found to virtually abrogate transfection activity of
bifunctional peptides in vitro. The process of heat-inactivation involves heating the
serum at 56°C for 30 minutes and this process only destroys heat sensitive complements
proteins C lq, C lr, C2, C8 , C9, as well as factors B and H (Gibco Inc., UK), which can
080kill foreign cells by binding to and lysing their cell membranes . This process of heat- 
inactivation still leaves enzymes such as proteases, nucleases and growth factors, 
present in serum largely unaffected. Therefore if GDVs were unable to protect DNA 
from degradation from serum nucleases, then that would partly explain the lack of 
transfection activity mediated by bifunctional peptides in the presence of serum. The 
use of the transfection medium Opti-MEM™ from Gibco Inc., UK, on the other hand, 
was able to support transfection activity mediated by bifunctional peptide/DNA 
complexes. Opti-MEM™ is a serum-free medium specifically designed for the in vitro
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transfection of mammalian cells; it is an enriched medium lacking in serum proteins like 
serum albumin, globulin and fibrinogen, which can interact with DNA/GDV complexes 
but contains the essential growth factors necessary to maintain cell viability (telephone 
communication with technical support, Gibco Inc., UK).
In order to investigate whether enzymatic degradation of the DNA condensed by the 
bifimctional peptide was responsible for the loss of the ability of K25AOAI to mediate 
transfection in vitro, a gel mobility assay was performed in the presence or absence of 
FCS. The enzymatic degradation of K25AOAI (by serum proteases) would result in its 
loss of ability to protect DNA from degradation (by serum nucleases). At a charge ratio 
of 0.5, smearing of K25/DNA or K25AOAI/DNA complexes was seen to occur, as 
partially neutralised DNA, with a mixture of various net charges, travelled at varying 
speeds through the agarose gel under constant voltage (Figure 3.27). The results showed 
that when DNA was complexed with K25 or K25AOAI at a charge ratio of neutrality 
(1.0) and above, smearing did not occur, thus confirming that the DNA was fully 
complexed. At a charge ratio of +/-3.2 (optimum charge ratio for transfection 
experiments in vitro), K25AOAI/DNA or K25/DNA complexes remained in the well 
during electrophoresis and there was an absence of a nick-circular DNA band, providing 
evidence that the DNA in the peptide/DNA complex had been fully complexed and 
protected from the degradative nature of serum nucleases. Therefore degradation was 
not the course of loss of activity during transfection. Transfection with K25AOAI/DNA 
complexes in the presence of 10% (w/v) BSA, which does not possess enzymatic 
activity, resulted in 3-4-fold decrease in transfection activity. This observation goes 
some way into supporting the view that binding of negatively charged serum 
macromolecules and not enzymatic degradation, was responsible for the loss of activity 
in the presence of serum. The use of enzyme degradation-resistant DK25AOAI did not 
prevent the loss of transfection activity in the presence of serum, again confirming that 
enzyme degradation of the bifunctional peptide and subsequently DNA was not the 
cause of loss of transfection activity.
The barrier of binding anionic macromolecules must be overcome if GDVs based on 
K25AOAI bifunctional peptide structure is to be active in vivo, particularly following 
systemic administration. Serum has been reported to have effects on the transfection
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efficiency of many gene delivery vectors. Serum proteins readily adsorb onto positively 
charged particles, initiating rapid blood clearance by macrophage uptake (a first step in 
the removal of polyplexes by the innate immune system). PLL-based polyplexes are 
eliminated quickly with a half-life less than 5 minutes. Clearance from blood has been
11Qshown to correlate with the amount of plasma associated with the particles . The 
effects of serum appear to be dependent on the cell type as well as the GDV under 
study. Feigner et al. observed that the transfection of mouse cells with lipofectin was 
reduced by 95% in the presence of 10% (v/v) serum whilst in COS-7 cells transfection 
was unchanged55. Legendre and Szoka reported an 80% reduction in transfection 
efficiency in CV-1 cells in the presence of 10% (v/v) serum with Lipofectin but in 
HepG2 cells, serum had no effect283. The transfection efficiency of DOTAP in B16 
cells was unaffected by the presence of serum (data not shown); this is because the 
external surface of a DOTAP/DNA complex is likely to be uncharged lipid tails (in a 
micellar structure) and thus will not bind to negatively charged proteins present in 
serum.
In order to decrease the effect of serum macromolecules on oligolysine/DNA GDVs, 
one approach would be to create particles with overall near neutral charge capable of 
condensing DNA but which do not coagulate. However, formulation of polyplexes at 
near neutral zeta potential results in rapid aggregation of particles due to van der Waals 
interactions, therefore polyplexes are formulated at high positive charge ratios (zeta 
potential) for charge-mediated uptake to overcome the problem of coagulation. Another 
approach investigated by researchers is to graft uncharged hydrophilic polymers like 
PEG or HPMA to cationic polymers prior to complexing with DNA (see section 1.4). 
This approach, whilst successful in reducing protein adsorption to complexes, has been 
met with the problem of reduced DNA-binding affinity of the cationic polymer and 
reduced transfection efficiency141. To overcome the problem of reduced affinity and 
transfection efficiency resulting from modification of cationic polymers with 
hydrophilic polymers (pre-polyplex modification), some researchers have demonstrated 
improved salt and serum stabilization by modifying pre-formed polyplexes with 
hydrophilic polymers like PEG or HPMA144,145 (post-polyplex modification). 
PEGlylation of preformed DNA/Tf-PEI complexes resulted in significantly increased 
blood circulation time and tumour-site gene expression after systemic injection in mice .
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Unfortunately, the success of post-polyplex modification in decreasing protein 
adsorption cannot be adopted in a bifimctional peptide/DNA complex system to achieve 
a similar beneficial effect. In theory, post-complex modification of K25AOAI/DNA 
complexes with hydrophilic polymers would have the advantage of increasing solubility 
of complexes and reduce adsorption of serum proteins to complexes. The disadvantage 
with such a modification, however, is that the fusogenic moiety of the bifimctional 
peptide will not be able to interact with membrane surfaces and the endosomal escape 
property of the bifimctional peptide will be lost. However, these approaches of using 
hydrophilic polymers to decrease protein adsorption of polyplexes stem from the fact 
that the cationic polymers used in these polyplexes were not custom-made for gene 
delivery. Work in this project has shown that K25AOAI/DNA complexes have a higher 
solubility in the presence of salts than K25/DNA (section 3.3.2.4), possibly due to the 
limited degree of steric stabilisation provided by the fusogenic moiety of the 
bifimctional peptide. It may thus be possible to design and construct a single molecule 
with a dimeric fusogenic component or another peptide sequence with mainly negatively 
charged amino acid residues, which would have the advantage of decreasing serum 
protein adsorption. The fact that DOTAP/DNA complexes could transfect cells in vitro 
in the presence of serum, suggests that modifying the structure of a multifunctional 
peptide with a relatively short hydrocarbon chain (compared to PEG with molecular 
weight >1 kDa) could reduce protein binding, albeit with the associated risk of reduced 
solubility in aqueous solutions. To improve salt and serum stability, a second 
bifimctional peptide consisting of oligolysine (DNA-binding moiety) and a combination 
of serine and aspartic/glutamic acid residues (hydrophilic moiety) could be synthesized 
and mixed with K25AOAI before mixing with DNA. This approach, although simple to 
formulate, is a retrograde step in design of formulations for gene delivery vehicles, as it 
will result in complexes of less defined structure, similar to ternary and quaternary 
complexes involving polylysine/polylysine-transferrin/DNA/fusogenic peptide. A 
preferred approach to increasing the salt stability and decreasing the surface positive 
charge of a peptide/DNA particle (and hence decrease serum protein adsorption) will be 
to include a number of serine and aspartic or glutamic acid residues as an extension to 
the fusogenic moiety of K25AOAI, or attach it to the e-amino of the lysine residue next 
to the fusogenic moiety.
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3.3.17 R e s u l t  a n d  d i s c u s s i o n : E f f e c t  o f  o m is s io n  o f  a s p a r a g in e  in  f u s o g e n ic
SEQUENCE OF IN BIFUNCTIONAL PEPTIDE
Omission of a single amino acid (asparagine, Asn) to form dK2sAOA1 (N) resulted in 
substantial decrease in transfection activity. dK2sAOA1 (N) was over 1 0 0 -fold less 
active than corresponding peptide (DK25AOAI) without the asparagine omission 
(Figure 3.16 and Figure 3.17).
The omission of one amino acid within the fusogenic sequence of the bifimctional 
peptide caused a disruption in the pH mediated alpha helical structure resulting in 
diminution of disruptive membrane activity and corresponding decrease in transfection
1RR 1RQ 7 f\activity ’ . In agreement with observations by Gottschalk and colleagues and Plank
and colleagues , these results show that whilst individual residues to the original HA-2 
sequence may be replaced to produce enhancement of transfection activity, complete 
omission of an amino acid residue was counter productive.
3.3.18 In f l u e n c e  o f  o l e o y l - f u s o g e n ic  p e p t i d e  o n  d o t a p  t r a n s f e c t i o n  a c t iv it y
The inclusion of oleoyl-AOAl peptide to DOTAP/DNA complex at a DOTAP to 
peptide molar ratio of 34:1 resulted in a modest increase (2-fold) in the transfection 
activity of DOTAP in B16 cells. Further increases in the proportion of peptide resulted 
















ratio of DOTAP to oleoyl-AOA1
Figure 3.28 Investigating the effect o f inclusion o f  oleoyl-fusogenic peptide on the transfection efficiency 
o f  DOTAP in B16 cells. Molar ratios o f  DOTAP:oleoyl-AOAl o f  34, 23, 19, 16, 14 and 11:1 were 
preformed by a modified reverse phase method by adding various quantities o f  oleoyl-AOA 1 to a fixed 
quantity o f  DOTAP (11.52 pg). The DOTAP/oleoyl-AOAl mixtures were then resuspended in 800 pi 
HBS. Complexes formed between pRSV/acZ (6.4 pg in 800 pi) and DOTAP/oleoyl-AOAl (in 800 pi 
HBS) were incubated for 30 minutes before adding a 500 pi aliquot (containing 2 pg per 6-well plate) to 
cells. Cells were incubated with complexes for 4 hours at 37°C and harvested 48 hours post initiation o f 
transfection for analysis. Data represent the mean o f triplicate samples ± SEM.
3.3.19 T h e  in f l u e n c e  o f  a n  o l e o y l -f u s o g e n ic  p e p t id e  o n  d o t a p  t r a n s f e c t io n
ACTIVITY
The rational behind this part of the project was to investigate if providing the cationic 
lipid DOTAP with an extra endosomal escape capability by adding a fusogenic peptide 
to the complex. In an attempt to facilitate the inclusion of the fusogenic peptide in the 
DOTAP/DNA complex through hydrophobic interaction, an oleoyl chain was attached 
to the fusogenic peptide via the side chain 8  amino of a lysine residue through an amide 
bond. A schematic view of the aimed structure of the DOTAP/Oleoyl-AOAl/DNA 
complexed structure is shown in Figure 3.29. The achievement of this structure 
depended on the order in which the three components were mixed. However, difficulties 
in getting the oleoyl-AOA 1 component, to mix with DOTAP, coupled with an attempt 
not to expose plasmid DNA to potentially damaging conditions, meant that the DOTAP
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and oleoyl-AOAl had to be assembled first and then DNA added. Under these 
conditions, ionic interactions would ensure that the charge head group of DOTAP 
would be associated with the negatively charged residues of the fusogenic component 
of the peptide. The introduction of negatively charged DNA in solution would cause a 
dynamic restructuring by attracting the positive head groups of DOTAP and repelling 
the negatively charged fusogenic peptides towards the surface of the complex.
I -
/
O L E O Y L - F U S O G E N I C  D N A
P E P T I D E
D O T A P / O L E O Y L - F U S O G E N I C  P E P T I D E / D N A  C O M P L E X
F ig u re  3.29 Schematic representation o f structure o f DOTAP/OLEOYL-PEPTIDE/DNA complex
Preliminary transfection results of the effect oleoyl-AOAl on the transfection activity 
of DOTAP suggested that an inclusion of a fusogenic element to a DOTAP/DNA 
complex, could improve the transfection efficiency of DOTAP. The formulation of this 
three-component complex has yet to be optimised. Studies on the mechanism by which 
cationic liposomes deliver DNA have shown that endocytosis was the main process of 
internalisation for lipid/DNA complexes107. Therefore, the inclusion of an endosomal 
membrane destabilization component to a lipidic gene delivery vector must be 
beneficial as it has the potential to increase the release of complexes or free DNA 
release into the cytoplasm. The inclusion of fusogenic peptides in lipid/DNA complexes 
have been reported by Simoes et al. who demonstrated a modest enhancement in the 
transfection activity of DOTAP/DOPE complexes by GALA or an HA-2 derived 
peptide in HeLa cells210. The formation of ternary complexes involving Lipofectin and 
a bifunctional integrin-targeting peptide with an oligolysine tail has been shown by
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Jenkins et al. to be better than Lipofectin/DNA and comparable to adenovirus-mediated 
gene transfer in pulmonary gene transfer in mice . These reports demonstrate that the 
gene transfer activity of cationic lipids can be improved by the inclusion of peptide 
sequences that target different aspects (e.g. integrin-targeting or endosomal escape) of 
the gene transfer process. The pursuance of this approach of using a lipidic fusogenic 
peptide in combination with a cationic lipid could be rewarding if the compound can be 
successfully synthesized and purified.
3.3.20 E f f e c t  o f  a t t e m p t e d  in c l u s io n  o f  o l i g o h i s t i d y l  r e s i d u e s  i n  a
BIFUNCTIONAL PEPTIDE SEQUENCE
Attempts were made to synthesize two oligohistidyl analogues of K25AOAI, 
K25H10AOAI and K25H20AOAI. The idea behind these constructs was to incorporate a 
“proton sponge” element to the construct. The histidyl molecules, which are partially 
protonated at physiological pH would become protonated at the lower pH environment 
of the endosome triggering osmotic swelling and destabilisation of the 
endosomal/lysosomal vesicle. However the target compounds K25H10AOAI and 
K25H20AOAI, showed no in vitro transfection ability (data not shown). MALDI-TOF 
mass spectrometry of target compounds K25H10AOAI and K25H20AOAI (Chapter 2) 
indicated that the fractions of peptide collected during purification did not have the 
target peptide. Attempts at using electrospray mass spectrometry (at the University of 
Bath) to confirm the mass of collected purified fractions containing oligolysine was 
unsuccessful due to multiple protonation of the species, which made interpretation of 
the mass spectra impossible. The lack of access to a MALDI-TOF mass spectrometer at 
the time of the peptides was being synthesized and purified meant that as with all the 
other peptides synthesized, in vitro experiments had to proceed on the assumption that 
the sharpest and largest peak was that of the target peptide. MALDI-TOF mass 
spectrometer analysis on K25H20AOAI revealed that the peak collected during 
purification by HPLC had a mass of 6443 whereas the calculated mass was 8477. The 
lack of transfection activity of the target compound is likely to be due to the 
unsuccessful synthesis of K25H20AOAI. It seems that in this case the largest peak did 
not correspond to the target peptide, the strongest evidence being its lack of haemolytic 
activity.
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3.3.21 D i s c u s s i o n :  E f f e c t  o f  a t t e m p t e d  i n c l u s i o n  o f  o l i g o h i s t i d y l  r e s i d u e s  in  a
BIFUNCTIONAL PEPTIDE SEQUENCE
Histidine has a protonable nitrogen with a pKa of 6.0. At a physiological pH of 7.4, it is 
predominantly unionised but at an endosomal pH of 5, it will be predominantly ionised 
(about 8 6 %) and should provide some buffering capacity to protect DNA from 
lysosomal degradation and trigger an osmotic swelling effect. Partial histidylation (38 ± 
5%) of the e-amino groups of polylysine has been recently shown to mediate the 
transfection of various mammalian cell lines in vitro without the aid of endosmolytic
joa
agents such as chloroquine or fusogenic peptides . Even more significantly, the 
transfection activity of the histidylated polylysine was shown to be unaffected by the 
presence of up to 20% (v/v) serum. Although researchers found that histidylated 
polylysine was up to 20-fold less active than PEI, this finding is encouraging and 
provides support for the idea of including oligohistidine in the structure of a synthetic 
multifunctional peptide.
As mentioned in Chapter 2, all the compounds synthesized in this project were tested 
for their ability to mediate transfection before a MALDI-TOF mass spectrometer 
became available to identify compounds being used. The complete abolition of 
transfection activity of K25AOAI after the inclusion of 10 and 20 histidine residues in 
the sequence, to produce what was thought to be K25H10AOAI and K25H20AOAI 
respectively, was therefore initially postulated to be due to the histidyl component 
interfering with the either the DNA binding function of K25 or the membrane disruptive 
activity of the fusogenic moiety. Retrospective analysis of K25H10AOAI and 
K25H20AOAI by MALDI-TOF mass spectrometery revealed that either the synthesis 
had been unsuccessful or the fractions collected during purification did not contain the 
target peptides (Figure 2.30). As it was shown in section 3.3.2 the resulting compound 
could bind to DNA and exclude ethidium bromide, but lacked fusogenic activity, which 
indicated that the target compound was not isolated.
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3 .4  I n  viv o  t e s t i n g  o f  b i f u n c t i o n a l  p e p t id e
3.4.1 In tr o d u c tio n
The in vivo models used to test the transfection activity of the bifimctional peptide 
K25AOAI were murine intramuscular and intratumour injection. The easy accessibility 
of the muscle was one reason for the choice of this model, but there are practical reasons 
why muscle expression is of interest. Firstly there are several publications in the 
literature on gene expression following injection of naked DNA into muscle, which 
could be used as a control. In addition the muscle is a site for expression of antigens for 
vaccine applications, or for correction of the single gene defects Duchenne muscular 
dystrophy. The latter clinical indication will require a huge improvement in efficiency, 
but remains a possibility. Given that reporter genes are expressed with sufficient 
sensitivity in muscle to allow easy detection, even after injection of DNA in solution, 
the muscle represented the most obvious test bed to compare condensed DNA with 
naked DNA. Injection into tumour was carried out because the group at Bath were 
interested in the concept of expressing immune-stimulatory genes in tumours. Naked 
DNA gives rise to low gene expression in tumours, so an improvement against naked 
DNA would be encouraging.
3 .4 .2  Resu lts  of i n  v i v o  testing  of bifu n c tio n a l  peptide
Attempts to formulate K25AOAI/DNA complexes containing greater than 0.5 pg/pl 
DNA at a charge ratio of 3.2 resulted in a thick white gelatinous precipitate. A 
formulation containing approximately 0.3 pg/pl DNA complexed with K25AOAI at a 
charge ratio of 3.2  (6 .25 pg pCMV luc DNA plus 16.7 pg K25AOAI in a total volume 
of 20  pi Of 5% (w/v) glucose) resulted in a white suspension (with fine white 
precipitate) which could be drawn through a 30 gauge syringe needle. Figure 3 .30  shows 
the results of expression of luciferase following injection of the above formulation 7 
days before harvesting into the right hind leg muscle tissues, and a second dosing into 
the left hind leg muscle 5 days before harvesting.
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The tumours growing on the back of the mice were injected with the same dose of 
complexes 2 days before excising the tissues. Clearly, the DNA complexes with either D 
or LK25AOAI did not result in luciferase expression in either muscle or tumours, 
whereas naked DNA resulted in expression (Figure 3.30) both in muscle and tumour. 
Also, it appeared that expression in the leg hind leg muscle, dosed 5 days before 
harvesting was greater than the right hind leg muscle dosed 7 days before harvesting.
The lack of in vivo transfection activity in the previous experiment using 
K25AOAI/DNA complexes at a DNA concentration of 6.25 pg/ 20 pi of 5% (w/v) 
glucose solution (charge ratio of 3.2) was thought to be due to fact that the particles of 
the complex were
too large thereby prohibiting internalisation via the endocytotic pathway. Formulation 
of condensed DNA is a challenging problem, which at this stage was not resolved 
satisfactorily. Published literature indicated that the dose of DNA should be in excess 
of 10 pg. Typically 50-100 pg DNA is injected to allow detection of gene expression. 
Given that the volume of solution that can be injected into mice thigh in practice should 
be kept to a reasonable volume, which we considered to be less than 2 0  pi, a serious 
formulation problem is evident. Due to the cost and availability of materials it was not 
possible to study in detail the size of complexes versus concentration of DNA in the 
mixture. From earlier work it was known that DNA could be used at 50-100 pg/ml, but 
ideally the concentration required for in vivo work was ten times as high. It was 
necessary to strike a balance between the need for a high dose and the threat that the 
DNA may not be available from aggregated complexes.
In later experiments complexes were formed using 6.25 pg DNA (in 20 pi 5% (w/v) 
glucose solution) at lower charge ratios of 1 . 6  and 0 . 8  and also at a lower quantity of 
3.125 pg DNA (in 20 pi of 5% (w/v) glucose solution) at charge ratios of 3.2, 1.6 and 
0.8. The muscle injections were performed only in the right hind leg muscle at 7 days 
prior to harvesting and the tumour injections at 2 days prior to harvesting. The results of 
gene expression following muscle and tumour injections are shown in Figure 3.31 and 
Figure 3.32. Injection of 3.125 pg DNA produced no significant gene expression with 
the exception of one unrepresentatively high expression from one muscle tissue injected 
with naked DNA (Figure 3.31). Injection of 6.25 pg of DNA produced expression in
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both tumour and muscle (Figure 3.31). Gene expression mediated by K25AOAI/DNA 
(in 20 pi, 5% w/v glucose) at charge ratio of 0.8 was about 2-fold and 3-fold greater that 
expression mediated by naked DNA muscle in tumour and muscle respectively (Figure 
3.32), but these increases were not statistically significant. A two-sample Student t-test 
(performed at a confidence interval of 95% using Minitab™ statistic program) between 
“DNA only” and K25AOAI/DNA complex at a charge ratio of 0.8 in muscle and tumour 
returned p-values of 0.21 and 0.37 respectively. There was near total loss of 
transfection activity at a charge ratio of 1.6 in both tumour and muscle tissues. The 
formulation of K25AOAI/DNA complex containing 6.25 pg DNA at a charge ratio of 
1 . 6  was a hazy suspension (not a clear solution) unlike the other formulation at a charge 




LLM LK25AOAI/DNA complex injected in Left hind leg Muscle
DLM DK25AOAI/DNA complex in Left hind leg Muscle
CLM Control DNA only injected in Left hind leg Muscle
LRM LK25AOAI/DNA complex injected in Right hind leg Muscle
DRM DK25AOAI/DNA complex injected in Right hind leg Muscle
CRM Control DNA only injected in Right hind leg Muscle
LT LK25AOAI/DNA complex injected in Tumour
DT DK25AOAI/DNA complex injected in Tumour
CT Control DNA only injected in Tumour
F igure 3.30 Effect o f  LK25AOAI/DNA complex mediated transfection on luciferase expression in mice 
muscle and tumour compared to naked DNA (Control). 6.25 pg pCMVluc complexed with 16.7 pg 
LK25AOAI or DK25AOAI (+/- charge ratio o f  3.2) in a total volume o f  20 pi o f  5% (w/v) glucose was 
injected directly into muscle or tumour tissue. Control: 6.25 pg DNA in 20 pi o f 5% (w/v) glucose 
solution. The left and right hind leg muscle o f  each mouse was injected with the preparations 5 and 7 days 
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DNA only 0.8 T 1.6 T 3.2 T DNA only 0.8 M
(T) (M)
1.6 M 3.2 M
C h arge  ratio o f  LK25AOA1/DNA com  p lex
F igure 3.31 Effect o f  LK25AOAI/DNA complex mediated transfection on luciferase expression in mice 
muscle (M ) and tumour (T) compared to naked DNA (Control). 3.13 pg pCM Vluc complexed with 8.35,
4.18 or 2.09 pg o f  LK25AOAI (corresponding to +/- charge ratio o f  3.2, 1.6 or 0.8 respectively) in a total 
volume o f  20 pi (5% (w/v) glucose) was injected directly into muscle or tumour tissue. Control: 3.13 pg 
DNA in 20 pi o f  5%  (w/v) glucose solution. The tumour and right hind leg muscle tissue o f each mouse 
was injected 2 and 7 days respectively, before sacrificing the mice (and excising the tissues). n=4
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DNA only 0.8 (T) 1.6 (T) DNA only 0.8 (M)
(T) (M)
C h a r g e  ratio o f  K25AOA1/DNA com  p lex
1.6 (M)
Figure 3.32 Effect o f  LK25AOAI/DNA complex mediated transfection on luciferase expression in mice 
muscle (M) and tumour (T) compared to naked DNA (Control). 6.25 pg pCMVluc complexed with 8.35 
pg or 4.18 pg LK25AOAI ( corresponding to +/- charge ratio o f 1.6 or 0.8 respectively) in a total volume 
o f  20 pi (5% (w/v) glucose) was injected directly into muscle or tumour tissue. Control: 6.25 pg DNA in 
20 pi o f  5% (w/v) glucose solution. The tumour and right hind leg muscle tissue o f  each mouse was 
injected 2 and 7 days respectively, before sacrificing the mice (and excising the tissues). n=4
3 .4.3 D is c u s s i o n
The lack of transfection activity of K25AOAI/DNA complexes at a charge ratio of 3.2 at 
a DNA concentration of 6.25 pg/ 20 pi was probably the result of aggregation of the 
complex resulting in large particles, which could not be taken up by cells by through the 
process of endocytosis. K25AOAI/DNA formulation at a charge ratio of 1.6 was less 
turbid (as visualised by the naked eye). Though a charge ratio of 1.6 is sub-optimal for 
in vitro transfection, this resulted in greater gene expression compared to naked DNA. 
At this stage it is not clear whether this is explained by the ability of these complexes 
better to diffuse within the tissue, or whether the intrinsic activity of these complexes is 
higher in vivo. It is also possible that the activity of complexes formed at low charge
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ratio could have been explained by some naked DNA in the formulation. Naked DNA 
was certainly active following injection into muscle in vivo. This is in agreement with 
observations by other workers ’ ’ , but the mechanism by which myocytes take up
plasmids in vivo, or how the DNA escapes lysosomal degradation is not yet known94. 
Even though there appeared to be an increase in transfection efficiency in muscle and 
tumour as a result of formulation with K25AOAI, this improvement was not statistically 
significant. This was because of one exceptionally large luciferase expression in the 
sample group transfected with K25AOAI/DNA complex, both in muscle and tumour. A 
larger sample size (n=8 ) would have been preferable during in vivo experiments which 
are prone to wider variations in transfection efficiency. However, an improvement of 2 
or 3-fold in transfection efficiency is too modest given the cost of producing K25AOAI. 
The inability to formulate K25AOAI/DNA complexes at higher concentration in small 
volumes ( 2 0  pi), means that these modest improvements would be offset by injecting 
larger quantities of naked DNA. The poor activity of condensed DNA in vivo has also 
been reported after intratumour or intramuscular injection of lipoplexes. Quite why 
condensed DNA has low activity is not clear. Uptake into cells could be limited by 
movement of the particles through the interstitial fluids, and aggregation would have 
added to the problem of mobility. Thus in the future it will be important to use methods 
which prevent aggregation of primary particles. One method by which the concentration 
of bifunctional peptide/DNA formulation could be increased and reduce the risk of 
precipitation is to formulate the complex in a large volume and concentrate it to a
11Csmaller volume by ultrafiltration . Some researchers have got around the volume 
constraints imposed by injection into solid tissue, by using a micropump delivering 2 0  
pl/min which permitted injection of a volume of 100 pi into solid tumour43. Lack of 
time and resources did not permit this method to be tried. In the medium term, solubility 
of complexes could be increase by inclusion of hydrophilic groups (-OH) e.g. the amino 
acid serine, into the structure of a multifunctional peptide.
Other future work in vivo should include testing of K25AOAI/DNA complexes in the 
lungs by bronchial instillation as much higher volumes can be instilled, thereby 
avoiding the volume constraints encountered in this study.
186
4 CONCLUDING REMARKS
The main objective of this project was to develop a single multifunctional peptide, 
which would complex plasmid DNA in order to mimic the attributes of capsid viruses 
such as adenoviruses. The viral genome is condensed and packaged by capsid proteins 
to facilitate entry into target cells through receptor-mediated endocytosis. After 
internalisation of the virus, the acidic pH of the endosome triggers activation of viral 
proteins that disrupt the endosome and release the viral capsid into the cytosol before 
there is fusion of endosome with primary lysosomes. Plank et al formed virus-free, 
synthetic systems by ionically binding fusogenic peptides (analogues of the 23 N- 
terminal amino acids of HA-2 protein) unto the surface of DNA/polylysine complex to 
create a self-assembled ternary complex and these authors demonstrated that
• 1 (\Htransfection was improved several fold by the presence of the fusogenic peptides . The 
addition of fusogenic peptides to DNA-polylysine complexes provided endosome 
escape activity in the absence of a viral capsid, but was not able to fully reproduce the 
efficiency of the whole viral particle1.
Such ‘three-component’ self-assembly systems rely on ionic interactions between 
positively charged polylysines and phosphate groups in DNA as well as negatively 
charged residues on fusogenic peptides. Although the formation of complexes of some 
description is not in doubt, a question remains whether the whole (three-dimensional 
structure) of the fusogenic sequence is available for interaction with membranes after 
complexation within the self-assembled system. We aimed to stabilise the localisation 
of the fusogenic peptide at the surface of the particle and allow the full sequence to be 
available for interaction with the target lipid bilayers. The working hypothesis was that 
a fusogenic peptide which is not partially engaged in binding to polylysine should be 
better at transfection in cells.
One reported method of binding fusogenic peptides to polylysine involves the use of a
1 A7streptavidin-biotin bridge . Plank et al. reported that monomeric influenza peptide 
INF3 sequence did not significantly enhance gene transfer through self-assembly by 
ionic interactions, whereas a 100-fold increase in gene expression was observed when 
INF3-biotin was incorporated into a transfection complex using a complex with
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streptavidin-polylysine and transferrin polylysine. It is very likely that transferrin- 
mediated uptake was the main contributory factor to this improvement in transfection 
efficiency but as there was no control group without transferrin, it is not possible to 
determine the effect of the streptavidin-biotin bridge in their report. Streptavidin is a 
large polypeptide (127 residues). When used in conjunction with long polylysine chains
1 f t le.g. polylysine29o, the large size of streptavidin is not inhibitory . But with short chain 
oligolysine, it was thought that the size of streptavidin would sterically inhibit the 
binding of the lysine chain to plasmid DNA and interfere with the interaction between 
the fusogenic peptide and cell/endosomal membrane. The reliance on ionic interaction 
and/or a streptavidin-biotin bridge in self-assembled systems by previous workers has 
been explored because commercially available polylysine is cheap, but this approach has 
the drawback of heterogeneity and inability subsequently to covalently link active 
peptides in a controlled manner due to unprotected amino groups present.
An alternative method of coupling fusogenic peptides to polylysine was the hitherto 
unreported method of synthesizing a single linear peptide with DNA-binding oligolysine 
chain covalently linked to a fusogenic peptide by means of solid-phase synthesis. It was 
suspected that the presence of a 23-residue fusogenic moiety covalently linked to the 
oligolysine would interfere with the ability of the oligolysine to bind to DNA. The 
initial aim of this project was to determine the optimum length of lysine residues 
required for effective binding to DNA whilst retaining the functionality of the fusogenic 
moiety. It was planned to synthesis K 5 ,  K 1 0 ,  K 1 5 ,  K 2 0 ,  K 2 5  analogues of the fusogenic 
peptide INF7 and a single amino acid mutant of INF7 called AOA1. Due to the 
difficulties encountered during the peptide synthesis and purification, and the lack of 
resources to contract outside help with synthesis, only K10 and K25 analogues of INF7 
and the K25 analogue of AOA1 were synthesized. This at least allowed the project to 
establish that K10 was too short, but it is possible that it is not necessary to use a chain 
as long as K 2 5 .  The future determination of the minimum number of lysine residues 
required in this construct would be beneficial in terms of reducing the cost and also 
reduce the degree of heterogeneity of the construct due to unnecessary lengthening of 
the oligolysyl chain.
188
The project was able to establish that a single bifunctional peptide K25AOAI was a 
much superior GDV to the ternary self-assembly complex of K25/AOAI or K8/JTS1 in 
transfection in vitro. This work provided proof in principle that a single linear peptide 
consisting of DNA-binding K25 and an endosomal escape mediating fusogenic peptide is 
able to retain the functions of its constituent parts.
Only a limited amount of physical characterisation work could be carried out in this 
project due to the limited amount of peptide available. Particle sizing and zeta potential 
measurements showed that K25AOAI/DNA complexes were more stable than K25/DNA 
complexes. This finding is important because it signals that the close proximity of non­
charged peptide sequences has a stabilizing effect on the resulting peptide/DNA 
complex. If K25H10AOAI and/or K25H20AOAI had been successfully synthesized and 
isolated by HPLC it would have been interesting to see the effect these compounds 
would have on particle stability of the DNA/peptide complex.
F u t u r e  w o r k
The attributes that a virus-like particle must possess to be an efficient GDV in non­
dividing cells in vitro can be speculated to include DNA-condensing, receptor mediated- 
uptake, endosomal escape, movement along microtubules to the nucleus and uptake into 
the nucleus. In addition to these attributes, the in vivo environment provides an extra set 
of challenges that required the GDV to possess tissue targeting and ionic solution 
stability and serum stability. The ability for gene delivery researchers to include many of 
these attributes in a single gene delivery particle requires an accurate knowledge and 
control over where ligands are positioned on a gene delivery particle and the effect of 
altering these positions. One of the advantages of a relatively successful non-viral gene 
delivery reagent, PEI, is that it is inexpensive. However, the presence of multiple 
reactive sites on PEI means that researchers have, to date, been unable to incorporate 
more than one potentially beneficial attribute to a PEI/DNA particle in addition to PEI’s 
inherent DNA condensing and endosomal escape properties. The post-polyplex 
formation PEGylated Tf-PEI/DNA complex is probably the most advanced polymer- 
based particle that has been designed86,145. These particles were shown to be more stable 
in serum and ionic solutions and able to increase tumour-site gene expression, but the
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scope for improving on the gene delivery attributes of such a particle is limited because 
of the lack of further reactive sites to attach ligands post PEGylation.
In order to be able to create gene delivery particles with a predetermined molecular 
structure, there may need to be a departure from the use of polymers with multiple 
reactive sites to designing proteins with the aid of solid phase peptide synthesis. The 
advantage of using solid phase synthesis to produce proteins is that by using a 
combination of different permanent protecting groups and synthetic conditions, different 
ligands can be attached to a synthetic protein in a specific position and the effect of that 
modulation can be determined with a greater certainty.
In this project, HPLC and mass spectra analysis showed that peptides with the size of 48 
amino acid residues had a low yield of the target peptide in the crude product. The 
transfection experimental data suggest that the difference between a whole peak and the 
corresponding peak splicing batch is a 20% decrease in transfection activity. In addition 
to the fact that the estimated percentage of the target compound was probably less than 
10% in the peak splicing batch of K25AOAI (#2) according to HPLC, an important 
inference from this project is that the use of HPLC purification method and analysis of 
peptides of this size and composition by HPLC and mass spectra was perhaps more 
stringent than was required for gene therapy purposes. In other words, crude products of 
solid phase peptide synthesis are much less heterogeneous than products that could be 
generated by for instance reacting polymers; for example, three molar equivalents of 
PEI with one molar equivalent of activated MeOPEG2000 (PEG2000 monomethyl 
ether).
The advantages of using solid-phase synthesis method to create bifunctional peptides 
capable of promoting the transfection of dividing mammalian cells have been 
demonstrated in this project. Bifunctional peptides with two fusogenic sequences per 
molecule could increase the fusogenic property and further improve the ionic salt 
stability of the construct by reducing the zeta potential on the surface of the 
DNA/bifunctional peptide particle. A successful synthesis and purification of a peptide 
containing oligolysine, oligohistidine and a fusogenic component, perhaps with the 
oligohistidyl sequence furthest from the fusogenic sequence, could potentially have two 
advantages: firstly the ability of the imidazole side chain to be ionised at lower pH
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within the endosome could produce a proton sponge effect similar to that attributed to 
the activity of PEI and increase the endosomolytic potency of such a compound; 
secondly the builder imidazole ring which will be only partially ionised at a pH of 7 
could increase the ionic solution and serum stability of the DNA/peptide formulation 
against precipitation. Ligands could also be attached to K25AOAI to improve uptake in 
non-dividing cells.
This project shows that the ability to design and create a single more defined 
multifunctional gene delivery vehicle using solid-phase peptide synthesis method will 
be advantageous but will come at a considerable financial cost.
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